The role of the cell-mediated immune response to rotavirus infection by Heath, Richard Rhead
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
A Thesis Submitted for the Degree of PhD at the University of Warwick
http://go.warwick.ac.uk/wrap/55440
This thesis is made available online and is protected by original copyright.
Please scroll down to view the document itself.
Please refer to the repository record for this item for information to help you to
cite it. Our policy information is available from the repository home page.
THE ROLE OF THE CELL-MEDIATED IMMUNE 
RESPONSE TO ROTAVIRUS INFECTION 
by 
RICHARD RHEAD HEATH, B. Sc. (Manchester) 
A thesis submitted for the degree of 
Doctor of Philosophy to the 
University of Warwick 
All research was conducted in the 
Department of Biological Sciences, 
University of Warwick 
Submitted in July 1996 
To my mother and father 
CONTENTS 
Contents 
List of figures 
List of tables 
Acknowledgements 
Declaration 
Summary 
List of abbreviations 
CHAPTER 1. THE ROTAVIRUSES 
1.1 Introduction 
1.2 Rotavirus pathology and pathophysiology 
1.2.1 Intestinal changes following rotavirus infection 
1.2.2 Age restriction of rotavirus infection 
1.3 Structure of the rotavirus particle 
1.4 The rotavirus genome 
1.5 Properties of rotavirus proteins 
1.5.1 Rotavirus protein nomenclature 
1.5.2 Gene segment 1 (VP 1) 
1.5.3 Gene segment 2 (VP2) 
1.5.4 Gene segment 3 (VP3) 
1.5.5 Gene segment 4 (VP4) 
1.5.6 Gene segment 5 (NS53 or NSP1) 
1.5.7 Gene segment 6 (VP6) 
1.5.8 Gene segment 7 (NS35 or NSP2) 
i 
XI 
xvi 
xviii 
xix 
xx 
xxi 
I 
2 
2 
2 
3 
4 
6 
7 
7 
7 
8 
9 
9 
10 
11 
11 
1 
1.5.9 Gene segment 8 (VP7) 
1.5.10 Gene segment 9 (NS34 or NSP3) 
1.5.11 Gene segment 10 (NS28 or NSP4) 
1.5.12 Gene segment 11 (NS26/NS12 orNSP5/NSP6) 
1.6 Rotavirus genetic diversity 
1.6.1 Point mutation 
1.6.2 Reassortment 
1.6.3 Rearrangement 
1.7 Rotavirus groups, subgroups and serotypes 
1.7.1 VP6 contains the group and subgroup specific antigens 
1.7.2 VP7 contains the G serotype specific antigens 
1.7.3 VP4 contains the P serotype specific antigens 
1.8 Epidemiology of rotavirus infection 
1.8.1 Serotypic diversity in developed countries 
1.8.2 Serotypic diversity in developing countries 
12 
13 
13 
14 
14 
14 
15 
16 
17 
17 
20 
21 
22 
23 
24 
CHAPTER 2. THE CTL AND ITS ROLE IN THE IMMUNE RESPONSE 26 
2.1 Introduction 
2.2 Overview of T-lymphocytes in viral infection 
2.2.1 CTLs are critical for clearing many viral infections 
2.2.2 The role of Th-lymphocytes in clearing viral infection 
2.3 The structure and function of the MHC class I molecule 
2.3.1 The genes encoding the mouse MHC class I proteins 
2.3.2 Genetics of MHC class I polymorphism 
2.3.3 Structure of MHC class I molecules 
2.3.4 Peptides bound by the MHC groove 
27 
28 
28 
30 
31 
31 
34 
35 
35 
ii 
2.4 Assembly and transport of MHC class I molecules 38 
2.4.1 Generation of MHC class I components and transport into the ER 38 
2.4.2 Generation of peptides and transport into the ER 38 
2.4.3 Association of MHC class I and peptides 40 
2.4.4 Antigen presenting cells (APCs)/target cells 40 
2.5 Cell-mediated target cell killing 42 
2.5.1 Generation of effector CTLs following virus infection 42 
2.5.2 The structure of the T-cell receptor (TCR) complex 43 
2.5.3 CTL binding to target cells 45 
2.5.4 Signal transduction in the CTL following target cell binding 46 
2.5.5 CTL induced target cell killing 47 
2.5.6 Secretory and membranolytic induced cell death 48 
2.5.7 Non-secretory and receptor-mediated induced cell death 51 
2.5.8 Non-cytolytic virus resolution 51 
2.6 Intestinal intraepithelial lymphocytes 52 
2.7 Virus-specific memory CTLs 52 
2.8 Resume 54 
CHAPTER 3. THE IMMUNE RESPONSE TO ROTAVIRUS 56 
3.1 Introduction 57 
3.2 Components of the immune response during rotavirus infection 57 
3.2.1 Location of rotavirus infection 57 
3.2.2 Immune response following primary infection 58 
3.2.3 Location and isotype of rotavirus-specific antibodies 58 
3.2.4 Location and TCR type of rotavirus-specific CTLs 59 
iii 
3.2.5 Memory T- and B-lymphocytes are acquired following primary 59 
rotavirus infection 
3.2.6 Immune response following re-infection 60 
3.3 Both antibody and CTLs are involved in clearance of the primary 60 
rotavirus infection 
3.4 Neither antibody nor CTLs are involved in the clearance of the 61 
primary rotavirus infection 
3.5 General properties of protection from rotavirus re-infection 62 
3.5.1 Primary rotavirus infection protects the host from subsequent re- 62 
infection 
3.5.2 Heterotypic protection is generated following rotavirus infection 62 
3.5.3 Protection may correlate to the magnitude of the primary immune 63 
response 
3.5.4 Rotavirus replication is not required at the intestinal surface to elicit 64 
an immune response 
3.6 The role of the humoral immune response in protection from rotavirus 64 
re-infection 
3.6.1 Antibodies are involved in protection 64 
3.6.2 Serotype-dependent antibodies develop after primary infection, 65 
whereas, serotype-independent antibodies develop after re-infection 
3.6.3 Minor cross-neutralising epitopes may be involved in heterotypic 66 
protection 
3.6.4 Antibodies recognise most rotavirus proteins 66 
3.6.5 VP4 and VP7 both contain major neutralising, and minor cross- 67 
neutralising, antibody epitopes 
3.6.6 A role for non-neutralising VP6 antibodies in heterotypic protection 68 
iv 
3.6.7 Antibodies may not be directly involved in protection 69 
3.7 The role of the cell-mediated immune response in protection from 70 
rotavirus re-infection 
3.7.1 CTLs are involved in protection 70 
3.7.2 The involvement of CTLs in heterotypic protection 70 
3.7.3 CTLs recognise many rotavirus proteins 71 
3.7.4 The MHC class I haplotype affects the CTL response 72 
3.7.5 Serotype-independent VP7-specific CTL epitopes have been detected 72 
3.7.6 Location of epitopes recognised by CTLs 73 
3.7.7 CTLs may not be directly involved in protection 74 
3.8 Implications for rotavirus vaccine design 75 
CHAPTER 4. MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Standard buffers and solutions 
4.1.2 Tissue culture media and cell lines 
4.1.3 Primers 
4.1.4 Vectors 
4.1.5 Bacterial strains 
4.1.6 Rotavirus strains 
4.1.7 Vaccinia virus 
4.1.8 Animals 
4.1.9 Suppliers 
4.2 Cell culture 
4.2.1 Cell maintenance 
4.2.2 Freezing and recovery of cell stocks 
77 
78 
78 
78 
80 
80 
81 
82 
82 
82 
83 
83 
83 
84 
V 
4.3 Cloning techniques 
4.3.1 Rotavirus RNA extraction 
4.3.2 Quantification of nucleic acids 
4.3.3 Reverse transcription polymerase chain reaction (RT-PCR) 
4.3.4 Agarose gel electrophoresis 
4.3.5 Purification of DNA from agarose gels 
4.3.6 Direct cloning of PCR products 
4.3.7 Mini-plasmid preparation 
4.3.8 Restriction enzyme digestion 
4.3.9 Maxi-plasmid preparation 
4.3.10 Blunt ending of DNA 
4.3.11 Dephosphorylation of vector DNA 
4.3.12 DNA sequence analysis 
4.3.13 Ligation of DNA 
4.3.14 Electroporation 
4.3.15 Polymerase chain reaction (PCR) 
4.4 Construction and expression of recombinant vaccinia virus 
4.4.1 Transfection 
4.4.2 Selection of recombinants 
4.4.3 Extraction of vaccinia virus DNA 
4.4.4 Immunofluorescence of recombinant vaccinia viruses 
4.5 Virus propagation 
4.5.1 Plaque purification of vaccinia virus 
4.5.2 Preparation of vaccinia virus inoculum 
4.5.3 Large scale growth of vaccinia virus 
4.5.4 Preparation of rotavirus inoculum 
84 
84 
85 
85 
85 
86 
86 
86 
86 
86 
86 
87 
87 
87 
87 
88 
88 
88 
89 
89 
89 
90 
90 
91 
91 
91 
vi 
4.5.5 Large scale growth of rotavirus 
4.5.6 Rotavirus purification 
4.5.7 Titration of virus stocks 
4.6 Chromium-51 (51Cr)-release assay to measure CTL activity 
4.6.1 In vivo priming of mice 
4.6.2 Preparation of spleen cell suspension 
4.6.3 In vitro stimulation of splenocytes 
4.6.4 Preparation of target cells 
4.6.5 51Cr-release assay 
4.6.6 Calculation of the percentage specific lysis 
91 
92 
92 
93 
93 
93 
93 
94 
94 
95 
CHAPTER 5. CLONING OF ROTAVIRUS GENE 11 INTO THE pGS62 96 
VACCINIA SHUTTLE VECTOR 
5.1 Aims 97 
5.2 PCR amplification of rotavirus UKtc gene 11 97 
5.3 TA CloningTM of rotavirus gene 11 DNA 97 
5.4 pGS62 cloning of rotavirus gene 11 100 
5.5 Sequence analysis of pGS62 cloned rotavirus gene 11 DNA 103 
5.6 Conclusions 106 
CHAPTER 6. CONSTRUCTION OF RECOMBINANT VACCINIA 107 
VIRUSES 
6.1 Aims 108 
6.2 Production of recombinant vaccinia viruses containing rotavirus 109 
genes (using the pGS62 vector) 
vii 
6.3 Production of recombinant vaccinia viruses containing fragments of 115 
rotavirus genes (using the pSC11-30R. 2 vector) 
6.4 Conclusions 120 
CHAPTER 7. ANALYSIS AND EXPRESSION OF RECOMBINANT 124 
VACCINIA VIRUSES 
7.1 Aims 125 
7.2 Sequence analysis of recombinant vaccinia viruses containing 125 
fragments of UKtc gene 8 (VP7) 
7.3 Rotavirus protein expression following recombinant vaccinia virus 127 
infection of cells 
7.4 Conclusions 129 
CHAPTER 8. THE CTL RESPONSE TO INDIVIDUAL ROTAVIRUS 130 
UKtc PROTEINS IN THREE MHC CLASS I HAPLOTYPES 
8.1 Aims 131 
8.2 Rationale to the 51Cr-release assay 131 
8.3 CTL recognition of target cells expressing various rotavirus UKtc 133 
proteins in three different mouse MHC class I haplotypes 
8.4 Congenic mouse CTL recognition of target cells expressing 136 
homotypic rotavirus RRV VP7 protein 
8.5 Conclusions 138 
viii 
CHAPTER 9. THE CTL RESPONSE AGAINST ROTAVIRUS VP3 139 
PROTEIN 
9.1 Aims 140 
9.2 Rotavirus RRV primed CTL recognition of target cells expressing 140 
heterotypic rotavirus UKtc VP3 protein 
9.3 Conclusion 140 
CHAPTER 10. THE CTL RESPONSE AGAINST ROTAVIRUS NS53 142 
PROTEIN 
10.1 Aims 143 
10.2 CTL recognition of target cells expressing various heterotypic 143 
rotavirus NS53 proteins 
10.3 CTL recognition of H-2b target cells expressing the deletant mutant 146 
rotavirus P9DA5 NS53 protein 
10.4 CTL recognition of mouse Db and Kb restricted target cells expressing 146 
homotypic rotavirus NS53 protein 
10.5 Conclusions 149 
CHAPTER 11. THE CTL RESPONSE AGAINST ROTAVIRUS VP7 150 
PROTEIN 
11.1 Aims 151 
11.2 CTL recognition of target cells expressing various heterotypic 151 
rotavirus VP7 proteins 
11.3 CTL recognition of H-2b target cells expressing fragments of 151 
rotavirus UKtc VP7 protein 
ix 
11.4 CTL recognition of mouse Db and Kb restricted target cells expressing 154 
homotypic rotavirus VP7 protein 
11.5 Conclusions 154 
CHAPTER 12. GENERAL DISCUSSION AND FUTURE EXPERIMENTS 157 
REFERENCES 175 
X 
LIST OF FIGURES 
CHAPTER 1. THE ROTAVIRUSES 
Figure 1. Composite reconstruction of the rotavirus SA11 particle 5 
CHAPTER 2. THE CTL AND ITS ROLE IN THE IMMUNE RESPONSE 
Figure 2. The role of CD4+ Th-lymphocytes in the immune response 32 
Figure 3. Murine MHC class I haplotypes 33 
Figure 4. Structure of a MHC class I molecule 36 
Figure 5. A schematic representation of MHC class I assembly and peptide 41 
processing 
Figure 6. The a3T cell receptor complex 44 
Figure 7. Two pathways of CTL-mediated target cell cytotoxicity 49 
CHAPTER 5. CLONING OF ROTAVIRUS GENE 11 INTO THE pGS62 
VACCINIA SHUTTLE VECTOR 
Figure S. PCR amplified rotavirus UKtc gene 11 products 98 
Figure 9. Map of the pCRTM II vector from the TA CloningTM system 99 
Figure 10. Potential gene 11 clones digested from pCRTM II vector using 98 
EcoRI restriction enzyme 
Figure 11. Map of the shuttle plasmid vector pGS62 101 
Figure 12. Quantification of PCRTM II cloned gene 11 inserts digested with 102 
BamHI and Smal, and pGS62 vector digested with SmaI 
Figure 13. Confirmation of pGS62 cloned gene 11 insert direction by PCR 104 
amplification 
X1 
Figure 14. PCR amplified products of potential pGS62 clones containing 105 
rotavirus UKtc gene 11 and gene 11(ORF2) 
CHAPTER 6. CONSTRUCTION OF RECOMBINANT VACCINIA 
VIRUSES 
Figure 15. Generation of recombinant vaccinia virus 110 
Figure 16. Analysis of recombinant vaccinia virus by PCR 111 
Figure 17. Screening by PCR of potential recombinant vaccinia viruses 113 
containing various rotavirus UKtc genes 
Figure 18. Screening by PCR of potential recombinant vaccinia viruses 114 
containing gene 5 from various rotavirus strains 
Figure 19. Screening by PCR of potential recombinant vaccinia viruses 116 
containing the gene (7,8 or 9) encoding the VP7 protein of 
various rotavirus strains 
Figure 20. UKtc gene 8 (VP7 protein) fragments cloned into pSCI 1-30R. 2 117 
Figure 21. Map of the shuttle plasmid vector pSC11-30R. 2 119 
Figure 22. Screening by PCR of potential recombinant vaccinia viruses 121 
containing various fragments of UKtc gene 8 (VP7 protein) 
CHAPTER 7. ANALYSIS AND EXPRESSION OF RECOMBINANT 
VACCINIA VIRUSES 
Figure 23. Sequence analysis of vector-insert 5' junction within recombinant 126 
vaccinia virus TK7 gene 
Figure 24. Immunofluorescence of rotavirus proteins (VP2, VP3, VP6, NS26 128 
and NS12) expressed in recombinant vaccinia virus infected cells 
X11 
CHAPTER 8. THE CTL RESPONSE TO INDIVIDUAL ROTAVIRUS 
UKtc PROTEINS IN THREE MHC CLASS I HAPLOTYPES 
Figure 25. The 51Cr-release assay for CTL activity 132 
Figure 26. % specific lysis of targets expressing various UKtc proteins by 134 
UKtc primed C57BL/6 (H-2b) effectors 
Figure 27. % specific lysis of targets expressing various UKtc proteins by 134 
UKtc primed Balb/c (H-2d) effectors 
Figure 28. % specific lysis of targets expressing various UKtc proteins by 135 
UKtc primed C3H/He, mg (H-2k) effectors 
Figure 29. % specific lysis of targets expressing various UKtc proteins by 135 
RRV (3 weeks) followed by UKtc (1 week) primed Balb/c (H-2d) 
effectors 
Figure 30. % specific lysis of targets expressing RRV VP7 protein by RRV 137 
primed C57BL/10 (H-2b), B10. D2/n (H-2d), B10. BR (H-2k) and 
Balb, B (H-2b) effectors 
CHAPTER 9. THE CTL RESPONSE AGAINST ROTAVIRUS VP3 
PROTEIN 
Figure 31. % specific lysis of targets expressing UKtc VP3 protein by RRV 141 
primed Balb/c (H-2d) effectors 
Figure 32. % specific lysis of targets expressing UKtc VP3 protein by RRV 141 
primed C3H/He, mg (H-2k) effectors 
XIII 
CHAPTER 10. THE CTL RESPONSE AGAINST ROTAVIRUS NS53 
PROTEIN 
Figure 33. % specific lysis of targets expressing various NS53 proteins by 144 
UKtc primed C57BL/6 (H-2b) effectors 
Figure 34. % specific lysis of targets expressing various NS53 proteins by 144 
RRV primed C57BL/6 (H-2b) effectors 
Figure 35. % specific lysis of targets expressing various NS53 proteins by 145 
RRV primed Balb/c (H-2d) effectors 
Figure 36. % specific lysis of targets expressing various NS53 proteins by 145 
RRV primed C3H/He, mg (H-2k) effectors 
Figure 37. % specific lysis of targets expressing P9Dz5 NS53 protein by 147 
UKtc primed C57BL/6 (H-2b) effectors 
Figure 38. % specific lysis of targets expressing P9DA5 NS53 protein by 147 
RRV primed C57BL/6 (H-2b) effectors 
Figure 39. % specific lysis of targets expressing UKtc NS53 protein by UKtc 148 
primed C57BL/6 (H-2b) effectors 
Figure 40. % specific lysis of targets expressing RRV NS53 protein by RRV 148 
primed C57BL/6 (H-2b) effectors 
CHAPTER 11. THE CTL RESPONSE AGAINST ROTAVIRUS VP7 
PROTEIN 
Figure 41. % specific lysis of targets expressing various VP7 proteins by 152 
UKtc primed C57BL/6 (H-2b) effectors 
Figure 42. % specific lysis of targets expressing various VP7 proteins by 152 
RRV primed C57BL/6 (H-2b) effectors 
XIV 
Figure 43. % specific lysis of targets expressing fragments of UKtc VP7 153 
protein by UKtc primed C57BL/6 (H-2b) effectors 
Figure 44. % specific lysis of targets expressing fragments of UKtc VP7 153 
protein by RRV primed C57BL/6 (H-2b) effectors 
Figure 45. % specific lysis of targets expressing UKtc VP7 protein by UKtc 155 
primed C57BL/6 (H-2b) effectors 
Figure 46. % specific lysis of targets expressing RRV VP7 protein by RRV 155 
primed C57BL/6 (H-2b) effectors 
xv 
LIST OF TABLES 
CHAPTER 1. THE ROTAVIRUSES 
Table 1. P serotype (VP4 genotype), G serotype and subgroup of human 19 
and animal group A rotaviruses 
CHAPTER 2. THE CTL AND ITS ROLE IN THE IMMUNE RESPONSE 
Table 2. Examples of mouse MHC class I motif groups 
CHAPTER 4. MATERIALS AND METHODS 
Table 3. Description of cell lines and their culture media 
Table 4. Contents of growth media 
Table 5. Sequence of oligonucleotide primers 
37 
79 
80 
81 
CHAPTER 6. CONSTRUCTION OF RECOMBINANT VACCINIA 
VIRUSES 
Table 6. Constructed vaccinia shuttle plasmids provided 108 
Table 7. The rotavirus gene insert size (in pGS62 shuttle vector) and the 112 
predicted amplified PCR product size following successful 
construction of recombinant vaccinia viruses 
Table 8. The rotavirus UKtc gene 8 restriction enzyme fragment insert size 120 
(in pSCI 1-30R. 2 shuttle vector) and the predicted amplified PCR 
product size following successful construction of recombinant 
vaccinia viruses 
Table 9. Recombinant vaccinia viruses constructed to-date 122 
xvi 
CHAPTER 12. GENERAL DISCUSSION AND FUTURE 
EXPERIMENTS 
Table 10. Comparison of the VP7 amino acid sequence (between amino 170 
acid positions 33 and 40) corresponding to the H-2K b epitope 
detected by Franco et al. (1993) 
XV ll 
ACKNOWLEDGEMENTS 
I would first like to thank my supervisor Professor Malcolm McCrae for his guidance and 
patient supervision during my period of study. 
I also have to thank all my friends at the University of Warwick, especially 
Shirley Stagg, for their invaluable help and Pamela for the use of her computer. 
Finally I wish to thank my family and close friends for their love, support and 
patience over the years which has made this study possible. 
xviii 
DECLARATION 
I declare that all the work in this thesis was performed by myself, except the 
immunofluorescence which was performed by Prof. M. McCrae and N. Broughton and all 
other work where acknowledged. I also declare, to the best of my knowledge, that this 
work has not been previously been submitted for a degree in this or any other university. 
Richard Heath 
xix 
SUMMARY 
The objective. of this project was to determine the protein specificity of the cytotoxic T- 
lymphocyte (CTL) response to rotavirus infection in mice and to assess the rotavirus 
serotype/strain independent nature of this response. Previous work, involving the rotavirus 
group at Warwick, had shown that the outer shell glycoprotein VP7 is a major target 
antigen for a CTL response that is virus serotype-independent. However, that work did not 
cover all twelve rotavirus proteins, was confined to one strain of adult mice (C57BL/6, H- 
2b) and covered only two of the fourteen VP7 serotypes (serotypes 3 and 6) (Offit et al., 
1994). 
Recombinant vaccinia viruses expressing individual rotavirus UKtc proteins 
VP2, VP3, NS26 and NS12 were constructed to complete a set of recombinant vaccinia 
viruses covering the full complement of rotavirus proteins from the bovine UKtc strain. 
These were used to define rotavirus proteins eliciting a CTL response in three different 
mouse haplotypes. UKtc NS53 and UKtc VP7 stimulated a strong CTL response only in 
the H-2b MHC class I haplotype (UKtc NS53 and UKtc VP7 were restricted at H-2Db and 
H-2K b, respectively). Conversely, UKtc VP3 stimulated a strong CTL response in the H-2d 
and H-2k (but not in H-2b) MHC class I haplotypes. Work using congenic mouse strains 
was used to verify that the VP7 protein specific CTL response is restricted solely by the 
MHC class I antigens. 
Rotavirus RRV NS53 was not only found to elicit a CTL response in the H-2b 
MHC class I haplotype, similar to UKtc NS53, but also in the H-2d MHC class I 
haplotype. Thus, the individual rotavirus protein that elicits a CTL response not only 
depends on the MHC class I haplotype, but also on the actual rotavirus strain being tested. 
Many of the previous studies looking at the CTL response-to individual rotavirus proteins 
have, unlike this study, used several different rotavirus strains and, therefore, may have 
given an inaccurate representation of the rotavirus proteins that elicit a CTL response. 
Recombinant vaccinia viruses were also used to examine the serotype/strain 
independent nature of the CTL response against the major target antigens. The analysis 
was extended to cover VP3 from two different strains, NS53 from three different strains 
and VP7 from seven of the fourteen serotypes. VP3 and NS53 were found to elicit a strain- 
dependent response whereas the serotype-independent nature of the CTL response to VP7 
was confirmed. Since the serotype-independent nature of the rotavirus VP7-specific CTL 
response was found to cross-protect between half of the VP7 serotypes, irrespective of the 
immunising. serotype, it would be reasonable to speculate that the CTL response is 
serotype-independent between all the VP7 serotypes. 
Finally, recombinant vaccinia viruses were used to locate CTL epitopes on NS53 
and VP7. Recombinant vaccinia virus expressing a UKtc NS53 deletant mutant (P9DM5) 
showed there to be at least one strain specific epitope in the first 150 amino acids of the 
UKtc NS53 protein. Recombinant vaccinia viruses expressing four different UKtc VP7 
fragments spanning 46% of this protein were examined. It was found that the fragment 
spanning the restriction enzyme sites at nucleotide 90 (CIaI) and nucleotide 196 (Hhal), 
i. e. between amino acids 13 and 48 of the mature UKtc VP7 protein, contained a serotype- 
dependent CTL epitope. The finding suggests that the immunodominant epitope identified 
in the same region of VP7 by Franco et al. (1993) was not the serotype-independent 
epitope. 
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CHAPTER 1 
THE ROTAVIRUSES 
I 
1.1 INTRODUCTION 
Rotaviruses were first identified by electron microscopy in 1973 (Bishop et al., 1973; 
Flewett et al., 1973) and a wealth of knowledge concerning these viruses has been 
obtained in the last twenty years. They are nonenveloped, icosahedral viruses which 
belong to the family Reoviridae and have a segmented, double-stranded (ds) RNA genome 
(Kapikian and Chanock, 1990). 
Group A rotaviruses are the major etiological agents of acute viral gastro- 
enteritis, responsible for very large mortality and morbidity problems in humans and 
economic losses in agriculture. The virus causes a severe dehydrating diarrhoea primarily 
in the young of both humans, and a wide range of other mammals and birds. In Asia, 
Africa and Latin America, approximately 850,000 infants die of rotavirus-induced gastro- 
enteritis each year (WHO, 1989). In developed countries, rotavirus diarrhoea has a low 
mortality rate but a high morbidity rate as a result of the effective replacement of fluids 
and electrolytes lost during this viral induced disease. For example, rotavirus gastro- 
enteritis is believed to cause approximately 517 deaths and 209,000 hospitalisations per 
year in the United States (Ho et al., 1988; Blacklow and Greenberg, 1991). 
1 .2 ROTAVIRUS PATHOLOGY AND PATHOPHYSIOLOGY 
1.2.1 Intestinal changes following rotavirus infection 
Rotavirus infection is often asymptomatic (Zheng et al., 1989). Symptomatic virus 
infection has an incubation period of up to twenty four hours in the mouse and the 
infection spreads from the proximal small bowel to the ileum over the following one to 
two days (Starkey et al., 1986). Although infection normally lasts a total of one week in 
most animals and humans, the immuno-compromised host can develop a chronic infection 
which persists for weeks/months or until death (Dharakul et al., 1990; Gilger et al., 1992). 
2 
A detailed account of the pathological changes involved in rotavirus diarrhoea is 
beyond the scope of this thesis and has been recently reviewed by Greenberg et al. (1994). 
Briefly, rotavirus infection is restricted to the mature enterocytes on the tips of the small 
intestinal villi and leads to mild shortening of the villi, crypt hyperplasia and moderate 
round-cell infiltration of the lamina propria (Pearson et al., 1978; Pearson and McNulty, 
1979). The mechanism of rotaviral induced diarrhoea in the piglet involves a loss of viable 
absorptive cells which causes an increased faecal lactose loss and an increased faecal 
osmotic gap (Graham et al., 1984). It has been suggested that the malabsorption of 
carbohydrates results in an osmotic diarrhoea. The mouse model does not show 
carbohydrate malabsorption (Collins et al., 1988) and in this case diarrhoea is thought to 
arise from villus ischemia leading to a secondary net intestinal secretion (Osborne et al., 
1988). Very recent work by Ball et al. (1996) showed that the non-structural rotavirus 
protein NS28 is a viral enterotoxin in the mouse. They speculated that NS28 is released 
into the lumen from infected cells and then binds to a receptor on adjacent cells thus 
triggering intestinal secretory pathways. 
1.2.2 Age restriction of rotavirus infection 
Rotavirus associated diarrhoea typically occurs in 21% of children less than 6 months old, 
68% of children between 6-24 months old and only 8% of children between 24 months to 
13 years old (Kapikian et al., 1976). This apparent age restriction relates only to disease 
and not to asymptomatic rotavirus infection (Bridger, 1994). 
Proteolytic cleavage of rotaviral protein VP4 into VP5* and VP8* with trypsin is 
thought to be required for the efficient entry of rotavirus into tissue culture cells (Suzuki et 
al., 1985; Kaijot et al., 1988). Bass et al. (1992) found that the adult mouse stomach 
cleaved VP4 in a manner distinct from that of the suckling stomach (which cleaved VP4 
similarly to trypsin) and that rotaviruses showed a 10,000-fold decrease in titre following 
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passage through the adult stomach when compared to the passage through the suckling 
stomach. It was suggested that the development of gastric acid and pepsin secretions may 
offer the protection seen with increased age. 
The age dependency of rotavirus disease could also be conditional on the 
quantity of rotavirus-specific binding receptors on the epithelial cells (Riepenhoff-Talty et 
al., 1982) and/or the immunity gained following the asymptomatic infection of neonates 
with the nursery strains of rotavirus (Albert et al., 1987). 
1.3 STRUCTURE OF THE ROTAVIRUS PARTICLE 
Cryo-electron microscopy and computer image processing allowed the three dimensional 
structure of the virus particle to initially be determined to a resolution of 40 angstroms (A) 
(Prasad et al., 1988) and more recently to a resolution of 26A as shown in Figure 1 
(Yeager et al. 1994). 
The spherical rotavirus particle (377A in mean diameter) has a T=131 icosahedral 
surface lattice. In the centres of the 120 six-co-ordinated and 12 five-co-ordinated points 
are aqueous channels, 132 in all, which are approximately 55A in diameter and 140A in 
depth. These channels have been suggested as having a role in the transit of metabolites 
and nascent RNA transcripts in and out of the particle, respectively (Prasad et al., 1988). 
The triple-shelled virus particle is composed of the outer shell proteins VP4 and 
VP7. The 780 molecules of the VP7 protein form a smooth protein surface and the VP4 
dimers (200A in length and in contact with VP6 and VP7) form 60 spikes which are 
located next to the channels surrounding the icosahedral five-fold axis. Buried within the 
virion, the VP4 dimer NH2-terminus has a hexagonal base (85A in diameter). The VP4 
spike protrudes 110A from the surface of the virion and has a globular domain 55A in 
diameter (Prasad et al., 1990; Shaw et al., 1993). 
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FIGURE 1. COMPOSITE RECONSTRUCTION OF THE ROTAVIRUS SA11 
PARTICLE 
A computer generated image of a rotavirus SAl I particle prepared using cryo-electron 
microscopy at a resolution of 26A (Yeager et al., 1994). A segment of the particle has been 
removed to allow visualisation of the three concentric protein shells which form the mature 
virus. The outer shell proteins VP4 (yellow) and VP7 (blue), the intermediate shell protein 
VP6 (purple) and the inner shell protein VP2 (red) are distinguishable. VPI and VP3 are 
minor components of the virion core and are associated with the 11 segments of double 
stranded RNA (not shown). A total of 132 aqueous channels extend through the outer (VP7) 
and intermediate (VP6) shells to the virion core. 
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The outer shell of rotavirus (VP4 and VP7) can be removed using chelating 
agents such as ethylenediamine tetracetic acid (EDTA) to reveal what has historically been 
referred to as the single-shelled virus particle, although, the cryo-electron microscopy 
studies indicated that it is infact a double-shelled structure. The surface of this particle 
(299A in mean diameter) is composed of 260 trimers of VP6 and follows the same T=131 
icosahedral symmetry as the outer surface. The arrangement of the VP6 trimers form 
channels that run through this layer in accordance with the channels observed in the outer 
shell (Yeager et al., 1990). 
Beneath VP6 there is the single-shelled `core' (255A in mean diameter) 
composed of 180 molecules of the VP2 protein which follows the same T=131 icosahedral 
symmetry as VP6 (Yeager et al., 1990). In fact, empty VP2 particles, formed in insect 
cells infected with recombinant baculovirus containing rotavirus gene 2, showed that this 
layer could be made up of three VP2-related proteins [of molecular weights 94,85 and 77 
kilodaltons (kDa)] due to expression of truncated forms of VP2 (Zeng et al., 1994). 
Beneath the VP2 layer, there is speculation that a further structural entity exists 
`the subcore' which is composed of the VPl and VP3 minor proteins and the genome 
RNA (Prasad and Chui, 1994). 
1.4 THE ROTAVIRUS GENOME 
The rotavirus genome consists of 11 dsRNA segments which can be separated by 
polyacrylamide gel electrophoresis and the total average size of the genome is 18,550 base 
pairs (bp) (Desselberger and McCrae, 1994). The genome segments have conserved 
terminal sequences (5'.... GGCA/UA/UUA/UAA/UA/u.... 3' and 5'.... 
A/UUG/UU/o`'/UA/GCC.... 3' 
for the 5' and 3' ends, respectively) (Imai et al., 1983; McCrae and McCorquodale, 1983) 
and short non-coding sequences (up to 50 bp and 185 bp for the 5' and 3' ends, 
respectively) (Desselberger and McCrae, 1994). The conserved 5' end of all the genes 
6 
contains a cap (5' m'GpppG(m)GC.... 3') and all the genes are A+U rich (58 to 67%). The 
genes, however, have no 3'-terminal poly(A) tails (Imai et al., 1983; McCrae and 
McCorquodale, 1983). The untranslated 5' and 3' primary sequences and secondary 
structures may serve as recognition signals for the RNA binding proteins involved in RNA 
expression, synthesis and packaging (Clarke and McCrae, 1982). With one exception 
(gene 11), the genes have one reading frame and, in most cases, use the first initiation 
codon. 
1 .5 PROPERTIES OF ROTAVIR PROTEINS 
1.5.1 Rotavirus protein nomenclature 
The nomenclature of rotavirus proteins changes frequently and in this thesis the proteins 
will be named as viral proteins (VP) followed by a number of the structural protein, and 
non-structural (NS) proteins followed by a number indicating the molecular weight on gels 
(in thousands) (Mason et al., 1983; Liu et al., 1988). Where possible the order of proteins 
in this thesis relates directly to the genome pattern (i. e. gene 1 (VP1), 3302 bp through to 
gene 11 (NS26), 667 bp), however, it should be noted that RNA segments 7 to 9 (and also 
10 and 11) have differing migration patterns depending on the rotavirus strain. The 
following gene-protein assignment is that for the bovine rotavirus strain UKtc. 
1.5.2 Gene segment 1 (VP1) 
Gene 1 (3302 bp) encodes the VP1 structural protein (125 kDa) which is a minor 
component of the virion core and comprises 2% of the virion mass (Liu et al., 1988). The 
protein shows a high level of homology between different strains, 96% at the protein level 
(Both et al., 1994). 
There is evidence to suggest that VP1 is the viral RNA-dependent RNA 
polymerase in that it has conserved sequence homologies (between amino acids 517 and 
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636) to genes encoding putative RNA polymerases of other viruses (Cohen et al., 1989). In 
addition, VPI becomes cross-linked by the nucleotide analogue [(x- 32 P] azide-ATP in the 
presence of ultra-violet (UV) light and viral mRNA synthesis was decreased (Valenzuela 
et al., 1991). 
1.5.3 Gene segment 2 (VP2) 
Gene 2 (2691 bp) encodes the VP2 structural protein (94 kDa) which is the major 
component of the single-shelled virion core and comprises 12 to 15% of the virion mass 
(Liu et al., 1988). The protein shows a high level of homology between different strains, 
91% at the protein level (Both et al., 1994), and is accessible to VP2-specific antibodies 
even as a component of the double-shelled particle (Taniguchi et al., 1986). 
The conserved amino acid residues between 535 to 556 and 666 to 687 of the 
NH2-terminal half of VP2 contain leucines every seventh position which are hypothesised 
to form a `leucine zipper', a structure believed to be involved in the dimerisation of 
nucleic acid binding proteins (Kumar et al., 1989). Temperature sensitive (ts) mutants 
suggest the protein region around amino acid 387 may be involved in core assembly 
(Mansell et al., 1994). 
VP2 has been suggested to exhibit dsRNA replicase activity since VP2 core-like 
particles are the simplest structures that can bind and synthesise dsRNA (Mansell and 
Patton, 1990; Labbe et al., 1991). The use of baculovirus expressing truncated VP2 
proteins by Labbe et al. (1994) localised the non-specific nucleic acid binding domain 
between amino acids 1 to 132 and showed higher affinity binding of ss- than dsRNA and 
DNA. These experiments also revealed UV cross-linking of genomic RNA to only the 
VP2 protein in double-shelled particles and it was speculated that VP2 may package viral 
mRNA into the core during replication. 
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1.5.4 Gene segment 3 (VP3) 
Gene 3 (2591 bp) encodes the VP3 structural protein (88 kDa) which is a minor 
component of the virion core and comprises 0.5% of the virion mass (Liu et al., 1988). 
VP3 is thought to be the viral guanylyltransferase responsible for RNA capping 
due to the specific and reversible binding of GTP (Pizarro et al., 1991; Liu et al., 1992). 
1.5.5 Gene segment 4 (VP4) 
Gene 4 (2362 bp) encodes the VP4 structural protein (88 kDa) which is a minor 
component of the outer capsid and comprises 1.5% of the virion mass (McCrae and 
McCorquodale, 1982; Liu, et al., 1988). 
Dimers of VP4, as described in section 1.3, form the 60 spike like structures on 
the surface of the virion. Proteolytic cleavage of VP4 into VP5* (60 kDa) and VP8* (28 
kDa) occurs at amino acid sites arginine (Arg)-241 and Arg-247 releasing six nucleotides 
(Lopez et al., 1985). Arg-241 and Arg-247 are conserved between virus isolates, however, 
considerable amino acid variation occurs between, and adjacent to, the cleavage sites 
(Lopez et al., 1986) and this region of VP4 has been speculated to influence rotavirus 
virulence. 
VP4 has a number of important characteristics being the viral hemagglutinin 
(Fuetes-Panana et al., 1995) and carrying neutralising antibody epitopes (Hoshino et al., 
1985). (For an analysis of VP4 serotypes the reader is referred to section 1.7.3). There is 
evidence to suggest that VP4 has an important role in the growth and virulence of 
rotavirus in vitro (Burke et al., 1994; Taniguchi et al., 1994), but in vivo studies show 
conflicting results as to its involvement in rotavirus virulence (Flores et al., 1986; Broome 
et al., 1993). 
There is some debate as to the identity of the cell attachment protein of rotavirus 
(there being evidence in favour of both VP4 and VP7) and the argument for VP4 will be 
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discussed here. There appeared to be two routes of uptake of rotavirus, endocytosis and 
direct penetration (Suzuki et al., 1985), however, Kaljot et al. (1988) stopped endosomal 
formation with no decrease in virus yield. This result suggested a limited role for 
endosomal uptake and complemented the proposed fusion domain sequences found 
between amino acids 137 and 154 of VP5* (Mackow et al., 1988b). Neutralising antibody 
epitopes also map to this region of VP5* (Mackow et al., 1988b) although actual virus 
attachment was blocked by neutralising antibodies to VP8* (and not to VP5*) (Ruggeri 
and Greenberg, 1991). In addition, baculovirus expressed proteins forming virus-like 
particles (VLPs) indicated VP4 to be the viral attachment protein (Crawford et al., 1994), 
a conclusion also reached by Ludert et al. (1996) using reassortment viruses containing 
VP4 of different parental strains (which differ in their requirement for sialic acid during 
binding). 
1.5.6 Gene segment 5 (NS53 or NSPI) 
Gene 5 (1581 bp) encodes the NS53 non-structural protein (53 kDa) (Mason et al., 1983). 
The protein shows variable levels of amino acid conservation (34 to 96%) with the greatest 
diversity between strains of different species (Xu et al., 1994). 
The function of NS53 is still unclear, however, the protein does contain a 
conserved sequence motif between amino acids 37 and 81 encoding a metal binding 
domain (Xu et al., 1994). Proteins containing metal binding domains are known to 
associate with nucleic acids and, indeed, NS53 has been shown bind to all 11 rotavirus 
mRNAs (Hua et al., 1994). NS53 is present throughout the cytoplasm in association with 
cytoskeleton and there is evidence to suggest that NS53 binds to the 5' end of the rotavirus 
mRNA (Hua et al., 1994). It is speculated that NS53 may redirect the mRNA towards 
encapsulation and particle formation, rather than protein translation. 
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1.5.7 Gene segment 6 (VP6) 
Gene 6 (1356 bp) encodes the VP6 structural protein (41 kDa) which is the most abundant 
component of the virion, comprising 50% of the virion mass (Liu et al., 1988). 
VP6 is the outer protein of the double-shelled virus particle and occurs as a 
trimer (see section 1.3). VP6 contains both the group-specific antigens and sub-group A- 
specific antigens as detailed in section 1.7.1. In addition, Chen and Ramig (1993) showed 
that the transcriptase activity of the double-shelled particle is dependent on the presence of 
VP6. 
The VP6 protein of the double-shelled viral particle binds to the NS28 protein 
spanning the rough endoplasmic reticulum (RER) membrane prior to the budding of the 
particle into the lumen of the RER during the assembly process (Au et al., 1989; Meyer et 
al., 1989; Suzuki et al., 1993). The region of the VP6 protein which binds with NS28 is 
not known but is speculated to be conserved between rotavirus strains (Meyer et al., 1989). 
1.5.8 Gene segment 7 (NS35 or NSP2) 
Gene 7 (1059 bp) encodes the NS35 non-structural protein (35 kDa) (McCrae and 
McCorquodale, 1982; Mason et al., 1983) which is associated with viroplasms in infected 
cells (Petrie et al., 1984). 
NS35 is thought to be essential for genome packaging and replication since 
viruses carrying a is mutation in the corresponding gene produce RNA deficient particles 
at. the restrictive temperature (Ramig and Petrie, 1984; Gombold et al., 1985). More 
recently, NS35 has been shown to have a non-specific RNA binding capability (Kattoura 
et al., 1992) and to form IOS multimers, probably consisting of 6 to 8 copies of the 
protein, during infection of the cell (Kattoura et al., 1994). 
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1.5.9 Gene segment 8 (VP7) 
Gene 8 (1062 bp) encodes the VP7 structural glycoprotein (34 kDa) which is the major 
component of the outer capsid and comprises 30% of the virion mass (Both et al., 1983; 
Liu et al., 1988). The VP7 protein of almost all rotavirus strains is high mannose 
glycosylated at amino acid 69 and the protein has three other potential glycosylation sites 
at amino acids 146,238 and 318 (Both et al., 1994). VP7 also contains neutralising 
antibody antigens which are detailed in section 1.7.2. 
The gene contains two initiation codons in the same open reading frame (ORF) 
encoding for proteins 326 and 286 amino acids in length and, although the second 
initiation codon has a stronger consensus sequence, both proteins are detected in infected 
cells (Chan et al., 1986). Both VP7 proteins start with hydrophobic signal sequences (H1 
and H2) which may direct the nascent VP7 to the RER and both signal sequences appear to 
be cleaved at amino acid 51 (Stirzaker et al., 1987). The mechanism responsible for 
retaining the mature VP7 protein in the RER is not known. The H2 signal peptide and the 
first 31 amino acids of the mature VP7 protein have been shown to be involved in this 
process (Maass and Atkinson, 1994). However, because the uncleaved VP7 precursor has 
not yet been identified in cells (Stirzaker and Both, 1989), it has been speculated that 
retention involves the cleaved H2 signal peptide interacting with the first 31 amino acids 
of the mature VP7 protein. 
As mentioned in section 1.5.5, the identity of the cell attachment protein of 
rotavirus is debated, there being evidence in favour of both VP4 and VP7. VP7 is believed 
to be the cell attachment protein because purified VP7 binds to cells and, indeed, binding 
of infectious virus was inhibited by both monoclonal antibodies directed to VP7 and by 
competitive inhibition using the purified VP7 protein (Sabara et al., 1985, Fukuhara et al., 
1988). 
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1.5.10 Gene segment 9 (NS34 or NSP3) 
Gene 9 (1104 bp) encodes the NS34 non-structural protein (34 kDa) (Mason et al., 1983), 
however, its function is still unknown. 
NS34 was found to be associated with the cytoskeleton of the infected cell 
(Mattion et al. 1992) and to bind to the conserved 3' terminal mRNA sequences in a 
rotavirus group specific manner (Poncet et al., 1994). Poncet et al. (1994) suggested a role 
for NS34 in the assembly of the 11 viral mRNAs during precore formation. 
1.5.11 Gene segment 10 (NS28 or NSP4) 
Gene 10 (751 bp) encodes NS20 which is post-translationally glycosylated forming the 
NS28 non-structural protein (28 kDa) (McCrae and McCorquodale, 1982; Mason et al., 
1983). 
Three amino-terminal hydrophobic regions (H1 to H3 between amino acids 7 to 
21,28 to 47 and 67 to 85, respectively) anchor the protein to the RER, H2 spanning the 
membrane, and HI containing two high mannose glycosylation sites (within RER lumen). 
The carboxyl-terminal half of NS28 protrudes into the cytoplasm of the cell (Bergmann et 
al., 1989). 
Membrane anchored NS28 is involved in particle maturation and binds double- 
shelled particles via the VP6 protein with an affinity constant of 4.6 X 10-11 M. The 
tetrameric nature of NS28 and the trimeric nature of VP6 suggests a co-operative 
interaction between many receptors leading to the relatively high affinity constant (Taylor 
et al., 1993). A region of the NS28 protein critical for the binding of the double-shelled 
particle was located between amino acids 161 to 172 and binding was also highly 
dependent on the conformational integrity of the carboxyl-terminus (Au et al., 1993). 
NS28 also forms oligomeric structures with VP4 and VP7 during particle budding and 
assembly (Maass and Atkinson, 1990). 
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1.5.12 Gene segment 11 (NS26/NS12 or NSP5/NSP6) 
Gene 11 (667 bp) contains two initiation codons in different ORFS and encodes two non- 
structural proteins. The larger protein, NS26 (26 kDa), is phosphorylated and modified by 
the addition of O-linked N-acetylglucosamine monosaccharide residues which increase the 
molecular weight of the protein (28 kDa) (Welch et al., 1989; Gonzalez and Burrone, 
1991). The smaller protein, NS 12 (11 kDa), has also been shown to be expressed in 
infected cells (Mattion et al., 1991). The functions of the NS26 and NS 12 proteins remain 
unclear. 
Gene 11 from different rotavirus strains has been found to exhibit differing 
migration patterns following RNA gel electrophoresis (long, short and super-short) and 
this is due to gene rearrangements (see section 1.6.3) (Nuttall et al., 1989). 
1.6 ROTAVIRUS GENETIC DIVERSITY 
Section 1.5 describes the rotavirus genome consisting of eleven segments of dsRNA 
encoding twelve individual viral proteins. Sequence analysis of individual genes from 
rotaviruses isolated world-wide shows that genetic variation exists. The variation is 
thought to arise from three distinct mechanisms: point mutation, reassortment and 
rearrangement. Variation in the viral proteins involved in stimulating the hosts immune 
response may present an additional obstacle in the development of an effective vaccine. 
1.6.1 Point mutation 
The sequential accumulation of point mutations has not yet been observed in rotavirus 
isolates obtained from sequential epidemic seasons (Palombo et al., 1993). In theory, 
however, each rotaviral protein is subjected to varying host immune selection pressures 
and thus mutation frequencies. Resistant rotavirus mutants generated in vitro by culturing 
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the virus in the presence of monoclonal antibodies have provided an estimated mutation 
rate for the two outer capsid antigens (VP4 and VP7) of approximately 10'5 base 
substitutions per position per virus generation (Taniguchi and Urasawa, 1995). Host 
immune selection pressures may also act on the NS53 protein since gene 5 shows a great 
genetic diversity among strains from different species (Xu et al., 1994). However, being a 
non-structural protein, an antibody-mediated immune selection pressure would seem 
unlikely and, in fact, a cell-mediated immune response may provide the selection pressure 
(S. Stagg, personal communication). 
1.6.2 Reassortment 
Coinfection of mice with two different rotavirus strains resulted in 80 to 100% of the 
progeny virus containing assortments of gene segments by 96 hours post infection, 
however, gene segments 3 and 5 were found to segregate at a relatively low frequency 
(Gombold and Ramig, 1986). The co-segregation of certain genes was also found between 
gene 6 and gene 11 (Kobayashi et al., 1994) and the implication is that the rotavirus 
genome is adapted for optimal function as a group. 
It is not known how the assortment and packaging of viral RNA segments is 
regulated, although, there is speculation that the 5' and 3' untranslated regions may serve 
as recognition signals for the RNA binding proteins involved in this process. However, 
sequence diversity in the 5' and 3' untranslated regions is minimal and, consequently, the 
co-segregation of certain genes during rotavirus coinfection cannot be explained by 
sequence divergence in these regions (Clarke and McCrae, 1982). Interestingly, the host 
can also affect the reassortment frequency of specific genotypes which was discovered by 
comparing reassortment experiments in different cell lines (Graham et al., 1987). 
The phenotype of a reassortant virus is unpredictable because the background 
proteins of the recipient can influence the structure of the donor protein (Chen et al., 1989; 
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Dunn et al., 1994). For example, Chen et al. (1992) found using reassortants that the 
presence of a neutralising epitope on VP4 depended on the VP7 background. Therefore, 
reassortment could, in theory, lead directly to new serotypes since VP4 and VP7 appear to 
influence the conformation of each other and their antigenic sites. 
Ramig (1990) showed that a second viral infection of a cell line, twenty-four 
hours after the first, still resulted in the formation of reassortants. This absence of 
superinfection exclusion increases the potential for reassortment in the natural 
environment. In addition, natural rotavirus coinfections appear to be more frequent in 
developing countries than in more developed countries. For example, from 1986 to 1992, 
nineteen percent of patients showed coinfections in Brazil compared with just 1% of 
patients in Hungary (Timenetsky et al., 1994; Szucs et al., 1995). This may be due to 
lower levels of hygiene and frequent overcrowding in the developing countries. Although 
there is a potential in the natural environment for the appearance of new rotavirus strains 
by reassortment (Matsuno et al., 1988; Shif et al., 1994), the emergence and rapid spread 
of highly virulent rotavirus strains (as seen with the pandemic strains of influenza virus) 
has yet to be observed. 
1.6.3 Rearrangement 
Various rotavirus genes (5,6,8,10 and predominantly 11) can undergo rearrangements 
which, after polyacrylamide gel electrophoresis, are characterised by the RNA segment 
being missing from its normal position or by the appearance of additional dsRNA bands. 
This phenomenon has been detected in the natural infections of many animal species 
(Mattion et al., 1988; Tanaka et al., 1988; Scott et al., 1989), immunocompromised 
humans (Pedley et al., 1984; Hundley et al., 1987) and following the serial high passage of 
rotavirus in tissue culture cells (Hundley et al., 1985). 
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Examples of gene rearrangements include the UKtc variant P9D05 which has a 
shorter genome segment 5 due to a 308 base pair deletion starting at 460 bp which leads to 
a frame shift and to the generation of a premature stop codon a further 24 bp downstream 
of the deletion. A truncated form of NS53 consisting of the first 150 amino acids is 
encoded (Tian et al., 1993). The enlarged genome segment 10 of a rotavirus isolated from 
an immunodeficient child showed a partial duplication of the open reading frame (ORF) 
inserted immediately after the termination codon (Ballard et al., 1992). It has been 
speculated that this type of change in the viral genome is generated by the virus-associated 
RNA-dependent RNA polymerase falling back on its template during replication. 
The genes encoding the outer capsid proteins, which independently stimulate 
neutralising antibodies, have not been found to undergo rearrangement and, in fact, all 
affected genes found to-date have encoded non-structural proteins. However, since it 
appears that non-structural proteins (specifically NS53) stimulate cell-mediated immune 
responses (S. Stagg, personal communication) and viruses with genome rearrangements 
are not defective, this mechanism of variation has the potential to influence the 
antigenicity of the virus. It should be noted, however, that many of the rearrangements do 
not affect the coding potential of the genes concerned. 
ROTAVIRUS GROUP WUT AND SEROTYP 
1.7.1 VP6 contains the group and subgroup specific antigens 
VP6 is the major protein of the rotavirus particle, it is highly immunogenic but results in 
the production of non-neutralising antibodies (Svensson et al., 1987a/b). Initial serological 
studies identified that rotaviruses from diverse species shared common antigens which 
resided on VP6 (named `conventional' viruses) (Woode et al., 1976). More recently, 
rotaviruses lacking the common group antigen were identified and, consequently, the 
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viruses were separated into groups, A (the conventional viruses) to E, depending on their 
distinctive common antigen (Pedley et al., 1983/1986). 
The group A rotaviruses are a common cause of enteric disease in the young of 
most species. However, although non-group A rotaviruses have been identified in both 
humans and many animal species, the prevalence and significance of non-group A 
rotavirus infections still remains unclear. A description of the non-group A rotaviruses is 
beyond the scope of this thesis but a detailed review has recently been published by Saif 
and Jiang (1994). 
Subgroup determinants are also located on VP6 which divide group A 
rotaviruses into subgroup I (most animal and certain human rotavirus strains), subgroup II 
(most human and a few porcine and lapine' rotavirus strains), subgroup I and II (rare 
human or animal rotavirus strains) and neither subgroup I or II (rare human and animal 
strains and most avian rotavirus strains) (Kapikian et al., 1981; Hoshino et al., 198,7) (see 
Table 1). 
VP6 group specificity is thought to be determined by continuous determinants 
(Gorziglia et al., 1988). Sequence analysis has revealed four conserved VP6 regions 
(between amino acids 66 to 79,102 to 113,133 to 144 and 352 to 374) which may contain 
group epitopes (Ito et al., 1995). Studies using VP6 monoclonal antibodies against a panel 
of consecutive VP6 heptapeptides also identified four antigenic regions on VP6, but, in 
different locations from the aforementioned study (amino acids 32 to 64,155 to 167,208 
to 274 and 380 to 397) (Kohli et al., 1993). 
The subgroup specificity is thought to be determined by conformational epitopes 
which are present on the trimeric, but not the monomeric, VP6 (Gorziglia et al., 1988; 
Liprandi et al., 1990). Regions of VP6 that have been speculated to be part of the subgroup 
specific antigenic site(s) include: twelve conserved amino acids grouped into five regions 
(Gorziglia et al., 1988), conserved amino acids at positions 120,317 and 350 (Ito et al., 
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Table 1. P serotype (Y I! 4 genotype). G serotype and subgroup of human and animal 
group A rotaviruses. From Hoshino and Kapikian (1994) and Taniguchi and Urasawa 
(1995). 
VP4 
genotype 
VP4 (P) 
serotype 
Rotavirus Strain VP7 (G) 
serotype 
VP6 Subgroup Host 
species 
1 P6 NCDV, J2538, C486 G6 1, I, ? Calf 
P6 A5 G8 ? Calf 
P6 SAI I (4FEM, 4F, 4fM) G3 I Monkey 
2 ? SAIL (4SEM, TN-L2, TN-S1) G3 I Monkey 
3 P5 RRV G3 I Monkey 
? K9, CU-1 G3 I Dog 
? Cat97 G3 I Cat 
? HCR3 G3 I Human 
4 P1B DS-1, RV-5, S2 G2 I Human 
PIB L26 G12 I Human 
5 P7 Uktc, B641, IND, OK G6 I Calf 
P7 61A G10 I Calf 
6 P2A M37 GI 11 Human 
P2A 1076 G2 I Human 
P2A McN13, RV-3, WCN G3 II, II, ? Human 
P2A ST-3 G4 11 Human 
P2B Gottfried G4 II Pig 
7 P9 OSU, TRF-41 G5 I Pig 
P9 YM, A243.1 Gil I Pig 
P9 CRW8, Ben-307 G3 I, ? Pig 
P9 BMI-1, SB-lA G4 ?, II Pig 
8 P1A KU, Wa G1 II Human 
P1A P, YO, MO G3 II Human 
PIA VA70, Hochi, Hosokawa G4 II Human 
P1A WI-61, F45 G9 II Human 
9 P3A K8 G1 II Human 
P3A AU-1 G3 I Human 
P3A PA151 G6 I Human 
P3B Mc35 G10 I Human 
P3A Cat2, FRV-1 G3 I Cat 
10 P4 57M G4 II Human 
P4 69M G8 I Human 
11 P8 B223, A44, KK3, B-11, Cr GIO I, ?, I, I, I Calf 
P8 116E G9 I Human 
P8 1321 G 10 I Human 
12 ? H2, FI-14 G3 not I or 11,1+11 Horse 
? F123 G14 I Horse 
13 ? MDR13 G3 ? Pig 
14 P313 Mc35 G10 I Human 
15 ? Lp14 G10 ? Sheep 
16 P10 Eb G3 I Mouse 
17 ? 993/83 G7 ? Calf 
18 P11 PA169 G6 I Human 
P11 HAL1166 G8 ? Human 
19 ? L338 G13 I Horse 
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1995) and, with the use of mutants, amino acids at positions 172 and 305 (Lopez et al., 
1994). 
1.7.2 VP7 contains the G serotype specific antigens 
VP7 comprises the smooth layer of the outer shell of the rotavirus virion and contains 
major neutralising epitopes. To date, fourteen distinct G (for glycoprotein) serotypes have 
been defined for group A rotaviruses (see Table 1) and nine of the G serotypes have been 
identified in humans, most commonly GI to G4 (Beards et al., 1992; Gerna et al., 1992; 
Woods et al., 1992). 
Initial studies mapping the regions of VP7 involved in neutralisation applied the 
sequencing of the gene encoding VP7 from rotavirus mutants resistant to neutralising 
monoclonal antibodies (Dyall-Smith et al., 1986; Mackow et al., 1988a). This work 
suggested that three regions on VP7 determined the binding of serotype-specific 
neutralising antibodies (between amino acids 87 to 96,145 to 150 and 211 to 223, termed 
A, B and C, respectively) and that regions A and C were in close proximity in the native 
glycoprotein, thus forming a conformational domain. In fact, the conformation of VP7 
(conserved cysteine residues forming disulphide bonds) has been shown to be important 
for functional neutralisation epitopes (Svensson et al., 1994). Further analysis of eight 
serotypically distinct VP7 amino acid sequences identified nine variable regions (VR1 to 
VR9) of which VR5, VR7 and VR8 (between amino acids 87 to 101,142 to 152 and 208 
to 221, respectively) corresponded to the regions A, B and C (Green et al., 1989). 
Subsequently, it was shown that the majority of serotype-dependent neutralisation sites 
were located in VR5, VR7 and VR8 and, in addition, VR5 also contained the majority of 
serotype-independent neutralisation sites (Mackow et al., 1988a; Taniguchi et al., 1988a; 
Coulson and Kirkwood, 1991; Kobayashi et al., 1991a/b). 
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1.7.3 VP4 contains the P serotype specific antigens 
The VP4 protein forms the spikes which protrude from the outer shell, is the viral 
hemagglutinin and, like VP7, contains major neutralising epitopes. The VP4 and VP7 
neutralising antigens segregate independently of each other (Offit et al., 1986a). Eleven 
VP4 P (for protease) serotypes have been distinguished to-date and serotypes I to 3 are 
further distinguished into subtypes A and B depending on critical amino acid substitutions 
(see Table 1) (Gorziglia et al., 1990a). However, the P serotypes are difficult to 
differentiate serologically and, consequently, comparative VP4 amino acid homology 
sequence analysis (named `the VP4 genotype') is used to aid differentiation (Estes and 
Cohen, 1989). To-date, nineteen distinct VP4 genotypes have been defined for group A 
rotaviruses and nine of the VP4 genotypes have been identified in humans. Genotypes 4,8 
to 10 and 14 have been found to be most commonly associated with symptomatic 
infections (see Table 1) (Qian and Green, 1991; Das et al., 1993). 
Initial studies mapping the regions of VP4 involved in neutralisation applied the 
sequencing of gene 4 from rotavirus mutants resistant to neutralising monoclonal 
antibodies (Mackow et al., 1988b; Taniguchi et al., 1988b; Gorziglia et al., 1990b; 
Kobayashi et al., 1991c). This work identified that most VP4 amino acid substitutions 
generated by serotype-dependent antibodies mapped to the large hypervariable region in 
the VP8* subunit (between amino acids 92 and 192), whereas, amino acid substitutions 
generated by cross-neutralising antibody mapped to the conserved VP5* subunit (between 
amino acids 388 and 441). The binding of neutralising antibodies to synthetic peptides (18 
to 21 amino acids in length), corresponding to the regions around the position where each 
mutant had sustained its amino acid substitutions, suggested that some of these regions 
contained conformational epitopes and others contained linear epitopes (Taniguchi et al., 
1988b). 
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1.8 EPIDEMIOLOGY OF ROTAVIRUS INFECTION 
Rotaviruses are transmitted by the faecal-oral route (Ward et al., 1986). The world-wide 
distribution of the virus leads to the universal acquisition of rotavirus-specific serum 
antibody in 90% of all populations by the end of the third year of life and high rotavirus- 
specific serum antibody levels are maintained into adult life (Echeverria et al., 1983; 
Brussow et al., 1988). 
As mentioned in section 1.7, nine VP7 (G) serotypes have been found in humans, 
GI to G4 being most common and, in addition, nine VP4 genotypes have been detected in 
humans, VP4 genotypes 4,8 to 10 and 14 being frequently associated with disease. The 
VP4 and VP7 proteins can segregate independently of each other (Offit et al., 1986a), 
however, there is a correlation between the G serotype and the VP4 genotype of the 
circulating viruses (Timenetsky et al., 1994). Several G serotypes can co-circulate in a 
community (Gomez et al., 1990; Padilla-Noreiga et al., 1990) and initial studies suggest 
that a similar co-circulation of VP4 genotypes exists (Das et al., 1994; Timenetsky et al., 
1994). 
In general, the epidemiological patterns of rotaviruses are very complex and the 
predominating serotype circulating within a given population appears to change over time. 
To-date, no clear patterns of change which would permit predictions of the predominant 
serotypes have been discovered. In addition, the genetic processes driving the antigenic 
change are not known, however, mechanisms such as sequential point mutations in the 
antigenic regions of the genes encoding VP4 and VP7 (see section 1.6.1) and reassortment 
of the rotaviral genome (see section 1.6.2) are thought to be involved. Interspecies 
transmission of rotavirus to humans has also been indicated by the appearance of unusual 
G serotypes and VP4 genotypes in humans which are normally limited to a particular 
animal rotavirus strain (Nakagomi and Nakagomi, 1989; Das et al., 1993). 
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It should be noted that, unlike circulating strains within the community, rotavirus 
strains circulating in new-born nurseries often persist for many years with little diversity 
(Rodger et al., 1981; Perez-Schael et al., 1984). 
1.8.1 Serotypic diversity in developed countries 
Developed countries tend to display a repetitive pattern of rotavirus infection (due to their 
temperate locations) with peaks occurring in the cooler months of the year (Kapikian et 
al., 1976). Epidemiological studies by Masendycz et al. (1994) in Australia showed that 
the serotypic diversity increases as the rotavirus season advances and that major cities 
have a greater diversity of serotypes than rural communities. In the United States, 
rotavirus diarrhoea is seen to spread yearly starting from Mexico (and the Southwest) and 
ending in the Northeast (Ho et al., 1988). 
In the 1970's the G2 serotype was predominant in Australia (Bishop et al., 1991) 
and was thought to be predominant in much of Europe during this time (Maunula and 
Bonsdorff, 1995). However, the G1 serotype has predominated in most of the developed 
world during the 1980's/early 1990's (Beards et al., 1989; Gouvea et al., 1990; Bishop et 
al., 1991; Maunula and Bonsdorff, 1995) although it should be noted that the GI subtype 
varies seasonally (Bishop et al., 1991). Epidemic occurrences of the G4 serotype are 
common in the developed world (Beards et al., 1989; Maunula and Bonsdorff, 1995) and 
an Australia study showed that the G4 serotype had an episodic pattern of appearance, 
with peak incidences approximately every three years (Bishop et al., 1991). The G2 and 
G3 serotypes have generally been the least prevalent serotypes in the developed world 
during the 1980's/early 1990's and unpredictable in occurrence (Beards et al., 1989; 
Bishop et al., 1991; Maunula and Bonsdorff, 1995). Conversely, the G3 serotype was the 
most prevalent serotype in Houston during the 1987-1988 season, although, the G1 
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serotype was predominant in all the other American cities studied at that time (Gouvea et 
al., 1990; O'Ryan et al., 1990). 
Initial studies on the distribution of VP4 genotypes indicated that VP4 genotype 
8 was the most frequent, followed by genotype 4, among 400 samples collected from 
many areas of the world (Steele et al., 1993). Recently, studies by Santos et al. (1994) 
found that the GI serotype (VP4 genotype 8) predominated in the United States followed 
closely by the G3 serotype (VP4 genotype 8). 
1.8.2 Serotypic diversity in developing countries 
In developing countries, the GI to G4 serotypes are distributed more equally than in 
developed countries, albeit, that the G1 serotype is again often predominant (Gomez et al., 
1990; Padilla-Noriega et al., 1990). Similarly to the situation found in developed 
countries, the G3 or G4 serotypes can be predominant in developing countries (Brussow et 
al., 1990; Timenetsky et al., 1994). 
Natural rotavirus coinfections appear to be more frequent in developing countries 
than in the more developed countries, for example, from 1986 to 1992, nineteen percent of 
patients showed coinfections in Brazil compared with just 1% of patients in Hungary 
(Timenetsky et al., 1994; Szucs et al., 1995). This may be due to lower levels of hygiene 
and frequent overcrowding in the developing countries. In addition, the appearance of G 
serotypes and VP4 genotypes in humans which are normally limited to a particular animal 
rotavirus strain (Nakagomi and Nakagomi, 1989; Das et al., 1993) has been speculated to 
be a result of interspecies transmission. Indeed it is thought that interspecies transmission 
may occur more frequently in developing countries due to a closer contact of humans with 
animals. Consequently, it has been suggested that genetic reassortment within the host and 
interspecies transmission leads to the complex serotypic diversity of rotavirus strains seen 
in developing countries. 
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The serotypic diversity of rotavirus strains in developing countries has been 
observed in both the G serotypes and VP4 genotypes. For example, in addition to the GI to 
G4 serotypes, the G5 serotype was found to be associated with diarrhoea in Brazilian 
children during the 1980's (Gouvea et al., 1994) and an asymptomatic rotavirus G9 
serotype was predominant between 1986 and 1993 in new-borns from New Delhi, India 
(Das et al., 1994). VP4 genotype 8 is believed to be the most prevalent, followed by VP4 
genotype 4, in many areas of the world (Steele et al., 1993), however, unusual VP4 
genotypes 6 and I1 (both serotype G9) were predominant in new-borns from New Delhi, 
India between 1986 and 1993 (Das et al., 1994). In addition, although VP4 genotype 8 (in 
association with serotypes GI and G3) was predominant in Sao Paulo, Brazil from 1986 to 
1992, VP4 genotypes 3,4 and 6 were frequently linked with disease and each was 
associated with at least two different GI to G4 serotypes (Timenetsky et al., 1994). 
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CHAPTER 2 
THE CTL AND ITS ROLE IN THE IMMUNE RESPONSE 
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2.1 INTRODUCTION 
Major histocompatibility (MHC) class I and class II molecules are highly polymorphic cell 
surface proteins which present antigenic peptides to the thymus-educated (T)-lymphocytes 
of the immune system. They allow the differentiation of 'self' rom `non-self' so that 
defence mechanisms are normally directed towards virus infected cells, tumours, 
transplants and other foreign molecules without causing damage to host tissues (Madden, 
1995). Naive T-lymphocytes are educated to differentiate between MHC molecules 
containing peptides derived from `self or `non-self proteins by processes of positive and 
negative selection in the thymus (Allen, 1994). The two classes of MHC are similar at 
both the genomic and structural level (Jackson and Peterson, 1993; Wolf and Ploegh, 
1995). However, MHC class I molecules are found on most cell types and express peptides 
derived from intracellular proteins (including viral proteins) (Jackson and Peterson, 1993), 
whereas, MHC class II molecules are restricted to bursa-derived (B)-lymphocytes 
(antibody producing) and specialised antigen presenting cells (APCs), and express 
peptides derived from endocytic compartments (Wolf and Ploegh, 1995). 
Cytotoxic T-lymphocytes (CTLs), which express the CD3+ and CD8+ clusters of 
differentiation (CD) molecules, only recognise antigen in association with MHC class I 
molecules. CTLs destroy cells displaying `non-self antigens and are, therefore, central in 
combating intracellular pathogens (Jackson and Peterson, 1993). The other major subset of 
T-lymphocytes, T helper (Th)-lymphocytes, which express CD3+ and CD4+, only 
recognise antigen in association MHC class II molecules. Th-lymphocytes are regulatory 
cells which control the development and function of effector cells (Mosmann and 
Coffman, 1989). In some cases, however, the functions of the T-lymphocyte subsets 
overlap. CTLs are capable of secreting cytokines and controlling B-lymphocyte antibody 
production in vitro (Erard et al., 1993) and Th-lymphocytes can lyse target cells utilising a 
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perforin-dependent, antigen-specific cytotoxic mechanism (Williams and Engelhard, 
1996). 
2 .2 OVERVIEW 
OF T-LYMPHOCYTES IN VIRAL INFECTION 
2.2.1 CTLs are critical for clearing many viral infections 
The immune response to virus infection is still not completely understood and the 
underlying mechanisms leading to virus clearance are still under debate. Indeed, this is not 
surprising considering the fact that viruses differ greatly in their route of entry, site of 
replication, and escape of immune surveillance and release. The cell-mediated immune 
response to viruses is considered to be very important in the clearance of many primary 
viral infections. Studies have shown that the adoptive transfer of virus-specific CTLs into 
a host infected with homologous virus is sufficient to clear virus infection. For example, 
transferred CTLs appeared sufficient to clear murine cytomegalovirus (MCMV) from the 
lungs of immunocompromised mice (Reddehase et al., 1985/1987b) and prevent mortality 
of normal mice from high virulence strains of influenza virus (Bender et al., 1992). 
Transferred CTLs were also speculated to prevent cytomegalovirus (CMV) infection in 
immunodeficient humans (Riddell et al., 1992). The influenza virus-specific CTL response 
has been shown to be subtype-independent in vitro and to contribute to heterotypic virus 
clearance in vivo (Biddison et al., 1979; Liang et al., 1994). Serotype-independent CTL 
responses have been found in many virus systems including respiratory syncytial virus 
(RSV), lymphocytic choriomeningitis virus (LCMV) and human immunodeficiency virus 
1 (HIV-1) (Bangram and Askonas, 1986; Whitton et al., 1988a/b; Casement et al., 1995). 
The important role of CTLs in controlling virus infection was highlighted by 
studies on HIV-1 infection in humans. The transient control of HIV-1 replication in the 
early clinical latent phase correlates to a vigorous polyclonal CD8+ CTL response 
(Carmichael et al., 1993: Borrow et al., 1994). However, both the HIV-1-specific CTL and 
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the Th-lymphocyte count is decreased in patients with acquired immunodeficiency 
syndrome (AIDS) or AIDS-related complex (ARC) (Carmichael et al., 1993). 
Recently, two types of transgenic mice have been used to study the CTL 
response to viral infections more closely in vivo, (i) (32-microglobulin (ß2m) knockout 
mice, which fail to express class I proteins and are virtually devoid of CTLs and (ii) 
perforin deficient mice, which produce virus-specific CTLs deficient in cytotoxicity. The 
importance of the CTL response to LCMV infection was confirmed by the development in 
such knockout mice of a chronic LCMV infection (Lehmann-Grube et al., 1993; Kagi et 
al., 1994a). Nm-knockout mice also showed delayed clearance of both Sendai virus (Hou 
et al., 1992) and low virulence influenza virus (Bender et al., 1992). On the contrary, both 
types of transgenic mice cleared vaccinia virus infection normally (Spriggs et al., 1992; 
Kagi et al., 1995) and perforin deficient mice infected with either vesicular stomatitis virus 
(VSV) or Semliki forest virus (SFV) did not show increased mortality compared to normal 
mice (Kagi et al., 1995). 
These results suggest that although CTLs are important in the clearance of virus 
infections, systemic viruses which lead to the cytopathology of infected cells prior to their 
recognition by CTLs, are cleared with the help of other immune mechanisms. However, 
viruses differ greatly in both their site of replication (systemic or mucosal) and rate of cell 
cytopathology. Therefore, the exact contributions of the various cells of the immune 
system probably depends very much on the individual virus type. In addition, the plasticity 
of the immune system is speculated to compensate if virus-specific CTLs are absent (or 
non-functional) throughout the development of the immune response to a virus. Cells 
which have been suggested to help clear virus infection of mice in the absence of CTLs 
include antibody producing B-lymphocytes, cytokine [interferon (IFN)-y and tumour 
necrosis factor (TNF)] producing lymphocytes, Th-lymphocytes, y8 T-lymphocytes and 
natural killer (NK) cells. 
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2.2.2 The role of Th-lymphocytes in clearing viral infection 
Th-lymphocytes are thought to mediate viral clearance through the production of 
cytokines which act either directly to inhibit virus replication, or locally and systemically 
to regulate other components of the host's immune response. Murine Th-lymphocytes 
have been divided into three subsets (ThO, Thl and Th2) depending on their cytokine 
profiles (Mosmann et al., 1986; Paliard et al., 1991). 
ThO-lymphocytes have a cytokine profile which overlaps Thl and Th2- 
lymphocytes and were speculated to be the precursor of the two subsets (Paliard et al., 
1991). Depending on the predominant cytokines in the milieu of ThO-lymphocytes, they 
differentiate and/or selectively outgrow into either a Thi [promoted by IFN-y and 
interleukin (IL)-12] or Th2 (promoted by IL-4 and IL-10) lymphocyte population 
(Mosmann and Moore, 1991; Maggi et al., 1992; Hsieh et al., 1993). 
Thl-lymphocytes produce IL-2, IFN-y and TNF and these preferentially 
stimulate cell-mediated immune responses, including CTLs and delayed type 
hypersensitivity (DTH) (Cher and Mosmann, 1987). IL-2 is a major growth factor for T 
and B-lymphocytes, activates NK cells and promotes B-lymphocyte differentiation (Ferrar 
et al., 1982). IFN-y and TNF activate macrophages and NK cells (Staeheli, 1990), directly 
inhibit virus replication (Feduchi and Carrasco, 1991), promote resistance in uninfected 
cells to viral infection (Wong and Goeddel, 1986) and have showed direct antiviral activity 
(Kohonen-Corish et al., 1990; Sambhi et al., 1991). In addition, IFN-y can also promote 
CTL recognition of target cells by increasing MHC class I presentation (Burowski and 
Welsh, 1985). Because IL-2 is essential for the effective generation and expansion of a 
virus-specific CTL response (Reddehase et al., 1987a) and because IFN-y and TNF 
mediate various antiviral activities, the Thl-lymphocyte response is thought to be the most 
beneficial in resolving viral infections. 
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By contrast, Th2-lymphocytes produce IL-4, IL-5, IL-6 and IL-10 and these in 
turn preferentially stimulate antibody-mediated immune responses, and activate 
eosinophils and mast cells (Coffman et al., 1988). It should be noted that virus-specific 
antibody is important in limiting viral spread (Koszinowski et al., 1991) and is likely to 
have a significant role in the protection from re-infection of some viruses (Kagi et al., 
1995). A summary of the role of CD4+ Th-lymphocytes in the immune response is shown 
in Figure 2. 
2.3 THE STRUCTURE AND FUNCTION OF THE MHC CLASS I MOLECULE 
2.3.1 The genes encoding the mouse MHC class I proteins 
The mouse MHC genes are situated in the H-2 region of chromosome 17 (see Figure 3). 
There are approximately 30 class I genes in the haploid mouse genome. At least three class 
I genes encode the classical and highly polymorphic transplantation antigens, H-2K, H-2D 
and H-2L. Two class I genes K and K1 are situated in the H-2K region in a head-to-tail 
configuration and their expression depends on the particular mouse strain. The 
organisation of the H-2K region is similar in Balb/c (H-2d), C57BL/6 (H-2b) and 
C3H/He, mg (H-2k) mice with the expression of H-2Kd, H-2Kb and H-2K 
k, respectively 
(Hood et al., 1983; Weiss et al., 1984; Flavell et al., 1986). The number of genes not only 
present but also expressed in the D/L region varies between different haplotypes of mice. 
H-2d mice have five genes in this region but only two of them (H-2Dd and H-2L d) are 
expressed. The functions of the three silent genes (D2', D3d and D4d) are not known. By 
contrast, H-2b and H-2k mice only have one gene present and expressing in the D/L region, 
H-2Db and H-2Dk respectively, and these genes are in fact alleles of the H-2Ld gene in H- 
2d mice. The other protein of the MHC class I complex (32-microglobulin ((32m) is encoded 
outside the H-2 and Qa/Tla complexes and is not polymorphic (Hood et al., 1983; Weiss et 
al., 1984; Flavell et al., 1986; Watts et al., 1989). 
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FIGURE 2. TILE ROLE OF CD4` Th-LYMPIIOCYTES IN THE,. IMMUNE 
RESPONSE 
ThO-lymphocytes differentiate into Th I or Th2-lymphocytes depending on the predominant 
cytokines in the milieu of the precursor cell. The Th-lymphocyte recognises foreign peptide 
presented on the surface of antigen presenting cells (APC), in association with the MIIC 
class II molecule (indicated by back arrows). The cytokincs secreted by Till and 1112 
lymphocytes are shown as thick red and blue arrows, respectively, and mutually inhibitory 
interactions are represented by broken arrows. Thin arrows show the growth and 
differentiation of different cells of the immune system following stimulation by the relevant 
Th-lymphocyte cytokines. Antibodies produced by E3-lymphocytes can bind to the cellular 
Fc receptors and induce antibody-dependent cell-mediated cytotoxicity (ADCC). The Till- 
lymphocyte response is thought to preferentially stimulate a cell-mediated immune 
response, whereas, the Th2-lymphocyte response is thought to preferentially stimulate an 
antibody-mediated immune response. 
Modified from Male et al. (1991). 
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FIGURE 3. MURINE MIIC CLASS I IIAI'LOTYI'ES 
The upper part of the figure shows a schematic representation of the organisation of the 
murine 11-2 and Qa/Tla complexes. The 11-2 complex consists of class 1, class 11 and class 
III regions. The class I regions K (in light green) and D (in grey) encode MIIC class I 
molecules whereas. the class II regions I-A (in red) and I-C (in dark green) encode MIIC 
class II molecules. The class III region (in yellow) resides between the class I and class II 
regions and consists of a heterogeneous mixture of genes including complement 
components and TNF a and P. The murine Qa/TIa regions (in blue) contain genes encoding 
class I-like proteins. 
A schematic representation of the genes of the mouse I3alb/c (11-2'), C5713U6 (1111- 
2`') and C3I1/He, mg (11-2k) MHC class I haplotypes arc shown in the lower part of the 
figure. The MIIC class I genes in each haplotype of mouse arc shown by boxes, the solid 
boxes represent the expressed genes and the open boxes represent genes which arc not 
expressed. It should be noted that all three mouse strains express the 11-2K gene in the K 
region and that the Balb/c (11-2°) strain contains additional genes (D2. D3 and D4) in the D 
region which are thought to have arisen by gene duplication. 
Modified from Male el al. (1991) and Watts et al. (1989). 
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The other class I genes (class lb genes, reviewed recently by Stroynowski and 
Forman, 1995) are the non-polymorphic minor transplantation antigens which are situated 
in the adjacent Qa and Tla regions. The Qa and Tla regions encode clusters of class I genes 
which are expressed on limited cell types but do not act as restriction elements. 
An analogous system to the mouse occurs in the human MHC system with the 
Human Leukocyte Antigen (HLA) genes encoding the polymorphic transplantation 
antigens HLA-A, -B, and -C (Koller et al., 1989). 
2.3.2 Genetics of MHC class I polymorphism 
Although each individual expresses only a small number of different MHC molecules, 
each MHC molecule can bind to an array of different antigenic peptides and this, in turn, 
allows the immune system to respond to a variety of challenges. Part of the al and a2 
domains of MHC class I molecules comprise the peptide binding cleft (see next section) 
and this region shows the highest genetic polymorphism (Nathenson et al., 1986; Parham 
et al., 1988). 
Multiple nucleotide substitutions in the mouse MHC class I molecules are 
thought to arise principally from inter-locus gene conversion during recombination events 
(Nathenson et al., 1986). During inter-locus gene conversion; gene sequences from the 
MHC Qa and Tla regions, which represent a donor reservoir of potential sequence 
variability, generate diversity in the H-2 antigens (Weiss et al., 1983). An analogous 
genetic polymorphism occurs in the human HLA system, however, in the case of humans 
inter-allelic gene conversion and homologous recombination are thought to be the 
principle ways of generating MHC class I diversity, rather than inter-locus gene 
conversion (Parham et al., 1989; Lawlor et al., 1990). 
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2.3.3 Structure of MHC class I molecules 
MHC class I molecules consist of a highly polymorphic type I integral membrane 
glycoprotein heavy chain (46 kDa), containing three extracellular domains (al, a2 and 
a3), noncovalently associated with a soluble ß2-microglobulin subunit (ß2m) (12 kDa) 
(see Figure 4A). The al and a2 domains provide both the a helices and an eight stranded 
antiparallel fl-pleated sheet floor to form the antigen binding groove. The ß2m domain 
binds to all three a domains of the heavy chain (Bjorkman et al., 1987a/b). 
The peptide binding groove is 30A long and 12A wide (see Figure 4B) and 
contains pockets, separated by fixed distances, which extend between the floor and the 
helical walls of the al and a2 domains (Garrett et al., 1989). The amino acid residues of 
the peptide binding groove a helices (which are highly polymorphic) determine the shape 
of the binding site and, therefore, the peptides bound by each allelic protein. In contrast, 
the amino residues which block the ends of the MHC class I peptide groove are highly 
conserved (Matsumura et al., 1992; Madden, 1995). 
2.3.4 Peptides bound by the MHC groove 
Peptides and glycopeptides of eight to eleven amino acids in length are held in a largely 
extended conformation which runs the length of the binding groove (Fremont et al., 1992; 
Madden, 1995). Rarely, longer peptides can bind with one termini hanging beyond the end 
of the groove (Collins et al., 1994). The carboxy terminus of the peptide is either 
hydrophobic or charged (Rammensee et al., 1993) and is buried in the cleft to a lesser 
extent than the amino terminus (Fremont et al., 1992). Although there is a prominent arch 
which lifts the peptide main chain away from the floor of the binding groove, 73 to 83% of 
the peptide is concealed within the groove (Fremont et al., 1992; Madden et al., 1993; 
Young et al., 1994). Peptide binding alters the structure of the MHC class I heavy chain 
and the resulting structure varies with the type of peptide bound (Fremont et al., 1992). 
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FIGURE 4. STRUCTURE OF A MIIC CLASS I MOLECULE 
A schematic representation of the human 11LA-A2 M11C class I molecule (Bjorkman et al., 
1987a). Thick arrows represent ß-strands in the amino to carboxyl direction, helical ribbons 
represent a-helices and two connected circles represent disulphide bonds. 
(A). A side view of the M11C class I molecule showing the highly polymorphic al and a2 
domains (the peptide binding site) and the membrane proximal a3 and ß2-microglobulin 
(ß2m) domains. The al and a2 domains consist of an eight stranded [1-pleated sheet covered 
by a-helices to form the peptide binding groove. 
(B). Top view of the MIIC class I molecule (al and a2) [90° from Figure 4 (A)] showing 
the peptide binding groove. The N terminus of the al domain is shown. The al and a2 
domains both consist of four anti-parallel ß-strands followed by a a-helical region. The al 
and a2 domains pair to form the eight stranded ß-pleated sheet covered by a-helices. 
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Thousands of different peptides, providing they adopt the required backbone 
conformation, can bind to one MHC allele because only a few positions on the peptide 
actually bind to the MHC groove. Non-allelic specific interactions at the peptide termini 
and allelic specific interactions between the peptide side chains and the MHC side pockets 
provide the bonding forces (hydrogen bonds and van der Waals bonds) of the MHC- 
peptide complex (Fremont et al., 1992 Matsumura et al., 1992; Young et al., 1994). The 
allele specific interactions between the peptide side chains and the side pockets of the 
MHC provide the binding `motif' of a particular MHC allele. In designating residues, P 
denotes the position of the residue in the peptide, starting from the amino-terminal end. 
Binding occurs at P2 in many cases, or at P3, P5 and P7 (see Table 2). A detailed review 
of MHC binding motifs has recently been published by Madden, 1995 and Rammensee, 
1995. 
Other peptide residues, which differ between peptides, can also make contact 
with MHC "loose" pockets. Within a particular MHC motif, certain non-anchor peptide 
residues are preferentially used or not used, and are involved in the fine tuning of the 
peptide specificity (Ruppert et al., 1993). For example, peptide bound to the mouse MHC 
class I alleles H-2Kb and H-2D b has been found to use secondary anchors in the P3 binding 
pocket (Matsumura et al., 1992; Young et al., 1994). 
Table 2. Examples of mouse MHC class I motif groups (Rammensee, 1995) 
P2 anchor P3 anchor P5 anchor P7 anchor Carboxy-terminal anchor MHC allele 
Tyr - Hydrophobic H-2K 
Pro Hydrophobic H-21, 
Negative - Hydrophobic H-2K 
Aromatic Aliphatic H-2K 
- Asn Aliphatic H-2D 
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Although peptides bind to MHC using only a few amino acid residues, the 
overall sequence of the peptide affects its main-chain conformation, the orientation of its 
side chains and, thus, the antigenic uniqueness of the resulting MHC-peptide complex 
(Fremont et al., 1992; Madden et al., 1993). The peptide also contains "flag" side chains 
which are orientated towards the T-cell receptor (TCR) and so could, therefore, affect TCR 
recognition (Silver et al., 1992). 
2 .4 ASSEMBLY AND TRANSPORT OF MHC 
CLASS I MOLECULES 
2.4.1 Generation of MHC class I components and transport into the ER 
It is believed that MHC class I heavy chains and ß2m are both translated, with a signal 
sequence, in the cytoplasm of the antigen presenting cell (APC). The signal sequences of 
the nascent polypeptides directs them to the endoplasmic reticulum (ER) where, following 
translocation into the ER, the signal sequences are cleaved by the resident ER signal 
peptide peptidase (Germain and Marguiles, 1993; Jackson and Peterson, 1993). 
2.4.2 Generation of peptides and transport into the ER 
Peptides for MHC binding are thought to be derived predominantly from nascent 
polypeptides generated in the cytoplasm of the APC (Moore et al., 1988; Yewdell et al., 
1988). The multi-catalytic protein protease (proteasome) is abundant in both the cytoplasm 
and nucleus of the cell and looks increasingly convincing as the key protease in the 
generation of peptides for class I molecules (Goldberg and Rock, 1992). Proteasomes are 
composed of more than 25 polypeptide subunits (total molecular weight approximately 
2000 kDa) and have been linked to an ATP-dependent proteolytic pathway in which 
proteins are initially marked for degradation following binding with the ubiquitin protein 
(Peters, 1994). Two of its ß subunits, low molecular weight polypeptides (LMP)2 and 
LMP7, are encoded by genes within the mouse and human MHC (Brown et al., 1991; 
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Glynne et al., 1991; Kelly et al., 1991; Martinez and Monaco, 1991). LMP2 and LMP7 are 
induced by IFN-y but are not essential for normal peptide generation (Zhou et al., 1994). 
Following IFN-y induction, LMP2 and LMP7 replace the constitutive and highly 
homologous proteasome 3 subunits (which are also down regulated by IFN-y) (Fruh et al., 
1994; Belich et al., 1994). This replacement is speculated to narrow the proteasome's 
polypeptide cleaving properties so that the proteasome preferentially provides `finished' 
peptides for MHC class I binding (Gaczynska et al., 1994). 
Peptides enter the ER using an ATP-dependent, transporter associated with the 
antigen processing (TAP) pathway (Neefjes et al., 1993; Shepherd et al., 1993) and an 
ATP-independent pathway of unknown identity (Dobberstein, 1992). The TAP 
heterodimer is a typical ATP-binding cassette transporter which, like LMP2 and LMP7, is 
encoded by genes within the mouse and human MHC (Monaco et al., 1990; Spies et al., 
1990; Trowsdale et al., 1990). TAP favours the transport of peptides which are the correct 
size for MHC class I loading (Momburg et al., 1994a; Schumacher et al., 1994), however, 
longer peptides (up to 33 amino acids long) also appear to be dependent on TAP for 
transport into the ER (Urban et al., 1994; Neisig et al., 1995). There is also evidence to 
suggest that TAP shows specificity for the carboxyl termini amino acid of the peptides it 
transports. Experiments by Momburg et al. (1994b) showed that this specificity varies 
between different species, mouse TAP being restricted to the transport of peptides with 
hydrophobic carboxy termini, whereas, human TAP can transport all carboxy-terminal 
amino acids except proline and possibly glycine. Generally, the experiments on TAP 
suggest that it preferentially transports `finished' peptides for MHC class I binding. 
Recent work suggests that most viral proteins which cross directly into the ER, 
via their signal sequences, cannot associate with MHC class I molecules (Hammond et al., 
1995; Hombach et al., 1995). The authors suggest that these viral proteins are mislocalised 
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to the cytosol where they then enter the supply and transport of peptides presented by 
MHC class I molecules. 
2.4.3 Association of MHC class I and peptides 
Within the biosynthetic compartment of the ER, the MHC class I heavy chains transiently 
bind to resident ER membrane chaperone proteins, including calnexin and 
immunoglobulin binding protein (BiP) (Nößner and Parham, 1995). It has been speculated 
that subsequent (32m binding to the MHC heavy chain results in the dissociation of the 
chaperone (Ortmann et al., 1994; Nößner and Parham, 1995). It then appears that the 
heterodimers bind to components of the TAP protein within the ER (Ortmann et al., 1994; 
Suh et al., 1994). TAP is believed to deliver a peptide to the heterodimer which, following 
its stabilisation, dissociates from the TAP protein (Suh et al., 1994). Finally, the MHC- 
peptide is transported through the Golgi apparatus to the cell surface (Jackson and 
Peterson, 1993). A summary of the generation of peptides and subsequent MHC class I 
binding is shown in Figure S. 
2.4.4 Antigen presenting cells (APCs)/target cells 
Although MHC class I molecules are expressed by the majority of human cell types (Male 
et al., 1991), APCs can be divided into both professionals and amateurs (Sprent, 1995). 
Professional APCs, such as macrophages and dendritic cells, express higher levels of co- 
stimulatory molecules than amateur APCs (Steinman, 1991; Schwartz, 1992). Professional 
APCs are scattered throughout the body but are concentrated particularly in T- 
lymphocyte-dependent areas of the lymphoid tissues, such as the spleen and lymph nodes. 
These cells are believed to acquire (and process) antigen and transport it to the lymphoid 
tissues (Macatonia et al., 1989; Hill et al., 1990). It is also possible that free virus particles 
or proteins could enter the afferent lymph and be acquired by professional APCs resident 
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FIGURE 5. A SCHEMATIC REPRESENTATION OF MIIC CLASS I ASSEMBLY 
AND PEPTIDE PROCESSING 
MIIC class I heavy chains and ßI-microglobulin (ß2m) arc both translated in the cytoplasm 
of the antigen presenting cell (APC) and signal sequences direct the nascent polypeptides 
into the lumen of the endoplasmic reticulum (ER). The signal sequences are cleaved by 
resident ER signal peptide peptidases and the class I heavy chains bind to ER membrane 
chaperone proteins, including calnexin and immunoglobulin binding protein (Bil'). It has 
been speculated that the binding of the ß2m to the class I heavy chains triggers the 
dissociation of the heterodimer from the chaperone. 
Peptides for MHC class I binding arc derived predominantly from nascent 
polypeptides translated in the cytoplasm of the APC. It is believed that the multi-catalytic 
protein protease (proteasome) generates the peptides for MIIC class I presentation in the 
cytoplasm of the cell. The majority of these peptides are thought to enter the lumen of the 
ER via the transporter associated with the antigen processing (TAP transporter) pathway. 
Transported peptides are believed to load into class I molecules that arc physically 
tethered to the TAP transporter. Binding of the peptide triggers stabilisation and, 
consequently, release of the MIIC-peptide from the TAP transporter. The newly formed 
MIIC-peptide is transported through the Golgi apparatus to the cell surface %khcrc CTLs 
examine it for peptides derived from foreign proteins. 
Modified from Jackson and Peterson (1993). 
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within the lymph nodes (Eichelberger et al., 1991). At these sites, primary stimulation of 
naive CTL to virus antigenic peptides probably occurs via the professional APCs (London 
et al., 1987; Hamilton-Easton and Eichelberger, 1995). 
It is generally accepted that activated CTL stimulation can occur via amateur 
APCs such as infected cells at a peripheral site of infection (leading to direct target cell 
killing) or B-lymphocytes and fibroblasts in adjacent areas of the lymphoid tissue 
(Macatonia et al., 1989; Fuchs and Matzinger, 1992; Azuma et al., 1993). It has been 
speculated that activated CTL stimulation (or cytotoxic activity) does not require the 
amateur APCs to possess the high levels of co-stimulatory signals required for the primary 
stimulation (Croft, 1994). 
2 .5 CELL-MEDIATED-TARGET CLL KILLING 
2.5.1 Generation of effector CTLs following virus infection 
Experiments have attempted to calculate the frequency of different subsets of CTL at the 
site of virus infection (lung) and lymph node following infection by influenza A virus 
(Allan et al., 1990) or Sendai virus (Nou and Doherty, 1993). Between four and seven 
days after a low or moderate primary dose of either virus, naive CTLs within lymph nodes 
are activated and divide [named precursor CTLs (CTLp)]. The number of virus-specific 
CTLp in the mediastinal lymphoid tissue appears to increase at least ten-fold. 
Activated CTLs are directed to sites of inflammation following endothelium 
binding and extravasation. Several receptor/ligand interactions [including lymphocyte 
functional antigen (LFA)-1/intercellular adhesion molecule (ICAM)-1 and very late 
antigen (VLA)-4/vascular cell adhesion molecule (VCAM)-1] have been implicated in this 
role (reviewed in Shimizu et al., 1992). It appears that the receptors on activated CTL, and 
the ligands on endothelial cells at the sites of inflammation, are up-regulated (Christensen 
et al., 1995). 
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However, recent experiments have speculated that only a minority of the CTLp 
that localise at the site of infection are specific for the virus and develop into effector CTL 
(Hou and Doherty, 1993). As explained in the above section, activated CTLs appear to 
recognise virally infected target cells directly and this results in CTL degranulation and 
target cell death (Hahn et al., 1994). 
Following elimination of the infected cells (usually within two weeks), activated 
CTLs traffic in large numbers to the gut (Peyer's patches and lamina propria) and the 
spleen. In these areas, the CTLs die within a few days and the resulting cellular debris 
appears to be engulfed by phagocytes (reviewed in Sprent, 1994). However, not all virus- 
specific CTLp are eliminated and some become `memory' CTL (see section 2.7). 
2.5.2 The structure of the aß T-cell receptor (TCR) complex 
The TCR is a multi-subunit complex on the surface of the majority of T-lymphocytes (see 
Figure 6). Contained within the TCR is the disulphide linked aß heterodimer (or in a 
minority of the T-lymphocyte population, a structurally similar TCR-yö as described in 
section 2.6) which is responsible for the recognition of the MHC-peptide complex on the 
surface of the target cell (Dembic et al., 1986). The diversity of the TCR is due to the a 
and ß chains having numerous V, D and J gene segments which can also undergo gene 
rearrangement (Davis and Bjorkman, 1988). 
The a and ß chains contain an immunoglobulin-like extracellular domain, a 
transmembrane region and a short cytoplasmic tail of five to twelve amino acids in length 
(Allison and Lanier, 1987). Recently, the crystal structure of the extracellular portion of 
the ß chain was determined at a resolution of 1.7A and confirmed the immunoglobulin- 
like nature of the receptor (Bentley et al., 1995). The a/ß heterodimer is noncovalently 
associated to the invariant CD3 y, S and two £ chains. These chains are similar to the a and 
ß chains, but have a longer cytoplasmic domain ranging from 40 to 80 amino acids 
43 
FIGURE 6. TIIE aß T CELL RECEPTOR COMPLEX 
A schematic representation of the T cell receptor ap complex showing (A) the common ý 
chain homodimer and (B) the small percentage of TCR a3 containing the hetcrodimcr of i; 
chain complexed to the r1 chain. 
The TCR binds to MIIC-peptide via the a and 5 chains (in blue) however, 
extracellular binding events are transduced to the intracellular signalling machinery via both 
the y, S and two E chains of the CD3 complex (in red) and the C, homodimer or C, /11 
heterodimer chains (in green). The locations of the immunoreceptor tyrosine activation 
motifs (ITAMs) on the intracellular domains of the y, S, c, C, and in chains arc shown as solid 
grey boxes (see accompanying text). 
Modified from Chan et al. (1994) and Bolen (1995). 
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(Clevers et al., 1988). The TCR complex also contains aý chain homodimer and each ý 
chain consists of a short extracellular domain, a transmembrane region and a cytoplasmic 
domain of 113 amino acids (Weissman et al., 1988). A small percentage of TCRs contain 
a grl heterodimer due to alternative splicing of the ý product (Jin et al., 1990). 
2.5.3 CTL binding to target cells 
Initially, there is a specific interaction between the TCR and the target cell MHC class I in 
association with antigenic peptide (O'Rourke, 1990). The TCR is believed to interact with 
both the peptide and the a-helices of the MHC binding groove (Fremont et al., 1992). The 
low affinity TCR/MHC-peptide interaction (KD- 1X10-6 to 1X10-7 M) is similar to that of 
other molecules involved in cellular adhesion (Corr et al., 1994; Sykulev et al., 1994). It 
has been predicted that the affinity follows the law of mass action and, in addition, an 
activated CTL requires an epitope density of less than ten complexes per target cell for 
half-maximal target cell lysis (Sykulev et al., 1995). The TCR binding to MHC-peptide is 
short lived (a half life of seconds) and there is a fast dissociation rate (Corr et al., 1994; 
Matsui et al., 1994). This has been linked to an increased stimulatory capacity and a `serial 
engagement' in which a small number of MHC-peptide complexes could stimulate a larger 
number of TCR complexes (Valitutti et al., 1995). 
Following initial TCR/MHC-peptide binding, CD8 is "activated" and binds to 
the target cell MHC class I determinant to stabilise the CTL-target cell interaction 
(O'Rourke et al., 1990). Other molecules including CD2, CD28, CD43 and LFA-1 on the 
CTL surface, and LFA-3, B7, CD22 and ICAM-1 or 2 on the target cells are also involved 
in a "zipping-up process" (reviewed in Dustin and Springer, 1991). Target cell binding is 
rapid with a half-time of 1.4 minutes (Perez et al., 1985). 
Regardless of whether CTLs binds to individual target cells or to several target 
cells simultaneously, the cytolytic activity always proceeds in a sequential manner 
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(Zagury, 1982). The CTL detaches following delivery of a "lethal hit" to the target cell, 
however, the mechanisms involved in detachment are not known. In experiments by Berke 
et al. (1972) CTLs were calculated to undergo multiple cycles of target cell lysis at a 
constant rate during a five hour in vitro incubation. 
2.5.4 Signal transduction in the CTL following target cell binding 
The mechanisms involved in the CTL signal transduction following target cell binding are 
only briefly described in this thesis. Recent detailed reviews have been published 
concerning: - protein tyrosine kinases (PTKs), Chan et al. (1994) and Bolen (1995); protein 
tyrosine phosphatases (PTPs) (and especially CD45), Chan et al. (1994) and Okumura and 
Thomas (1995); immediate early (IE) T-lymphocyte genes and their products, Kelly and 
Siebenlist (1995). 
Following MHC-peptide binding by the TCR a/ß chains, the chains of the CD3 
and ý are known to be involved in the signal transduction of the CTL response (Sussman et 
al., 1988; Letourneur and Klausner, 1992). Within the cytoplasmic domains of these 
chains are immunoreceptor tyrosine activation motifs (ITAMs) composed of two tyrosine- 
X-X-leucine (where X is any residue) paired sequences separated by six to eight amino 
acids. ITAMs occur in triplicate on ý chains and as a single copy on the CD3 chains (Reth, 
1989). 
Fyn, Lck and Zap-70 are cytoplasmic PTKs thought to be involved in the signal 
transduction pathway (Chan et al., 1994). As mentioned previously, CD8 participates in 
TCR/MHC binding and this molecule also contains a cytoplasmic binding domain for Lck 
(Turner et al., 1990). CD8 bound Lck is speculated to phosphorylate the ITAMs on the c 
and ý chains of the TCR allowing Zap-70 to subsequently bind to these chains (Chan et al., 
1994). 
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It should be noted that CD45, a member of the family of transmembrane PTP, is 
an abundantly expressed polymorphic antigen which is required for T-lymphocyte 
function (Weaver et al., 1991). CD45 is believed to regulate signal transduction pathways 
in T-lymphocytes by controlling the activities of both Lck and Fyn (Mustelin et al., 1989; 
1992) 
The activation of Zap-70 results in the tyrosine phosphorylation of a variety of 
proteins including phospholipase C (Kim et al., 1991) which in turn leads to both an 
increase in intracellular Ca2+ and the activation of protein kinase C (PKC) (Berridge and 
Irvine, 1984). 
This signal cascade eventually lead to the transcription and translation of IE T- 
lymphocyte genes (Kelly and Siebenlist, 1995). The activation of T-lymphocytes can 
result in cell proliferation, IL-2 production, induction of cell surface antigens and target 
cell killing. 
2.5.5 CTL induced target cell killing 
Following target cell binding, the CTL reorganises its microtubule organising centre 
(MTOC) and centrioles so that they are proximal to the binding site (Geiger et al., 1982). 
The microtubules move the Golgi apparatus and lysosomal granules (at rates of up to 3 
µms I) to the vicinity of the contact region probably using the phosphorylation of kinesin- 
associated proteins (Hahn et al., 1994; Mcllvain et al., 1994). The gathering of lysosomal 
granules may direct a "lethal hit" in the observed sequential fashion and target cells are 
destroyed without adjacent cells, not expressing the relevant antigens, being affected 
(Hahn et al., 1994). CTL killing of target cells is characteristically unidirectional (Hahn et 
al., 1994), however, the mechanisms which protect the CTL from its own cytotoxic 
mediators are not known. New data by Isaaz et al. (1995) suggests that synthesis of 
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granule contents occurs during target cell killing to re-fill the granules and that some of 
this newly synthesised material is released from the cell in a granule independent manner. 
Experiments using perforin or Fas-knockout mice showed clearly that there are 
at least two separate cytolytic pathways used by CTLs; (i) a secretory and membranolytic 
delivery of a perforin based lethal hit and (ii) a non-secretory, Fas/APO-1 (CD95) receptor 
mediated triggering of target cell apoptosis (see Figure 7). Kagi et al. (1994a/1995) 
showed that perforin deficient mice were unable to recover from LCMV infection, 
whereas, Fas deficient mice recovered from LCMV infection similarly to normal mice. 
These experiments showed that CTLs were critical for the clearance of LCMV infection in 
vivo and that the perforin pathway was the mechanism of cytotoxicity used by these CTLs. 
The involvement of the Fas pathway in the clearance of virus infection by CTLs in vivo is 
still unknown, however, LCMV infected target cells could, in fact, be lysed by perforin 
deficient CTLs in vitro (Walsh et al., 1994). The Fas pathway was attributed to this in 
vitro target cell killing because only Fas-bearing targets cells were destroyed by the 
perforin deficient CTLs (Kagi et al., 1994b; Lowin et al., 1994). It has been speculated 
that the two different mechanisms of CTL-mediated lysis may have evolved to protect 
against the multitude of escape strategies used by invading pathogens (Lowin et al., 1994). 
2.5.6 Secretory and membranolytic induced cell death 
This mechanism involves Ca2+ dependent granule exocytosis and secretion of the pore- 
forming protein perforin along with a series of granule enzymes (granzymes) into the 
localised environment between the effector and target cell (Ishiura et al., 1990; Peters et 
al., 1991). 
The lysosomal granules are unique organelles which contain a dense central core 
surrounded by a multivesicular cortex (Peters et al., 1991). Components found in these 
granules include perforin, serine esterases (granzymes), cathepsin B and the calcium 
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FIGURE: 7. TWO PATHWAYS OF CTLAII: I)IATE) TARGET CELL 
CYTOTOXICITY 
('TL. s recognise specific antigen in association with Ml IC class I (in green) on the surface of 
target cells via its TCR/CD3 complex (in grey). Signals are transmitted from the TCRJCD3 
complex. along with co-stimulatory signals from other adhesion molecules, to activate the 
c)totoxic processes. There are believed to be two main pathways by which the cytotoxic 
effects of CTI-s arc mediated: 
(1) Non-secretory cytotoxicity is believed to involve the ile novo synthesis of Fas ligand 
(Fast) (in dark blue) and also the translocation of pre-made Fast, to the CTL cell surface. 
Following interaction of the CTLs FasL and the Fas (in burgundy) on the target cell, the Fas 
molecules transmit a "death signal" which initiates target cell apoptosis. 
(ii) Secretory cytotoxicity involves the translocation and secretion of cytoplasmic granules 
containing perform (in red), granzymes A to G (in blue) and other cytotoxins. Many perform 
proteins, in the presence of Ca'', bind to the target cell membrane and polymerise to fonn 
aqueous pores. Granzymes and other cytotoxins enter the target cell and transmit a "death 
signal" which initiates target cell apoptosis and lysis. 
The biochemical signals involved in CTL induced apoptosis remain to be revealed. 
Modified from Berke (1994) and Takayama (1995). 
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binding protein, calreticulin (Peters et al., 1991; Dupuis et al., 1993; Griffiths and Isaaz, 
1993). The mannose-6-phosphate receptor has also been found in some granules and has 
been implicated in the transport of granzymes to these granules (Peters et al., 1991; 
Griffiths and Isaaz, 1993). There is also evidence to suggest that the cytoplasmic granules 
are kept acidic by a H+-ATPase pump (Kataoka et al., 1994). 
Perforin is a glycoprotein of 534 amino acids (molecular weight, 66 to 70 kDa) 
and shows sequence homology in its middle third with the membrane spanning/pore 
forming domain of the C9 complement component (Shinkai et al., 1988). It is generally 
accepted that perforin monomers (in the presence of Cat) sequentially insert into the 
target cell membrane and then polymerise to form polyperforin channels. The amino 
terminal 33 amino acids of perforin are thought to be important in the formation of the 
channels (Ojcius et al., 1991). The mechanisms by which perforin channels mediate lysis 
are not known, however, the abolition of the electrochemical gradient across the target cell 
membrane, leading to a net water influx and osmotic bursting, may be involved. 
In addition to perforin, the lysosomal granules also contain granzymes and, to- 
date, seven mouse (named A to G) and two human (named A and B) granzymes have been 
characterised (Smyth and Trapani, 1995). Granzymes are rich in basic amino acids and 
contain highly conserved amino acid sequences (Brunet et al., 1986; Lobe et al., 1986). 
Granzyme A displays trypsin-like cleavage properties, whereas, granzyme B (the most 
abundant granzyme in CTL) displays Asp-ase cleavage properties (Poe et al., 1991; Smyth 
and Trapani, 1995). Granzymes have been speculated to enter the target cell through the 
perforin channels and to activate a target cell DNA degradation pathway (Shi et al., 1992). 
The observed granzyme induced DNA fragmentation is characteristic of apoptosis (see 
next section) which may have initially served to destroy transcribed viral DNA and thus 
prevent viral spread. 
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2.5.7 Non-secretory and receptor-mediated induced cell death 
Unlike perforin induced cell death which may result in membrane disruption and target 
cell necrosis, CTL-mediated target cell killing can also result in Ca2+ independent 
programmed cell death (apoptosis) via the Fas (mouse) or APO-1 (human) [CD95] 
receptor pathway (Rouvier et al., 1993). Fas and APO-1 are cell surface glycoproteins 
(molecular weight, 35 kDa) which are found on both lymphoid and non-lymphoid tissues 
(Itoh et al., 1991; Oehm et al., 1992). 
During CTL induced apoptosis, the target cell's DNA undergoes chromatin 
condensation and fragmentation (Russell, 1983). The target cell's plasma membrane 
undergoes blebbing which leads to cell fragmentation and the formation of sealed 
membrane fragments (apoptotic bodies) (Hahn et al., 1994). 
It has been suggested that following TCR and MHC-peptide binding, a signal is 
produced in the CTL via protein tyrosine kinase (PTK) to express the Fas ligand (FasL) 
(Anel et al., 1994). FasL is presented on the CTL cell surface where it binds with Fas on 
the surface of the target cell (Suda et al., 1993). This binding is believed to trigger second 
messengers including PTK which may affect the expression of the proto-oncogene Bcl-2 
(Eischen et al., 1994; Schroter et al., 1995). The endogenous DNase I-like endonucleases 
are also thought to be involved in the target cell DNA fragmentation (Ucker et al., 1992). 
2.5.8 Non-cytolytic virus resolution 
Although CTLs have been known to mediate a potent cytolytic activity in vitro for some 
time, the questions concerning the mechanisms of CTL activity both in vitro and in vivo 
have only recently been answered using the perform-knockout mouse (see section 2.5.5). 
However, it should be noted that antiviral cytokines such as IFN-y and TNF-a are 
produced by CTLs (and Th-lymphocytes) in response to viral infections and probably 
contribute to intracellular virus resolution (Ramsay et al., 1993). For example, CTL 
51 
antiviral cytokines have been shown to non-cytolytically prevent mouse cells from 
expressing hepatitis B virus (HBV) genes in vivo (Guidotti et al., 1994). 
2.6 INTESTINAL INTRAEPITHELIAL LYMPHOCYTES 
In addition to the circulating ap TCR T-lymphocytes, there is a population of intestinal 
intraepithelial lymphocytes (ilELs) located between the epithelial cells lining the intestinal 
lumen. The iIELs are almost entirely T-lymphocytes which undergo thymus-independent 
development and selection within the intestinal epithelium (Guy-Grand et al., 1978; 
Mosley et al., 1990; Poussier et al., 1992). The majority of mouse ilELs are CD8+ T- 
lymphocytes, however, the TCR subset of these cells varies. The number of TCR-yS cells 
appears to decrease, in parallel to the TCR-aß subset increase, as the mouse ages (Maloy 
et al., 1991; Takeuchi et al., 1993). In humans, the majority of iIELs appear to be CD8+ 
and TCR-aß, although, up to thirty seven percent were TCR-yS (Jarry et al., 1990; Deusch 
et al., 1991). 
TCR-y6 lymphocytes appear to recognise the heat shock proteins, which are 
normally generated during the course of an infection, in an MHC-independent manner 
(Born et al., 1990). TCR-y8 lymphocytes have also been found to interact with viral 
proteins in the absence of processing or MHC presentation (Sciammas et al., 1994). For 
these reasons, it is thought that the TCR-y5 iIELs may act early in the immune response 
and provide a first line of defence against pathogens. 
2.7 VIRUS-SPECIFIC MEMORY CTLs 
The T-lymphocyte response to acute infection not only mediates viral clearance but 
provides the host with immunological memory, characterised by an increased frequency of 
memory T-lymphocytes (Th-lymphocytes and CTLs) responsive to antigenic epitopes 
expressed by the pathogen. 
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Influenza A virus infection of the mouse allows life-long recall of enhanced, 
virus-specific CTLs following in vitro stimulation (Effros and Walford, 1984). However, 
influenza A heterotypic protection (which is probably mediated by CTLs) appears to 
diminish in vivo at about five months after the primary infection (Liang et al., 1994). In 
humans, memory CTLs to influenza A virus decline within two to three years after 
primary infection (McMichael et al., 1983a). Also, humans vaccinated with variola virus 
(smallpox vaccine) have memory CTL to variolar virus in their peripheral blood for at 
least two to four years (Demkowicz and Ennis, 1993: Erickson and Walker, 1993). 
From the current knowledge, it generally appears that naive CTL and memory 
CTL show contrasting cell surface markers; naive CTL display CD45Rh', L-selectinh` and 
CD4410, whereas, memory CTL display CD45RI0, L-selectinh0 and CD44hi (Budd et al., 
1987; Lee and Vitetta, 1991; Vitetta et al., 1991). Human memory CTLs appear to have a 
much more rapid turn-over than naive CTLs (Michie et al., 1992), however, recent studies 
in the mouse have detected a proportion of memory CTLs (about twenty percent) which 
appear to be long lived and non-dividing (Tough and Sprent, 1994). Memory CTL 
generally circulate within the secondary lymphoid tissues (Razvi et al., 1995). 
It is not known how memory CTLs continue in circulation. Initial experiments 
showed that memory CTL responses to LCMV declined within days after the virus- 
specific CTLs were adoptively transferred to donor mice in the absence of antigen (Oehen 
et al., 1992). These results suggested that memory CTLs may engage in continuous low- 
grade responses to residual depots of antigen. Follicular dendritic cells are known to 
sequester antigen on their surface for months or years (Tew et al., 1990) and were 
speculated to maintain the survival of at least memory Th-lymphocytes (Sprent, 1994). 
More recently, however, LCMV-specific memory CTLs have been shown to survive for 
more than a year (Lau et al., 1994) and Sendai virus-specific memory CTLs for more than 
100 days (Hou et al., 1994), following adoptive transfer into mice in the absence of 
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antigen. Hou et al. (1994) speculated that the primary clonal burst size may be the major 
influence in the longevity of memory CTL. 
Akbar et al. (1993) suggested that the small percentage of T-lymphocytes which 
survived cell death, following the primary immune response to an antigen, were saved by 
accessory cells providing IL-2. IL-2 could switch on survival genes, including bcl-2, and 
allow the memory CTLs to survive in the absence of antigen. 
Lastly, Selin et al (1994) have shown that memory CTLs specific for one virus 
could cross-react and contribute to the primary CTL response of an unrelated virus. 
Pichinde virus, vaccinia virus and MCMV all cross-reacted with LCMV-specific CTLs at 
the clonal level. Thus, memory CTLs may be constantly reactivated by remotely cross- 
reactive infectious agents and environmental antigens. 
2.8 RESUME 
The current view is that following virus infection at a peripheral site, professional antigen 
presenting cells (APCs) acquire, process and transport virus proteins to the lymphoid 
tissues. It is believed that viral proteins are degraded into peptides by the multi-catalytic 
protein protease (proteasome) in the cytoplasm of the professional APC and transported to 
the ER via the TAP transporter. In the ER, the peptides bind to MHC class I molecules and 
are then expressed on the cell surface. The highly polymorphic nature of the MHC proteins 
affects which viral peptides will be presented and, therefore, the nature of the CTL 
response. Precursor CTLs recognise, via their a/ß TCR heterodimer, foreign (viral) 
peptide in association with MHC on the surface of the professional APC (MHC class I 
restriction) and become `activated' effector CTLs. 
Effector CTLs re-enter circulation and are directed to the peripheral site of virus 
infection. Virtually all somatic cells express MHC class I molecules and these amateur 
APCs are believed to present newly synthesised viral proteins in association with MHC 
54 
class I using the same pathway as the professional APCs. Effector CTL recognition of 
infected `target' cells leads to target cell binding and then lysis, principally by the 
secretory (perforin) pathway. 
Following resolution of the virus infection, it is believed that a small population 
of the effector CTLs survive and become memory CTLs. These cells are believed to 
circulate the host, respond rapidly to virus re-infection and protect the host from disease. 
Memory CTLs are particularly believed to be involved in the observed virus serotype- 
independent protection which can not be easily explained by the neutralising antibody 
response. 
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CHAPTER 3 
THE IMMUNE RESPONSE TO ROTAVIRUS 
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3.1 INTRODUCTION 
Despite the great deal of knowledge gained on the molecular biology of rotaviruses, the 
immunological mechanisms responsible for the clearance and subsequent protection from 
rotavirus infection still remains unclear. Indeed, the reason behind the mixed efficacy 
exhibited in the many vaccine trials that have been carried out is not known (reviewed in 
Conner et al., 1994). Consequently, the relative importance of the antibody- versus the 
cell-mediated immune response to rotavirus infection is subject to much debate, especially 
in relation to the design of an effective vaccine. However, it should be noted that these two 
effector functions (and indeed other immunological mechanisms) may be inseparable. 
The immune response following rotavirus infection has been studied most 
extensively in the mouse and, for this reason, the chapter will concentrate on the immune 
response in this animal model. It should be noted that in all the animals studied to-date, 
including humans and new-born calves, the mechanisms of the immune response appear to 
be fairly similar (Davidson et al., 1983; Saif et al., 1983; Sheridan et al., 1983; Conner et 
al., 1991). 
UMPONENTS OF THE IMMUNt RF, SPa ROTAVIR 
INFECTION 
3.2.1 Location of rotavirus infection 
Following oral inoculation of the suckling mouse with rotavirus, the virus replicates in the 
mature villus epithelial cells of the small intestine (Sheridan et al., 1983). Although acute 
rotavirus disease is self-limiting, and the symptoms are normally resolved within a few 
days, the actual mechanisms of the immune response may depend on whether it is a 
primary infection or a secondary re-infection. 
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3.2.2 Immune response following primary infection 
Following a primary rotavirus infection, professional antigen presenting cells (APCs), 
such as macrophages and dendritic cells, most probably acquire and process rotavirus 
antigens and transport them to the lymphoid tissues (Macatonia et al., 1989; Hill et al., 
1990). Alternatively, infectious rotavirus (or viral antigen) might directly enter the blood 
and lymphatics, migrate to the spleen and mesenteric lymph nodes (MLN), and be taken 
up by local APCs (Eichelberger et al., 1991). Regardless of the mode of travel, rotavirus 
antigens have been detected in the spleen by five days post infection (p. i. ), and the MLN 
between three and twenty days p. i. (Dharakul et al., 1988). 
Within the lymphoid tissues, the professional APCs probably present rotavirus 
antigens to Th-lymphocytes, CTLs and antibody producing B-lymphocytes (London et al., 
1987; Hamilton-Easton and Eichelberger, 1995). The rotavirus-specific lymphocytes are 
likely to return to the site of infection following endothelium binding and extravasation 
(reviewed in Shimizu et al., 1992). At this site, Th-lymphocytes probably release 
cytokines which promote B-lymphocyte antibody production and CTL activity. 
3.2.3 Location and isotype of rotavirus-specific antibodies 
Rotavirus-specific immunoglobulin (Ig)A secreting B-lymphocytes appear at the intestinal 
lamina propria four to six days p. i., peak in number at three weeks p. i., and remain for at 
least eight weeks (Merchant et al., 1991). Although rotavirus-specific IgG secreting B- 
lymphocytes are also found in the lamina propria, albeit at a ten-fold lower number than 
IgA-secreting B-lymphocytes (Merchant et al., 1991), the capacity of IgG to protect at the 
intestinal surface is not clear. The epithelial cell transcytosis of IgG cross-linked through 
multivalent antigen to polymeric IgA has been detected (Kaetzel et al., 1994). IgG could, 
therefore, help mediate viral clearance through intracellular association with antigen and 
subsequent activation of complement. 
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Circulating 13-lymphocytes also produce rotavirus-specific serum antibodies. 
Rotavirus-specific IgM appears in the serum three days p. i. followed by IgG and IgA 
(Sheridan et al., 1983). Although it appears that only intestinal antibodies are directly 
involved in the clearance and protection from rotavirus infection (Offit and Clark, 1985a), 
it should be noted that dimeric serum IgA is removed from circulation by the liver and 
transported into the intestine via bile (Mestecky, 1987). 
In humans, the subtype of IgA produced in response to rotavirus infection is 
largely IgAl. Older children and adults produce greater quantities of IgA2 which is more 
resistant to bacterial proteases and may correlate better with protection against rotavirus 
disease (Friedman et al., 1996). 
3.2.4 Location and TCR type of rotavirus-specific CTLs 
Rotavirus-specific CTLs are detected in the intestinal intraepithelial lymphocytes (iIELs), 
Peyer's patch, MLN and spleen six days p. i. (Offit and Dudzik, 1989a) and are of the aß 
CD8+ subset (Off it et al., 1991b). 
3.2.5 Memory T- and B-lymphocytes are acquired following primary rotavirus 
infection 
Following primary infection of mice with the murine rotavirus strain EDIM, the level of 
virus-specific faecal IgA decreased to ten percent of its peak within two months, but did 
not decrease further over the next twelve months. During this time the level of virus- 
specific serum IgA remained fairly constant and serum virus-specific IgG steadily 
increased (McNeal and Ward, 1995). Similarly in humans, the rise in faecal rotavirus- 
specific IgA is frequently transient (Coulson et al., 1992; Matson et al., 1993), whereas, 
serum IgA levels persist for at least four months (Grimwood et al., 1988). 
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Although it is not known how long rotavirus-specific memory CTLs persist 
following rotavirus infection, this question has been addressed in other virus systems. It 
appears that influenza virus-specific CTLs remain in the mouse for the remainder of its 
life (Effros and Walford, 1984), however, protection from influenza re-challenge 
diminishes at about five months after the primary infection (Liang et al., 1994). Also in 
humans, memory CTLs specific for influenza or variola virus exist for approximately three 
years in the absence of further challenge (McMichael et al., 1983a; Demkowicz and Ennis, 
1993; Erickson and Walker, 1993). 
3.2.6 Immune response following re-infection 
Following rotavirus re-infection, it is likely that amateur APC (probably including 13- 
lymphocytes) acquire and process rotavirus antigens and present them to rotavirus-specific 
memory lymphocytes within the local site of infection, Peyer's patches and lamina propria 
(Macatonia et al., 1989; Fuchs and Matzinger, 1992; Azuma et al., 1993). 
RE INVOLVED IN CLEARANCE OF TH 
PRIMARY ROTAVIRUS INFECTION 
A number of studies have indicated that both the cell-mediated and humoral immune 
response mechanisms are required for the proficient clearance of a primary rotavirus 
infection. 
Firstly, chronic rotavirus infections of SCID mice were ablated by the passive 
transfer of CTLs from MHC class I matched Balb/c mice previously inoculated with 
infectious rotavirus (or single rotavirus proteins expressed by recombinant baculoviruses). 
However, rotavirus shedding recurred at a low level which indicated that either, (i) the 
CTLs were generating a selection pressure and this selection pressure was generating a 
variant viral population, or (ii) that CTLs alone were not sufficient in clearing chronic 
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rotavirus infections (Dharakul et al., 1990/1991). Very recently, JHD-knockout mice (B- 
lymphocyte-deficient) were found to clear primary murine rotavirus infection as would 
normal mice, suggesting that CTLs are involved in the clearance of rotavirus infection. 
The same experiments were carried out in 1tMT-knockout mice (B-lymphocyte-deficient) 
and, although the initial infection was cleared, these mice suffered from subsequent bursts 
of renewed virus shedding. Depleting the CTLs from both these two mice strains either 
ablated rotavirus clearance (JHD-knockout mice) or prolonged virus clearance (µMT- 
knockout mice) and confirmed that CTLs were involved in the resolution of primary 
rotavirus infection (McNeal et al., 1995). 
Secondly, ß2m-knockout mice (CTL-deficient) cleared primary rotavirus 
infection at a delayed rate (Franco and Greenberg, 1995) and increased viral release was 
also seen in calves treated with an anti-CD8 monoclonal antibodies (Oldham et al., 1993). 
Thus, taking these experiments together, it appears that both T- and B- 
lymphocytes participate in the resolution of the primary rotavirus infection (Franco and 
Greenberg, 1995; McNeal et al., 1995). 
3 .4 NEITHER ANTIBODY NOR 
CTLs ARE INVOLVED IN THE CLEARANCE 
R ftOT VI E (IN T 
T-lymphocyte-deficient (nude) mice have been found to clear rotavirus infection in the 
absence of a significant antibody response or a functional T-lymphocyte response (Eiden 
et al., 1986). Also, the resolution of rotavirus in JHD and tMD-knockout mice (B- 
lymphocyte-deficient), depleted of CD8+ CTLs, showed that other effector functions may 
also have a role in the clearance of rotavirus infection (McNeal et al., 1995). These include 
both immunological mechanisms such as CD4+ CTLs, natural killer (NK) cells, and non- 
immunological mechanisms such as the depletion of susceptible villus epithelial cells. 
However, although these mice cleared the primary infection, the mice were not actually 
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protected from re-infection. This strongly suggests that either memory T- and/or 13- 
lymphocytes are required for subsequent protection (McNeal et al., 1995). 
3 .5 GENERAL PROPERTIES OF PROTECTION FROM ROTAVIRUS RE- 
INFECTION 
3.5.1 Primary rotavirus infection protects the host from subsequent re-infection 
There are numerous examples of both humans and animals being protected from rotavirus 
re-infection following primary infection. Mice orally inoculated with EDIM were 
protected against re-infection with the same virus (Ward et al., 1990c) and this protection 
remained for at least fourteen months (most of the lifetime of the mouse) (McNeal and 
Ward, 1995). Protection from subsequent episodes of serious rotavirus disease has also 
been observed in infants following the recovery from either symptomatic or asymptomatic 
natural infections (Bishop et al., 1983; Bernstein et al., 1991; Coulson et al., 1992; Ward 
and Bernstein, 1994). 
The role of the immune system in amelioration of primary infection and 
protection from re-infection and/or disease is supported by the fact that severe combined 
immunodeficiency (SCID) mice become chronically infected with rotavirus (Riepenhoff- 
Talty et al., 1987) as do immunodeficient children (Hundley et al., 1987). 
3.5.2 Heterotypic protection is generated following rotavirus infection 
The hosts immunity to rotavirus not only protects against re-infection and/or disease by 
rotavirus of the same VP7 (G) and VP4 (P) serotype (homotypic protection/serotype- 
dependent) but may also protect against rotaviruses of different G and P serotypes 
(heterotypic protection/serotype-independent). There are, however, conflicting reports as 
to whether this heterotypic protection develops following primary infection (Bridger and 
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Oldham, 1987; Woode et al., 1987) or following two or more infections (Snodgrass et al., 
1991; Brussow et al., 1991a/b). 
3.5.3 Protection may correlate to the magnitude of the primary immune response 
As mentioned in sections 3.5.1 and 3.5.2, natural infection with rotavirus can offer 
protection to subsequent infection and/or disease. However, protection following rotavirus 
infection has also been seen to be limited in infants and to not prevent multiple rotavirus 
illnesses (Friedman et al., 1988; Coulson et al., 1992) or multiple asymptomatic infections 
(Matson et al., 1993). 
One possible reason for the variability in protection following rotavirus infection 
was revealed in vaccine trials. Candidate vaccine strains for infants based on heterologous 
rotaviruses, which are known to replicate poorly in humans, have provided only partial 
protection (Berstein et al., 1990; Santosham et al., 1991). A similar situation occurs in the 
mouse model in which the murine rotavirus EDIM protected mice from subsequent EDIM 
infection whereas the heterologous RRV virus failed to provide protection from 
subsequent EDIM infection (Ward et al., 1992). Using rotavirus EDIMIRRV reassortants, 
no individual EDIM protein was found to correlate with protection, whereas, rotavirus 
replication (measured by levels of both rotavirus shedding in stools, and serum IgA) was 
found to correlate with protection (McNeal et al., 1994). Although the level of rotavirus 
replication is an attractive hypothesis for the variability seen in rotavirus protection, it 
does not account for the fact that parenterally inoculated, non-replicating, rotaviruses also 
offer protection to re-infection via the natural route, as described in the next section. 
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3.5.4 Rotavirus replication is not required at the intestinal surface to elicit an 
immune response 
Although rotaviruses normally enter the host by the faecal-oral route and replicate in the 
epithelial cells of the small intestine, rotavirus replication or diarrhoea is not actually 
required for the generation of protection. For example, rotavirus-specific T- and B- 
lymphocytes develop following: (i) oral inoculation of the adult mouse, which does not 
support rotavirus replication, and (ii) parental inoculation of both suckling and adult mice, 
where virus does not encounter the intestine (Offit and Dudzik, 1989a/b; Conner et al., 
1993). The route of rotavirus inoculation does, however, alter the antibody response. For 
example, the parenteral inoculation of mice leads to an increase in rotavirus-specific 
intestinal IgG, and to a decrease in intestinal rotavirus-specific IgA which is associated 
with infection by the natural route (Coffin et al., 1995). 
DOLE OF THE HUMORAL IMMUNE PONSE IN PRO UIN TI 
FROM ROTAVIRUS RE-INFECTION 
3.6.1 Antibodies are involved in protection 
As described in section 3.2.3, clearance of rotavirus infection by the host is accompanied 
by the appearance of rotavirus-specific antibodies and the levels of these antibodies have 
been correlated with protection from subsequent re-infection. For example, active 
immunity against rotavirus infection has been correlated with pre-existing levels of serum 
and faecal rotavirus-specific IgA (but not serum IgG) in the mouse model (Feng et al., 
1994; McNeal et al., 1994; Bums et al., 1995). Also, serum rotavirus-specific IgA and IgG 
levels were correlated with protection against rotavirus infection and illness of infants in 
an orphanage (O'Ryan et al., 1994). In addition, faecal IgA alone was correlated with 
protection of children in hospitals and day care centres (Coulson et al., 1992; Matson et 
al., 1993). 
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More direct evidence of a role for antibodies in protection from rotavirus was 
shown when milk from rotavirus inoculated dams, administered orally to suckling mice, 
protected the suckling mice from subsequent disease following challenge (Offit and Clark, 
1985a; Offit and Dudzik, 1989b). Although rotavirus-specific milk IgA was found to be 
tenfold more potent than milk IgG, both could independently passively protect against 
disease (Offit and Clark, 1985a). 
3.6.2 Serotype-dependent antibodies develop after primary infection, whereas, 
serotype-independent antibodies develop after re-infection 
It is generally accepted that the primary exposure to rotavirus produces a serotype- 
dependent neutralising antibody response against the serotype of the infecting strain and 
that the serotype-independent antibody response develops with subsequent infections. For 
instance, children with high G serotype 3 serum antibodies (but not those with high G 
serotype 1,2 or 4, but low 3, serum antibodies) were protected from disease following 
serotype 3 challenge (Chiba et al., 1986). Re-infections of children were found to boost 
antibody levels to more than one G serotype (Coulson et al., 1992) and adults elicited a 
broad heterotypic antibody response following rotavirus infection (Ward et al., 1989). 
There are two hypotheses concerning the generation of serotype-independent 
antibodies. The older view is that re-infections with different rotavirus strains boost 
neutralising antibodies against the different serotypes to which the host has previously 
been exposed. However, the re-infections do not broaden the response to include serotypes 
to which the host has not previously encountered (Offit and Clark, 1985b; Snodgrass et al., 
1984; Zheng et al., 1988). 
More recently, studies in both calves and children have revealed that the 
serotype-independent antibody response is generated without previous exposure to those 
serotypes (Snodgrass et al., 1991; Brussow et al., 1991a/b). This has lead to the new 
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hypothesis that a broad serotype-independent antibody response develops after exposure to 
only a few different serotypes because of the presence of minor cross-neutralising epitopes 
(see next section). 
3.6.3 Minor cross-neutralising epitopes may be involved in heterotypic protection 
The serotype-independent antibody response may result from the existence of minor cross- 
neutralising antibody cpitopes which are masked by immunodominant neutralisation 
epitopes during primary infection. It is speculated that if the primary and secondary 
infections are very similar, then the bulk of the antibody response will be directed to the 
major neutralisation antigens of the second virus. If, however, the primary and secondary 
rotavirus infections are sufficiently different, then the bulk of the antibody response will 
be directed, via memory B-lymphocytes, to the minor serotype-independent epitopes. This 
process (named antigenic sin) will also direct the antibody response toward the primary 
rotavirus epitopes (Snodgrass et al., 1991). 
A good example of this was seen when administrating the WC3 bovine vaccine 
strain (serotype 6) after a natural rotavirus infection (serotype 1) (Ward et al., 1990d). 
Primary infection with the high replicating natural rotavirus strain elicited a heterotypic 
response to serotype I (the infecting strain) followed by serotype 3, and low response 
against serotype 4 and 2. Following WC3 re-infection, the neutralising antibody responses 
to all these serotypes were boosted (approximately twelve-fold) in proportion to each 
other. 
3.6.4 Antibodies recognise most rotavirus proteins 
Human sera obtained during the convalescent phase following rotavirus infection 
contained IgG antibodies directed against inner capsid proteins VP I, VP2, VP3 and VP6, 
outer capsid proteins VP4 and VP7, and non-structural proteins NS53, NS34 and NS35. 
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The non-neutralising VP2 and VP6 rotavirus proteins were immunodominant (Svensson et 
al., 1987a/b). This polyclonal antibody response to various rotavirus proteins appears to be 
mirrored by the serum IgAl antibody response (Johansen et al., 1994). It is worth noting 
that both the IgG and IgAl antibody responses to the neutralising VP4 and VP7 proteins 
were low compared to the other rotavirus proteins. 
3.6.5 VP4 and VP7 both contain major neutralising, and minor cross-neutralising, 
antibody epitopes 
The external virion shell proteins VP4 and VP7 produce neutralising antibodies and, 
therefore, form the basis of rotavirus serotyping. Consequently, the protective antibody 
response to these two proteins has been studied extensively. Offit et al. (1986a) showed, 
using VP4 and VP7 reassortant rotaviruses, that both these proteins could independently 
evoke virus-neutralising antibodies in the milk of inoculated dams which passively 
protected suckling mice against diarrhoea. This passive protection was also generated 
using monoclonal antibodies directed against either VP4 or VP7 (Offit et al., 1986b; 
Matsui et al., 1989). 
Having confirmed that VP4 and VP7 could separately evoke a protective 
antibody response, disagreement then arose as to which of the these two proteins was 
immunodominant. VP4 and VP7 reassortant rotavirus experiments in humans showed, in 
some cases, that approximately ninety-five percent of the neutralising antibody response 
was directed against VP4 (Ward et al., 1988; Flores et al., 1989). The immunodominance 
of VP4 over VP7 has also been detected following natural infections of infants (Offit et 
al., 1993; Svensson et al., 1987a; Ward et al., 1993). However, other VP4 and VP7 
reassortant rotavirus experiments showed that the majority of the neutralising antibody 
was directed at VP7 (Ward et al., 1990b). Possible reasons for the conflicting results 
include, (i) a changing immunodominant protein which depends on whether the antibodies 
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were generated following primary or secondary infection, or (ii) experiments involving 
reassortants may give unpredictable results associated with the fact that the antigenicity of 
VP7 depends on the VP4 background, and vice versa (Chen et al., 1989/1992; Dunn et al., 
1994). 
The earlier experiments by Off it et al. (1986b) and Matsui et al. (1989) also 
showed that monoclonal antibodies directed against either VP4 or VP7 passively protected 
suckling mice against diarrhoea induced by different rotavirus serotypes. These results 
suggested that both VP4 and VP7 contained serotype-independent epitopes. More recently, 
experiments by Taniguchi et al. (1991) showed that the polyclonal antibody response 
generated following the re-infection of children with rotavirus included neutralising 
antibodies directed at minor, serotype-independent, epitopes on both VP4 and VP7. The 
authors speculated that this response probably followed the principles of antigenic sin as 
described in section 3.6.3. 
The locations of the VP4 and VP7 major neutralising, and minor cross- 
neutralising, antibody epitopes have been described in sections 1.7.2 and 1.7.3. 
3.6.6 A role for non-neutralising VP6 antibodies in heterotypic protection 
Recently, a functional role for non-neutralising serum IgA antibody was found by 
implanting mice with hybridoma cells secreting VP6-specific IgA antibody (Burns et al., 
1996). VP6-specific serum IgA (but not passively fed VP6-specific IgA) protected the 
mice from infection with both homotypic and heterotypic rotavirus strains and, indeed, 
VP6 is antigenically conserved among different mammalian Group A rotaviruses 
(Gorziglia et al., 1988). VP6 has also been shown to contain rotavirus strain-independent 
Th-lymphocyte epitope(s) (Bruce et al., 1994) and is highly immunodominant for both the 
IgG and IgA antibody responses in infants (Svensson et al., 1987a; Johansen et al., 1994). 
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The locations of the VP6 non-neutralising, antibody epitopes have been 
described in section 1.7.1. 
3.6.7 Antibodies may not be directly involved in protection 
Antibody responses are only one of the mechanisms employed by the immune system to 
clear virus infection. In fact, other mechanisms may be involved in primary rotavirus 
clearance and protection from re-infection or disease, and antibody may only serve as an 
indicator of their presence. 
There are a number of reasons why the role of the antibody response in clearance 
and protection from rotavirus infection is questioned. Firstly, Ward et al. (1992) found that 
certain rotavirus strains protected mice from EDIM re-infection even though EDIM- 
specific neutralising antibodies in the intestine were not detectable at the time of re- 
inoculation. Also in mice, correlations between protection and titres of serotype-specific 
antibodies in the serum or faeces were not observed (McNeal et al., 1992). 
Gnotobiotic calves inoculated with either avirulent or virulent rotavirus strains of 
one serotype were protected against a virulent rotavirus strain of a different serotype in the 
absence of rotavirus-specific neutralising antibodies in either the serum or faeces to the 
challenge strain (Bridger and Oldham, 1987; Woode et al., 1987). 
Finally, infants immunised with the WC3 or RIT 4237 vaccines, which are 
serotypically distinct from human strains, were protected from disease caused by serotype 
I human rotavirus despite the absence of virus-specific antibodies in their sera (Vesikari et 
al., 1985; Clark et al., 1988). Moreover, Ward et al. (1990a) predicted, from serum 
rotavirus-specific IgG titre, that thirteen out of twenty adults would have been infected 
after homotypic re-challenge with the CJN strain. In fact only three subjects were infected 
upon re-challenge which indicated that a second effector arm of the immune system may 
be associated with protection against rotavirus re-infection. 
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3 .7 THE ROLE OF THE CELL-MEDIATED IMMUNE RESPONSE IN 
PROTECTION FROM ROTAVIRUS DISEASE 
3.7.1 CTLs are involved in protection 
CTLs, in the absence of rotavirus-specific antibody, have been shown to clear rotavirus 
infection and prevent disease. Firstly, suckling mice intraperitoneally inoculated with 
splenic lymphocytes from adult C57BL/6 (H-2b) or Balb/c (H-2d) mice inoculated with 
murine rotavirus, provided them with protection against disease caused by murine 
rotavirus challenge (Off it and Dudzik, 1990). Further, SCID mice orally administered with 
CTLs from adult Balb/c mice, previously inoculated intraperitoneally with murine 
rotavirus, ablated a chronic murine rotavirus infection (Dharakul et al., 1990). 
RRV rotavirus-specific CTLs generated in C57BL/6 mice were able to lyse H- 
2Db, but not H-2Kb, restricted target cells infected with RRV rotavirus within two hours in 
vitro (Offit et al., 1989). The production of infectious RRV rotavirus takes between four 
and eight hours in these target cells and this may have important consequences during 
natural rotavirus infections. Indeed, a logarithmic phase of rotaviral growth involving 
multiple cycles of viral replication usually occurs 36 to 48 hours after infection in mice 
(Starkey et al., 1986). Effector CTLs are generated from CTL precursors within 48 hours 
after infection and could therefore lyre virus infected cells prior to the logarithmic phase 
of infectious virus production (Off it et al., 1989). 
3.7.2 The involvement of CTLs in heterotypic protection 
The ability of rotavirus-specific CTLs generated to one rotavirus serotype to kill target 
cells infected with rotavirus of another serotype has been described. For example, CTLs 
generated from C57BL/6 (H-2b) mice inoculated with either bovine, simian or human 
rotaviruses could lyse target cells infected with rotaviruses of different serotypes (Offit 
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and Dudzik, 1988). In fact, Offit and Svoboda (1989) showed that the protection of infants 
against serotype I rotavirus provided by the serotypically distinct WC3 vaccine, may be 
explained by the CTL response. Mice orally inoculated with WC3 developed CTLs which 
could lyse target cells infected with heterotypic serotype I rotavirus. Lastly, the passive 
transfer of CTLs generated from adult mice, previously inoculated with one of many 
different rotavirus serotypes, could ablate a chronic murine rotavirus infection of a 
different serotype in SCID mice (Dharakul et al., 1991). 
3.7.3 CTLs recognise many rotavirus proteins 
In C57BL/6 (H-2b) mice inoculated with UKtc, SAIL or RRV, a rotavirus-specific CTL 
response was directed against target cells expressing VP7. In addition, CTLs from mice 
inoculated with UKtc or SAIL weakly lysed target cells expressing UKtc VP4 or SAl I 
VP6, respectively (Offit et al., 1991a). Further studies found rotavirus VP7, but not VP I, 
VP2, VP4, NS53, VP6, NS35, NS28 or NS26, -specific CTLs were generated in C57BL/6 
mice inoculated with recombinant vaccinia viruses expressing the individual SAIL 
proteins (Offit et al., 1994). Thus, using the recombinant vaccinia virus system to 
individually express nine (of the twelve) rotavirus proteins, there only appeared to be a 
response to the VP7 protein in C57BL16 mice. The vaccinia expression system has also 
been used to express individual rotavirus RF proteins for use in CTL assays. In this case, 
as well as VP7, a rotavirus-specific CTL response was again detected against VP6, but not 
VP1, VP2 or VP3, when rotavirus RF was used to inoculate C57BL/6 mice (Franco et al., 
1994). 
Individual rotavirus proteins expressed by recombinant baculoviruses were also 
used to inoculate mice instead of infectious rotavirus. Earlier experiments showed that 
transferred rotavirus-specific CTLs, which mediated the clearance of chronic rotavirus 
infection from SCID mice, could be independently generated by inoculating Balb/c (H-2d) 
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mice with baculovirus individually expressed VP1, VP4, VP6 or VP7, but not VP2, NS53, 
NS35 or NS28 rotavirus proteins (Dharakul et al., 1991). Then, using RF recombinant 
baculovirus proteins to inoculate C57BL/6 mice, rotavirus-specific CTL responses were 
found against target cells expressing rotavirus VP3 and VP6 proteins, but not targets 
expressing VPI (Franco et al., 1994). Although these two experiments cannot be directly 
compared because of the use of different mouse strains and different rotavirus proteins, 
combining the results suggests that CTL epitopes are found on VP2, VP3, VP4, VP6, VP7 
and, with disagreement, VPI. 
3.7.4 The MHC class I haplotype affects the CTL response 
The rotavirus epitopes presented to CTLs depends on the particular MHC class I 
haplotype. To date, rotavirus-specific CTL epitopes in haplotypes of mouse other than H- 
2b have only been detected using the baculovirus expressed proteins to inoculate the mice. 
A rotavirus-specific CTL response directed to VP1, VP4, VP6 and VP7 has been detected 
in Balb/c (H-2d) mice (Dharakul et al., 1991), however, using VP1, VP2, VP3 and VP6 
proteins, Franco et al. (1994) found no RF-specific CTL response in Balb/c mice and only 
a VP3-specific CTL epitope in C3H/He, mg (H-2k) mice. 
3.7.5 Serotype-independent VP7-specific CTL epitopes have been detected 
Serotype-independent, rotavirus-specific CTLs generated in C57BL/6 mice after oral 
inoculation with rotavirus SA11 or RRV (both serotype 3), or UKtc (serotype 6), cross- 
lysed target cells expressing VP7 of serotypes 3 or 6 (Offit et al., 1991a). This was 
confirmed by Offit et al. (1994) when CTLs generated from the inoculation of mice with 
recombinant vaccinia viruses expressing rotavirus SA11 or UKtc VP7 lysed target cells 
infected with rotavirus serotypes 3 or 6. To-date, no other rotavirus proteins have been 
found to contain cross-specific CTL epitopes. 
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3.7.6 Location of epitopes recognised by CTLs 
Using allele-specific motifs to predict MHC class I mouse H-2b epitopes, a synthesised 
peptide covering amino acids 33 to 40 of the rotavirus RF VP7 protein (which overlaps the 
H2 signal peptide located between amino acids 33 to 48) was recognised by rotavirus- 
specific CTLs. This epitope was found to be restricted at H-2Kb (Franco et al., 1993) and, 
in addition, the region of the VP7 protein containing this epitope is conserved, although 
not completely conserved, between different rotavirus strains (Estes and Cohen, 1989). In 
the light of this, and the fact that there is known to be a serotype-independent CTL 
response against VP7, the view emerged that this region defined that serotype-independent 
epitope. However, no experimental evidence showing a serotype-independent CTL 
response to this epitope has been reported. 
A VP7-specific CTL response in other haplotypes of mice has only been detected 
using the baculovirus expressed rotavirus RRV protein to inoculate Balb/c (H-2d) mice. 
The location of the epitope(s) recognised by VP7-specific CTLs generated in Balb/c mice 
have yet to be determined (Dharakul et al., 1991). 
Using baculovirus expressed individual rotavirus RF proteins to inoculate 
C57BL/6 mice, VP3 and VP6 were found to contain CTL epitopes. Using allele-specific 
motifs to predict MHC class I mouse H-2b epitopes, peptides synthesised for VP3 (amino 
acids 585 to 593) and VP6 (amino acids 376 to 384) were recognised by rotavirus-specific 
CTLs; furthermore, both of these epitopes were restricted at H-2K b. Initial experiments 
have revealed that rotavirus RF VP3 contains epitopes recognised by CTLs generated in 
C3H/He, mg (H-2k) mouse, but, the location of the rotavirus-specific H-2k CTL epitope(s) 
in this protein have yet to be determined (Franco et al., 1994). 
Although various experiments using baculovirus expressed individual rotavirus 
proteins to inoculate mice have also identified a CTL response to other rotavirus proteins, 
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VPI, VP2 and VP4 (Dharakul et al., 1991; Franco et al., 1994), the location of the 
rotavirus-specific CTL epitope(s) in these proteins have yet to be determined. 
3.7.7 CTLs may not be directly involved in protection 
Very recent work showed that both JHD and 1tMT-knockout mice (B-lymphocyte- 
deficient), which had cleared a primary infection, were not protected from murine 
rotavirus re-infection, whereas, ß2m-knockout mice (CTL-deficient) were completely 
protected and this protection correlated with the development of a rotavirus-specific 
intestinal IgA response. Thus antibodies, not CTLs, appear to protect against rotavirus re- 
infection in these mice (Franco and Greenberg, 1995; McNeal et al., 1995). 
It should be noted that the genetically engineered mice used in these experiments 
have limitations due to the functional redundancy of the immune system. The inability of 
B-lymphocyte-deficient mice to resolve rotavirus re-infection can be explained in various 
ways: (i) following secondary rotavirus infection, it is probable that amateur APCs 
(including B-lymphocytes) present rotavirus antigens to Th-lymphocytes and CTLs within 
the local site of infection (Macatonia et al., 1989; Fuchs and Matzinger, 1992; Azuma et 
al., 1993). The presence of B-lymphocytes could, therefore, be essential for the direct 
stimulation of rotavirus-specific memory CTLs. Alternatively, the B-lymphocytes could 
present antigenic epitopes to Th-lymphocytes which then provide the cytokines necessary 
for memory CTL effector functions, (ii) memory CTL activity in vivo could, in part, be 
directed to rotavirus infected cells via antibody-dependent cell-mediated cytotoxicity 
(ADCC) or (iii) CTLs have the capacity to protect against disease, but not against the viral 
replication as measured in these studies. 
The ability of CTL-deficient mice to prevent rotavirus replication (as measured 
by viral shedding) only suggests that CTLs are not essential, nevertheless, CTLs may still 
be involved when present. For instance, heterotypic protection can not easily be explained 
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by the neutralising antibody response and, therefore, it would be interesting to see if CTL- 
deficient mice are also protected from heterotypic rotavirus re-infection. 
DNS FOR ROTA 
Studies on the immunity to rotavirus infection have highlighted three crucial parameters; 
(i) the immune response clears the primary infection, (ii) the immune response to the 
primary infection provides subsequent protection to rotavirus re-infection and/or disease, 
and (iii) the protection from re-infection and/or disease is serotype-independent 
(heterotypic protection). In principle, a rotavirus vaccine administered prior to the first 
exposure (at two to six months of age), which is capable of inducing protective immunity 
to all the prevalent circulating serotypes, could be developed. 
Several vaccine trials using live, oral, attenuated (heterologous animal) viruses 
"traditional vaccine", or genetic reassortant viruses containing genes encoding VP7 and/or 
VP4 of selected human rotavirus strains in an animal virus background "modified 
traditional vaccine", have been undertaken. Unfortunately, the large field trials with these 
vaccines have revealed mixed efficacy, regardless of the development of neutralising 
antibodies (reviewed in Conner et al., 1994). 
An antibody-promoting vaccine containing all the serotypes to which the host 
may encounter could be effective, but this type of vaccine will be difficult to construct and 
probably need to be updated frequently. In addition, single serotype-specific antibody- 
promoting vaccines will probably generate a broad immune response after two or more 
inoculations with different serotypes. This raises problems in that multiple doses could be 
difficult and expensive to administer, especially in many areas of the developing world. 
A CTL-promoting vaccine, on the contrary, has the potential to cross-protect 
against disease caused by many of the different rotavirus serotypes following a single 
dose, presenting a cheap vaccine in terms of both production and administration. However, 
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in contrast to the antibody response, the understanding of the rotavirus-specific CTL 
response is still in its infancy. An important step in the development of a CTL-promoting 
vaccine would be to identify all the rotavirus protein(s) which are involved in stimulating 
a CTL response, particularly if the CTL response generated by those proteins were 
serotype-independent. 
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CHAPTER 4 
MATERIALS AND METHODS 
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4.1 MATERIALS 
4.1.1 Standard buffers and solutions 
The following standard buffers and solutions were used throughout this study: 
10X loading buffer: 20% Ficoll 400, O. 1M ethylenediamine tetracetic acid (EDTA) pH 
8.0,1.0% sodium dodecyl sulphate (SDS), 0.25% bromophenol blue and 0.25% xylene 
cyanol 
TAE: 40 mM Tris. Acetate and 2 mM EDTA pH 8.0 
TBE: 89 mM Tris base, 89 mM boric acid and 2 mM EDTA pH 8.0 
Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCI, 4.3 mM Na2HPO4.7H20 
and 1.4 mM KH2PO4 
2X polymerase chain reaction (PCR) mixture: 50 µ1 lOX Reaction Buffer-Mg 2+ free 
(0.5M KCI, O. IM Tris-HCI pH 9.0,1% Triton X-100), 50µl 25 mM Mg2+, 4µ1 5 mM 
dNTPs, IOU Taq polymerase and distilled water to 250 µl total volume 
2X reverse transcriptase (RT)-PCR reaction mixture: as 2X PCR reaction mixture 
including 5U reverse transcriptase 
4.1.2 Tissue culture media and cell lines 
Sterile PBS, Versene (0.02% in PBS), neutral red (0.1% in Earles saline), L-glutamine, 
penicillin and streptomycin sulphate [l00,000,000U/100g in 200 ml PBS], trypsin (0.25% 
in PBS), 2X (2.8%) Noble Agar and tissue culture media including: Dulbecco's 
modification of Eagle's minimal essential medium (DMEM), Glasgow modification of 
Eagle's minimal essential medium (GMEM) plus non-essential amino acids (NEAA; 
0.89g L-alanine, 1.15g L-asparagine. H20,1.33g L-aspartic acid, 0.75g glycine, 1.45g L- 
glutamic acid, 1.15g L-proline and 1.05g L-serine per litre) 1X, 2X and Roswell Park 
Memorial Institute (RPMI) 1640 plus Hepes and NaHCO3, were all prepared by the media 
preparation staff of the Department of Biological Sciences, University of Warwick. 
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Table 3. Description of cell lines and their culture media 
Cell Type Description Culture Medium 
BS-C-1 African Green Monkey Kidney GMEM (5% FCS) 
(ATCC CCL 26) 
CV-1 African Green Monkey Kidney GMEM (5% FCS) 
(ATCC CCL 70) 
EL4 C57BL/6N mouse lymphoma RPMI (10% FCS) 
(ATCC TIB 39) 
HuTK- 143B Human osteosarcoma GMEM (5% FCS) 
Thymidine kinase negative 
5-bromo-2-deoxyuridine resistant 
(ATCC CCL 8303) 
Ltk- Mouse connective tissue DMEM (10% FCS) 
Thymidine kinase negative 
(Supplied by Dr. Quinn, 
University of North Carolina) 
L-D Mouse connective tissue DMEM (10% FCS) 
Restricted at Db 
Resistant to HAT 
(Supplied by Dr. D. Quinn, 
University of North Carolina) 
L-K Mouse connective tissue DMEM (10% FCS) 
Restricted at kb 
Resistant to G418 
(Supplied by Dr. D. Quinn, 
University of North Carolina) 
P815 DBA/2 mouse mastocytoma RPMI (10% FCS) 
(ATCC TIB 64) 
ATCC® is the registered trademark of the American Type Culture Collection. 
79 
Table 4. Contents of growth media 
1X Medium FCS/ 
Myoclone FCS 
L- glutamine ß-mercapto- 
ethanol 
Penicillin Streptomycin 
DMEM 10% FCS 2 mM - 100 U/ml 100 µg/ml 
GMEM 5% FCS 2 mM - 100 U/mI 100 µg/ml 
RPMI 10% FCS 2 mM - 100 U/ml 100 µg/ml 
RPMI DM 5%, 10% 
Myoclone FCS 
2 mM 50 µM 100 U/ml 100 µg/ml 
Dutch modified RPMI 1640 medium (RPMI DM), Foetal Calf Serum (FCS) and 
Myoclone super plus FCS were purchased from Gibco/BRL. FCS was routinely heat 
treated at 56°C for 1 hr before use. Table 3 shows the cell lines used along with their 
corresponding media, while Table 4 shows the contents of routinely used media. 
4.1.3 Primers 
The oligonucleotide primers utilised during this study are shown in Table S. Primers were 
synthesised by L. Ward, Department of Biological Sciences, University of Warwick using 
the Applied Biosystems 380B synthesiser, according to the manufacturer's instructions. 
4.1.4 Vectors 
The vectors used in this project were; (i) pCRTM II from Invitrogen's TA CloningTM 
system, (ii) pGS62 (Smith et al., 1987), (iii) rotavirus genes 2 and 3 of strain UKtc, gene 5 
of strains RRV, Hochi and P9DA5 and the gene ( 7,8 or 9) encoding the VP7 protein of 
strains RRV, A64, Hochi, 69M, Wa, and WI-61 cloned into pGS62 (constructed by Prof. 
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M. McCrae), (iv) pSCl1-30R. 2 [derived from pSC1I (Chakrabarti et al., 1985) by 
insertion of an oligonucleotide at the Smal site containing an initiator AUG downstream of 
which are three unique restriction enzyme sites (Ncol, Smal and Stul) providing for 
insertion of foreign gene fragments in each reading frame and finally stop codons in each 
of the three frames], and (v) rotavirus UKtc gene 8 fragments (VP7 protein) Cla1-Hha1 and 
Hinfl-EcoRV cloned into pSCI 1-30R. 2 (constructed by F. Xu). All cloning was performed 
in the rotavirus laboratory, University of Warwick. 
4.1.5 Bacterial strains 
The bacterial strains employed during the cloning of rotavirus genes were E. coli strain 
INVaF from Invitrogen's TA CloningTM system and E. coli strain MCI 061 obtained from 
Prof. M. McCrae, University of Warwick. 
Table 5. Sequence of Oligonucleotide Primers. Sequence in bold shows region of the 
primer that is complementary to the rotavirus gene 11 sequence. 
Primer name Sequence 
5' genet 1 5' TCCGGATCCAGATCTGGCCATGGCTTTTAAAGCGCT 3' 
3' genet 1. 3' GGGCCCGGGCACGTGGCCAGCTGCAGGTCACAAAACGGGA 5' 
5' gene II (orf2) 5' TCCGGATCCAGATCTAGACGTCGACGTGACGAGTCTTC 3' 
3' genet I(orf2) 3' GGGCCCGGGCATGCGGCCGCGGTACCTAGACACGCCAGCG/AT 5' 
5'P7.5 5' CATATGCCGGTAGTTGCGAT 3' 
5' TK 5' GAACGGCGGACATATTCAGT 3' 
3' TK 3' CATCGAGTGCGGCTACTATA5' 
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4.1.6 Rotavirus strains 
The bovine strain Compton UK tissue adapted (UKtc) (serotype 6) was originally provided 
by Dr. M. Thouless, East Birmingham Hospital, Birmingham. 
The simian strain RRV (serotype 3) was originally provided by Dr. D. 
Snodgrass, Moredun Research Institute, Edinburgh. 
Rotavirus was pre-treated with 10 µg/ml trypsin for 30 min at 37°C, and then 
propagated in the presence of 2 jig/ml trypsin. 
4.1.7 Vaccinia virus 
Recombinant vaccinia viruses were termed `vacc' followed by the rotavirus strain, protein 
number and restriction enzyme fragment, where appropriate. VaccUKtc. VPI, NS53, 
NS34, NS35 and NS28 were produced by S. Stagg, and vaccUKtc. VP4, VP6 and VP7 
were produced by R. Jenkins. VaccUKtc. VP7(Dral-EcoRV) and vaccUKtc. VP7(EcoRV- 
Hindu) were produced by F. Xu. All these virus recombinants were made in the rotavirus 
laboratory, University of Warwick. 
The wild-type vaccinia virus used was the Western Reserve strain WR+ and was 
provided by Prof. M. McCrae, University of Warwick. 
4.1.8 Animals 
Balb/c (H-2d) and C3H/He, mg (H-2k) mice were obtained from breeding colonies within 
the Department of Biological Sciences, University of Warwick. Balb, B (H-2b), C57BL/6 
(11-2b), C57BL/10 (H-2b), B10. D2/n (H-2d) and B10. BR (H-2k) mice were all purchased 
from Harlan UK limited, Bicester, Oxon. All mice were female and 6 to 10 weeks old 
when sacrificed. Mice were housed in negative pressure isolation units after inoculation 
with rotavirus. 
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4.1.9 Suppliers 
General chemicals were obtained from BDH Laboratory Supplies (Merck Ltd., Poole, 
Dorset), Fisons Scientific Equipment (Loughborough, Leics. ), and Sigma-Aldrich 
Company Ltd. (Poole, Dorset), and were of molecular biology or analytical grade. 
Equipment and other reagents (unless otherwise stated) were obtained from the 
following suppliers: Amersham International plc. (Little Chalfont, Bucks. ), 
Biotinylated goat anti rabbit IgG (H+L), Streptavidin fluorescein, 51Chromium-aqueous, 
Beckman Instruments Ltd. (High Wycombe, Bucks. ), centrifuge tubes, Becton 
Dickinson Ltd. (Oxford, Oxon. ), syringes, Difco Laboratories (Basingstoke, Hants. ), 
Bacto-agar, Bacto-tryptone, yeast extract, Gibco-BRL Life Technologies Ltd. (Paisley, 
Scotland), 1 Kb DNA ladder, restriction and modification enzymes, LipofectinTM, Dutch 
modified RPMI 1640 medium, Geneticin G418 sulphate, HAT supplement (50X) liquid, 
Invitrogen (R&D Systems Ltd., Abingdon, Oxon. ), TA CloningTM System, 
electroporation cuvettes and Nunclon (High Wycombe, Bucks. ), 75 cm2 and 150 cm2 
tissue culture flasks, 6-, 12-, 24-well tissue culture dishes and 96-well plates. 
4.2 CELL CULTURE 
4.2.1 Cell maintenance 
Cultured cells were maintained at 37°C in either a 5% CO2 incubator in a humidified 
atmosphere (for flasks) or on a rotary rolling bottle apparatus (Modular Cell Production, 
Model III) (for roller bottles), using the appropriate media (see section 4.1.2). 150cm2 
flasks and roller bottles of monolayer cells were passaged when confluent using 
trypsinNersene (1: 5) to detach the cells. 75 cm2 flask suspension cells (EL4 and P815) 
were subcultured when cell density reached 5X 106 cells/ml. All cells were reseeded at a 
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ratio of 1: 4 with fresh medium and manipulations were carried out under sterile conditions 
using standard aseptic techniques. 
4.2.2 Freezing and recovery of cell stocks 
Long-term cell stocks were prepared by suspending the cells from one 150 cm2 flask in 1.8 
ml of appropriate medium (see section 4.1.2) containing 30% FCS and 8% (v/v) 
dimethylsulphoxide (DMSO). The freezing vials were slowly cooled to -70°C and then 
immersed in liquid nitrogen. 
Cells were recovered by rapidly thawing the contents of one vial and transferring 
the cells to a 75 cm2 flask of pre-warmed medium. The medium was changed the 
following day. 
4.3 CLONING TECHNIQUES 
4.3.1 Rotavirus RNA extraction 
150 cm2 flask of confluent BS-C-1 cells were inoculated with rotavirus at a multiplicity of 
infection (moi) of 0.1. The cells were harvested at maximum cytopathic effect (cpe) 
following further incubation at 37°C, 5% CO2. The cells were pelleted by centrifugation 
and resuspended in 5 ml of lysis buffer containing 100 mM Tris-HCI pH 8.0,50 mM 
NaCl, 10 mM EDTA and 0.5% Nonidet P40. Following 10 min incubation on ice, the 
nuclei and unlysed cells were pelleted and the cytoplasmic supernatant collected. The 
supernatant was then incubated at 37°C for 3 hr following the addition of 0.5 mg/ml 
proteinase K and 0.5% SDS. The samples were then phenol extracted (three times), 
ethanol precipitated and resuspended in 50 µl of water. 
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4.3.2 Quantification of nucleic acids 
DNA and RNA were quantified in solution by spectrophotometry. Absorbance readings 
were taken at 260 nm (A260) where an absorbance of 1.0 was taken as indicating a 
concentration of 50 µg/ml for double-stranded DNA, or 40 µg/ml for RNA. 
Digested DNA was quantified using agarose gel electrophoresis (see section 
4.3.4) by comparing the band intensity of 1 µl of resuspended DNA with 200 ng of pGS62 
plasmid DNA. 
433 Reverse transcription polymerase chain reaction (RT-PCR) 
The reaction was set up in 50 µl containing RNA (approximately 100 ng), 4 µl of primer 
mixture (100 ng/µl) (see section 4.1.3) and 4 µl DMSO. This solution was then overlaid 
with 40 µl of liquid paraffin and subjected to 95°C for 2 min and 42°C for 2 min. 50 µl 2X 
RT-PCR reaction mixture (see section 4.1.1) was added to the solution and the incubation 
continued at 42°C for 33 min. 30 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 3 
min then followed using a DNA Thermal Cycler (Perkin Elmer Cetus). 
4.3.4 Agarose gel electrophoresis 
1.0% agarose in 1X TAE or TBE buffer (see section 4.1.1) was heated in a microwave for 
a few minutes and then cooled to about 50°C. 12.5 µg ethidium bromide was added to the 
agarose before pouring. 
DNA samples (and the routinely used 1 Kb ladder) were prepared by the addition 
of IOX loading buffer (see section 4.1.1) before being loaded into the preformed wells. 
Electrophoresis was performed at 90 mA for 60 min and the gels were photographed under 
UV light using Polaroid 665 or 667 film. 
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4.3.5 Purification of DNA from agarose gels 
A small quantity of agarose gel containing the required DNA fragment was prepared using 
a scalpel and the DNA was then purified using a BiolOl Gene Clean® II purification kit 
(Stratech Scientific, Luton, Beds. ). The manufacturers recommendations were followed. 
4.3.6 Direct cloning of PCR products 
The Invitrogen TA CloningTM System allowed for direct cloning of PCR products into the 
pCRTM II cloning vector. The manufacturer's recommendations were followed. 
4.3.7 Mini-plasmid preparation 
Mini-plasmid preparations (Maniatis et al., 1982) were used in the screening of 
transformants to prepare DNA for restriction enzyme digestion analysis. 
4.3.8 Restriction enzyme digestion 
Restriction enzyme digests were carried out under the conditions recommended by the 
suppliers. All reactions were carried out at 37°C. 
4.3.9 Maxi-plasmid preparation 
Plasmid DNA from positive transformants was amplified by maxi-preparation using the 
method described by Maniatis et a!. (1982). 
4.3.10 Blunt ending of DNA 
The 5' overhangs on digested DNA were removed using T4 DNA polymerase. A 20 µl 
volume containing digested DNA, 1X T4 polymerase buffer, 2 µl of 1 mM dNTPs and 1 
gi (0.1 units) T4 DNA polymerase was incubated at 11°C for 20 min. The enzyme was 
inactivated by the addition of 2 µl 0.5M EDTA. 
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4.3.11 Dephosphorylation of vector DNA 
10 µg of restriction endonuclease digested DNA was resuspended in 200 µl of IX calf 
intestinal phosphatase (CIP) buffer (0.5M Tris-HCI pH 9.0,10 mM MgCI2,1 mM ZnCI2 
and 10 mM Spermidine), including I pl CIP (1 unit/µl), and incubated at 37°C for 15 min 
followed by 60°C for 15 min. A further 1 µl of enzyme was added and the incubation 
repeated as before. The CIP was inactivated by the addition of 2 µl 0.5M EDTA. Samples 
were then phenol extracted (three times), ethanol precipitated and resuspended in 50 . tl of 
water. 
4.3.12 DNA sequence analysis 
DNA cycle sequencing was carried out using the Applied Biosystems 373A (version 1.2.0) 
Automated Sequencer by L. Ward, Department of Biological Sciences, University of 
Warwick, according to manufacturer's instructions. 
4.3.13 Ligation of DNA 
DNA fragments were ligated into phosphatased vector. Ligation was allowed to proceed at 
15°C overnight and contained DNA (insert (20): vector (1) mix), lOX ligation buffer 
(0.66M Tris-HCI pH 7.6,50 mM MgC12,50 mM DTT, 100 mM ATP) and I unit T4 DNA 
ligase, in a total volume of 15 µl. The DNA ligation mixture was ethanol precipitated and 
the vacuum dried pellet resuspended in 10 gl of distilled water. 
4.3.14 Electroporation 
Ligated DNA samples were electroporated into competent cells of the E. coli strain 
MCI 061 following the methods described in Maniatis et al. (1982). The cells were pulsed 
in a BIORAD Gene Pulser at 2.5 kV, with 25 µF set as capacitance and 200f1 on the pulse 
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controller. Cells were finally plated onto L-agar plates containing 100 µg/ml ampicillin. 
The plates were incubated at 37°C overnight and the DNA from potential clones was 
amplified using mini-plasmid preparation (see section 4.3.7). 
4.3.15 Polymerase chain reaction (PCR) 
A PCR was performed in a reaction volume of 25 µl. This contained DNA (approximately 
100 ng), I µI of primer mixture (100 ng/. tl) (see section 4.1.3) and IX PCR reaction 
mixture (see section 4.1.1). The solution was overlaid with 25 µl of liquid paraffin and 
subjected to 30 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 3 min. 10 µl of the 
reaction was analysed by agarose gel electrophoresis (see section 4.3.4). 
4 .4 CONSTRUCTION AND EXPRESSION 
OF RECOMBINANT VACCINIA 
VIRUS 
4.4.1 Transfection 
Approximately 90% confluent monolayers of CV-1 cells in 6-well tissue culture dishes 
were washed two times with PBS. Wild-type vaccinia virus (WR+) was added to the cells 
at an moi of 0.005 in a volume of 200 gl of PBS and the cells were incubated at 37°C, 5% 
CO2 for 90 min with gentle rocking every 20 min. 
Approximately 20 min before the end of the infection period, a transfection 
solution was prepared as follows: 15 µl of 1 mg/ml lipofectinTM was diluted into 1 ml of 
GMEM (no FCS) in a polystyrene tube. The tube was vortexed before 5 µg of plasmid 
DNA was added and the tube vortexed again. This solution was kept at room temperature 
for 15 min before being used. 
The virus inoculum was aspirated from the cell monolayer and the cells washed 
once in GMEM (no FCS). The plasmid DNA/lipofectinTM complex was added to each well 
of infected cells and the plates were returned to the 37°C, 5% CO2 incubator for 4 hr. 1 ml 
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of GMEM (10% FCS) was then added to each well and, after a further 48 hr incubation, 
the cells and medium were harvested using a rubber policeman and stored at -70°C. 
4.4.2 Selection of recombinants 
The TK selection method (Mackett et al., 1984) was used to screen for recombinant 
vaccinia virus. Transfected cells were freeze-thawed three times and sonicated for 30 sec 
to release virus. 10 and 100-fold dilutions were made in PBS. Confluent monolayers of 
HuTK" 143B cells in 6-well tissue culture dishes were washed in PBS (twice) and 200 µl 
of diluted virus was added to each well. Dishes were incubated at 37°C for 1 hr with gentle 
rocking every 20 min. Cells were then overlaid with 4 ml of GMEM (5% FCS) containing 
1.4% agar and 50 µg/ml 5'-bromodeoxyuridine (BrdU). Cells were incubated for 3 days 
before 0.1% neutral red (1: 3 diluted in PBS) was placed upon the agar overlays. After 4 hr 
incubation in the dark, the neutral red was removed and the dishes transferred to 4°C for 
30 min. Up to 20 isolated virus plaques were picked from each transfection, resuspended 
in 500 µl of GMEM (no FCS) and stored at -70°C. 
4.43 Extraction of vaccinia virus DNA 
Each well of a 12-well tissue culture dish of sub-confluent monolayer CV-1 cells were 
inoculated with 1/5 of a virus plaque (100 µl) and incubated at 37°C, 5% CO2. After 2 
days the cells were pelleted by centrifugation, resuspended in 200 µl of lysis buffer and 
treated as in section 4.3.1. 
4.4.4 Immunofluorescence of recombinant vaccinia viruses 
Confluent BS-C-l cells, grown on glass coverslips in 12-well tissue culture dishes, were 
infected with UKtc rotavirus (at an moi of 0.1), wild-type vaccinia virus (WR) or 
recombinant vaccinia virus (at an moi of 0.002). At 1 hr post-infection, cells were washed 
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and overlaid with 2 ml of GMEM (5% FCS). After a further 6 hr incubation at 37°C, the 
cells were fixed for 10 min with ice cold acetone/methanol (1: 1) and air-dried before 
washing twice in PBS. 
50 µl of primary antibody diluted 1/100 in PBS, rabbit anti-UKtc rotavirus third 
bleed (42148a UKtc, provided by Dr. S. Thomas, University of Warwick), was added to 
the cells and incubated at 37°C for 1 hr before washing twice in PBS. 50 Al secondary 
antibody diluted 1/200 in PBS, biotinylated goat anti rabbit IgG (H+L), was added to the 
cells and incubated at 37°C for 1 hr before washing twice in PBS. 50 µl streptavidin 
fluorescein diluted 1/400 in PBS was added to the cells and incubated at 37°C for 10 min 
before washing twice in PBS. The cover-slips were inverted and mounted onto slides in 
80% glycerol, 20% PBS and viewed under a UV microscope. 
4.5 VIRUS PROPAGATION 
4.5.1 Plaque purification of vaccinia virus 
Three wells of confluent monolayer CV-1 cells in a 6-well tissue culture dish were 
infected with 2/5 of a virus plaque (200 µl), 10-1 and 10-2 dilutions of the plaque, 
respectively, for 1 hr at 37°C and then overlaid with 4 ml of GMEM (5% FCS) containing 
1.4% agar. The cells were incubated for 3 days before 0.1% neutral red (1: 3 diluted in 
PBS) was placed upon the agar overlays. After 4 hr incubation in the dark, the neutral red 
was removed and the dishes transferred to 4°C for 30 min. Two isolated virus plaques 
were picked, resuspended in 500 µl of GMEM (no FCS) and three times freeze/thawed at - 
70°C. This procedure was repeated twice such that all vaccinia virus recombinants had 
been plaque purified three times before being propagated into virus stocks. 
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4.5.2 Preparation of vaccinia virus inoculum 
Confluent monolayer CV-1 cells in a 6-well tissue culture dish were infected with 2/5 of a 
plaque purified virus (200 µl) for 1 lhr at 37°C and 4 ml of GMEM was then added. The 
cells were incubated at 37°C until full cpe was observed and the cells were harvested into 
the growth medium. Confluent CV-1 monolayers in 150 cm2 flasks were then infected 
with the harvested virus in a total of 20 ml GMEM (5% FCS). Following complete cpe the 
virus was harvested. 
4.5.3 Large scale growth of vaccinia virus 
Virus was propagated using confluent CV-1 monolayers grown in two roller bottles. The 
cells were infected at an moi of s 0.1 and the virus inoculum was made up to 25 ml/bottle 
with GMEM (5% FCS). Virus was harvested following complete cpe and centrifuged at 
25,000 rpm, 4°C for 90 min in a Beckman SW28 rotor. Pellets were resuspended in 6 ml 
of GMEM (no FCS) and stored at -70°C until use. 
4.5.4 Preparation of rotavirus inoculum 
Confluent BS-C-1 monolayers in 150 cm2 flasks were washed with PBS, infected with 
trypsin treated rotavirus at an moi <_ 0.1 and made up to 15 ml with GMEM (no FCS). 
Virus growth was allowed to proceed for 3 to 5 days until complete cpe was observed. 
Virus was harvested and stored at -70°C. 
4.5.5 Large scale growth of rotavirus 
Trypsin treated rotavirus was propagated using confluent BS-C-1 monolayers grown in 30 
roller bottles. The cells were infected at an moi of <_ 0.1 and the virus inoculum was made 
up to 25 ml/bottle with GMEM (no FCS). Virus was harvested once complete cpe was 
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observed. Aprotinin (4 µg/ml) was added to the harvested virus to stabilise the double- 
shelled virus particles (Keljo and Smith, 1988). 
4.5.6 Rotavirus purification 
The viral and cellular debris were concentrated by centrifugation at 25,000 rpm, 4°C, for 
90 min in a Beckman SW28 rotor. Pellets were resuspended in virus resuspension buffer 
(50 mM Tris-HCI pH 8.0,10 mM NaCl, 1.5 mM 3-mercaptoethanol and 3 mM CaC12) and 
then homogenised with 1/10 volume of Arcton 113 (trifluoroethane) three or four times 
using a Virtis 123 homogeniser (3 min at half speed). The two phases were separated by 
low speed centrifugation (500 Xg, 4°C for 20 min). The aqueous phases from each 
extraction were pooled and back extracted with 1/15 volume of Arcton. The virus was 
concentrated by centrifugation at 25,000 rpm, 4°C for 2 hr in a Beckman SW28 rotor. The 
pellets were allowed to resuspend overnight at 4°C in 50 mM Tris-HCI pH 8.0. 
After resuspension by sonication, virus was loaded onto preformed p=1.2 to 1.4 
caesium chloride density equilibrium gradients. These were centrifuged at 20,000 rpm, 
4°C for 2 hr in a Beckman SW28 rotor. Double-shelled particles (p=1.36) and single- 
shelled particles (p=1.38) were collected together by side puncture, diluted in 50 mM Tris- 
HCl pH 8.0, and re-centrifuged as described for concentrating virus. The virus pellet was 
resuspended in 500 µl of Tris-HCI pH 8.0 and stored at -70°C until use. 
4.5.7 Titration of virus stocks 
CV-1 cells were used for vaccinia virus, whereas, BS-C-l cells were used for trypsin 
treated rotavirus. Serial 10-fold dilutions were prepared in PBS and 200 µl inoculated onto 
cells in 6-well tissue culture dishes. After incubation at 37°C for 1 hr, the cells were 
overlaid with GMEM (5% FCS) containing 1.4% agar and incubated for a further 4 days. 
The cells were fixed with formal-saline (30% formaldehyde in PBS v/v) for 5 hr and the 
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agar overlayers removed. The monolayers were then stained with 7.5% crystal violet for a 
few minutes and excess stain was removed with water. Clearly visible plaques were 
counted and the titre calculated. 
4.6 CHROMIUM-51 (" r)-RELEASE ASSAY TO MEASURE CTL ACTIVITY 
4.6.1 In vivo priming of mice 
Two mice (see section 4.1.8) were inoculated orally with purified, trypsin treated rotavirus 
of known titre [routinely 107 plaque forming units (pfu)] by proximal oesophageal 
intubation through a2 inch 18 gauge metal gavage (IMS, Cheshire). 
4.6.2 Preparation of spleen cell suspension 
Mice were sacrificed 7 days after oral, inoculation and the spleens removed. Single-cell 
suspensions were obtained by teasing the splenocytes through a 200 mesh stainless steel 
gauze using a5 ml plastic syringe plunger. The splenocytes were washed twice in RPMI 
DM (5% FCS) by centrifuging at 900 rpm for 5 min in a bench centrifuge (IEC Centra-7R) 
at room temperature. Red blood cells were removed using 2 ml of ice-cold water for 4 sec 
and the splenocytes were washed twice before being resuspended in 10 ml of RPMI DM 
(10% FCS) (responders). 
4.6.3 In vitro stimulation of splenocytes 
Splenocytes from primed mice (responders) were stimulated in vitro with rotavirus- 
infected, syngeneic splenocytes from unprimed mice (stimulators). The priming virus, at 
an moi of 1, was added to 2X 107 stimulators in a volume of 1 ml RPMI DM (no FCS) for 
1 hr at 37°C, 5% CO2. Using RPMI DM (10% FCS), responders were adjusted to 6X 106 
cells/ml and stimulators were adjusted to 3X 106 cells/ml. iml of both responders and 
stimulators were added to each well of a 24-well tissue culture plate. The final 
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concentration of cells per well was 9X 106 and the ratio of responders to stimulators was 
2: 1. The cells were cultured for 6 or 7 days in a 37°C, 5% CO2 incubator (effectors). 
4.6.4 Preparation of target cells 
Target cells (EL4, Ltk-, L-Db, L-Kb or P815) were washed once by centrifugation [1500 
rpm for 5 min in a bench centrifuge (IEC Centra-7R) at room temperature] and 
resuspended in 10 ml of RPMI DM (10% FCS) before being counted. 1X 106 cells were 
pelleted (as before) and the supernatant discarded. Wild-type vaccinia virus (WR) or 
recombinant vaccinia virus was added to the resuspended cells at an moi of 10 along with 
50 µCi of 51Cr in a total volume of 500 µl RPMI DM (10% FCS). The targets were 
incubated at 37°C, 5% CO2 for 90 min with occasional shaking of the tube by hand. 
Following this, excess 51Cr and virus were removed by washing three times (as before) in 
RPMI DM (5% FCS). The targets were resuspended in 3 ml of RPMI DM (10% FCS) and 
incubated at 37°C, 5% CO2 for a further 3.5 hr. The targets were again washed three times 
and resuspended in 10 ml RPMI DM (10% FCS) to give a final concentration of 1X 105 
cells/ml. 
4.6.5 51Cr-release assays 
In vitro primed splenocytes (effectors) were harvested by gentle pipetting, centrifuged at 
900 rpm for 5 min [bench centrifuge (IEC Centra-7R) at room temperature] and 
resuspended in 3 ml of RPMI DM (10% FCS). The effectors were counted and adjusted to 
3X 106 cells/ml with RPMI DM (10% FCS) to achieve a starting ratio of 30: 1 effector 
cells per target cell. 100 µl of effectors were then added to an equal volume of targets 
(invariably (X104 cells) in a 96-well round bottomed plate at ratios of 30: 1,10: 1,3: 1 and 
1: 1 in triplicate (for test 5 1Cr release). Twelve wells of the 96-well plate were left free of 
effector cells. To six of these wells, 100 µl of 5% Triton X-100 was added (for total S'Cr 
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release) and to the other six wells, 100 µl of RPMI DM (10% FCS) was added (for 
spontaneous 51Cr release). The plates were centrifuged at 900 rpm for 5 min and placed for 
5 hr at 37°C, 5% CO2 in a humidified incubator. 
100 µl of supernatant fluids were removed from each well, transferred into LP-2 
tubes (Luckhams) and sealed with 100 µl of molten paraffin wax. Radioactivity was 
measured for 1 min using a y-radiation counter (Packard Cobra auto-gamma). 
4.6.6 Calculation of the percentage specific lysis 
The percentage of specific lysis at each effector: target ratio was calculated using the 
following formula: 
% specific lysis = 100 X test 51Cr released - spontaneous 
51Cr released 
total 51Cr released - spontaneous 
51Cr released 
Positive CTL killing of target cells (infected with recombinant vaccinia virus) 
was defined by (i) a minimum 10% specific lysis, and (ii) a minimum threefold greater % 
specific lysis than the negative control (target cells infected with wild-type vaccinia virus). 
All assays were performed in triplicate and results were calculated as an average of three 
values. All experiments were performed at least twice with similar results. 
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CHAPTER 5 
CLONING OF ROTAVIRUS GENE 11 
INTO THE pGS62 VACCINIA SHUTTLE VECTOR 
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5.1 AIMS 
The aim of the work described in this chapter was to clone both the full length open 
reading frame of rotavirus UKtc gene 11 and the second, shorter, open reading frame 
[gene 11(orf2)] into the vaccinia shuttle plasmid pGS62. This would complete the cloning 
of the full complement of rotavirus UKtc genes into this vector. 
PCR AMPLIFICATION OF ROTAVIRUS UK'I 
Primers were designed based on the UKtc gene 11 sequence obtained from the EMBL 
database. Two sets of primers termed 5' and 3' gene 11 and 5' and 3' gene 11(orf2) (see 
Table 5) allowed amplification of the whole gene 11 and the second open reading frame 
(orf2) of gene 11, respectively. Primers were designed with various restriction enzyme 
sites added to their 5' ends to allow easier handling of the cloned gene 11 DNA. 
Two separate RT-PCR reactions were carried out, each using 100 ng of extracted 
rotavirus UKtc RNA and one of the primer pairs. The amplified DNA obtained was 
analysed using agarose gel electrophoresis (see Figure 8) and PCR products of the 
expected size, namely 713 base pairs (bp) for gene 11 and 304 bp for gene 11(orf2) were 
obtained in these RT-PCR reactions. The amplified cDNA's were excised from the gel and 
the DNA purified using the Gene Clean 9 II kit. 
IV LONI TM [(OTAVIR 
The gene 11 PCR products were first cloned using the TA cloningTM. system because this 
kit allows the direct ligation of amplified PCR products into the pCRTM II vector (see 
Figure 9). Insertional inactivation of pCRTM II leads to a frame shift and the formation of 
positive white colonies, whereas, negative blue colonies result from a T: T mismatch and 
self-ligation of the vector. 
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FIGURE 8. PCR AMPLIFIED ROTAVIRUS UKTC GENE 11 PRODUCTS 
Rotavirus UKtc gene 11 and gene I I(orf2) DNA were both amplified by RT-PCR using the 
protocol described in section 4.3.3 of Materials and Methods. The 5' and 3' gene II and 
gene 1 l(orf2) primers were used (Table 5) to amplify products of 713 bp and 304 bp, 
respectively. The products were analysed using a 1% agarose gel. Lane M shows the DNA 
size markers, lane I shows PCR amplified gene II and lane 2 shows PCR amplified gene 
II(orf2). 
FIGURE 10. POTENTIAL GENE 11 CLONES DIGESTED FROM pCRTM II 
VECTOR USING ECORI RESTRICTION ENZYME 
The PCR amplified gene 11 and gene I l(orf2) were directly cloned into pCRTM II plasmid 
from the TA cloning1M system as described in 4.3.6 of Materials and Methods. Following 
mini-plasmid preparation, potential clones were screened using restriction enzyme digestion 
as described in section 4.3.8 of Materials and Methods and the digestion products Were 
analysed using a 1% agarose gel. Digestion with EcoRl was used since the insertion site of 
the pCRTM 11 vector is flanked by sequences digested by this enzyme (5 bp either side of the 
insertion site). EcoRl sites are not present in the inserted sequences or elsewhere in the 
vector and, consequently, EcoRl digestion resulted in products of 731 bp and 322 bp 
(including the 5' overhangs produced) for gene II and gene Il(orf2) positive clones, 
respectively. Lane M shows the DNA size markers, lanes 1,2 and 3 show screening of 
potential pCRTM 11 clones containing genet l (all lanes were deemed positive) and lanes 4 
and 5 show screening of potential pCRTM II clones containing gene I1(orf2) (lane 5 was 
deemed positive). 
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FIGURE 9. MAP OF THE pCRTM II VECTOR FROM TILE TA CLONING TM 
SYSTEM 
The PCR amplified products (in red) were directly inserted into the pCRTM II vector using 
the TA cloningTM system. The non-template dependent activity of Taq polymerase used in 
PCR adds single deoxyadenosines to the 3'-end of all duplex molecules. The pCRTM II 
insertion site contains 3' T-overhangs which allow direct ligation of the PCR product. 
Surrounding the PCR product are several restriction enzyme sites (in blue) which allow 
easier handling of the cloned gene. (Although not employed in this study, the presence of 
the Sp6 and T7 promoter sequences allow transcription of insert DNA when used in the 
correct system). 
The pCRTM II vector contains a bacterial plasmid component including the E. coli 
DNA origin of replication (ColEI ori) to allow propagation in E. coli and both ampicillin 
(Amp`) and kanamycin (Kan) resistance genes to allow selection of bacteria carrying the 
plasmid. The presence of the c(-peptide of 3-galactosidase and its promoter, lacZa and Plac 
respectively, allow blue/white selection since insertional inactivation leads to a frame shift 
and the formation of white colonies. Blue colonies result from a T: T mismatch self-ligation 
of the vector. (Although not used in this study, the F1 origin of replication (F1 ori) allows 
replication of cloned single strand vector DNA following superinfection of E. coli with the 
F1 helper phage). 
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The DNA from mini-plasmid preparations of the positive white colonies were 
digested with EcoRl and analysed using agarose gel electrophoresis (see Figure 10). 
Colonies giving insert bands of the correct sizes, 731 bp for gene 11 and 322 bp for gene 
11(orf2), were deemed positive clones. 
5.4 pGS62 CLONING OF ROTAVIRU GENF, 11 
The second step was to sub-clone the cDNA into the pGS62 shuttle plasmid vector (see 
Figure 11). This vector was used since it ensures that the inserted sequences are inserted 
downstream of the vaccinia virus compound early/late P7,5 promoter which provides the 
vaccinia virus-specific transcription regulatory signals essential for efficient expression of 
the foreign gene. Flanking the P7,5 promoter (and inserted gene) is the non-essential 
vaccinia virus thymidine kinase (TK) gene. The TK gene allows homologous 
recombination to occur between the wild-type (WT) vaccinia virus genome and the pGS62 
vector thereby generating a recombinant vaccinia virus. 
The pGS62 shuttle vector was linearised by digestion at the unique Smal 
restriction enzyme site. The two pCRTM II clones, gene 11 and gene 11(orf2), were double 
digested using the Smal and BamHI restriction enzymes to release their cDNA inserts. The 
digestion products were fractionated by agarose gel electrophoresis and bands of the 
correct size, 703 bp for gene 11 and 394 bp for gene 11(orf2), were excised from the gel 
and the DNA purified using the Gene Clean II kit. The amount of vector and insert DNA 
were assessed by agarose gel electrophoresis (see Figure 12). 
The linearised pGS62 DNA was dephosphorylated using CIP to prevent self- 
ligation of the vector. The 5' overhang in the insert DNA produced by digestion with 
BamHI was removed using T4 DNA polymerase to allow blunt end ligation into the blunt 
ended Smal cut vector. 
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FIGURE 11. MAP OF THE SHUTTLE PLASMID VECTOR pGS62 
The pGS62 vaccinia shuttle vector contains a number of elements. The bacterial component 
(in blue) was generated from pBR328 and a consists of an origin of replication to allow 
plasmid propagation in E. coli and an ampicillin resistance gene (Amp`) to allow selection 
of the bacteria carrying the plasmid. The vaccinia virus component (in black) consists of the 
compound early/late gene promoter sequence derived from a gene encoding a 7.5-kDa 
structural protein (P7.5) joined to a multi-restriction enzyme linker sequence (in red). These 
elements have been placed within the vaccinia virus thymidine kinase gene. The P7.5 
promoter drives the trancription of the foreign gene (normally inserted within the multi- 
restriction enzyme linker sequence) and the flanking TK components allow recombination, 
within infected cells, between the shuttle plasmid and the wild-type (WT) vaccinia virus 
genome. This generates a recombinant vaccinia virus (with a TK7 phenotype) which 
contains the gene of interest and control elements for its expression during virus replication. 
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FIGURE 12. QUANTIFICATION OF PCRTM' II CLONED GENE 11 INSERTS 
DIGESTED WITH BAMHI AND SMAI, AND pGS62 VECTOR DIGESTED WITH 
SMAI 
The pGS62 shuttle vector was linearised by digestion at the unique SmaI site as described in 
Materials and Methods. Double digestion with BamHI and Smal restriction enzymes of 
positive pCRTM II clones resulted in products of 703 bp and 394 bp for gene 11 and gene 
II(orf2), respectively. The vector and insert fragments were excised from the gel and 
purified as described in section 4.3.5 of Materials and Methods. The vector and insert DNA 
was then quantified, following electrophoresis on a 1% agarose gel, by comparing the band 
intensity of I ial of purified DNA with 200 ng of uncut pGS62 (as described in section 4.3.2 
of Materials and Methods). Lane M shows the DNA size markers, lane I shows 200 ng of 
uncut pGS62, lane 2 shows 1 µI of linearised pGS62 (-100 ng/gl), lane 3 shows 1 µl of 
digested genel 1 (-100 ng/µl) and lane 4 shows 1 gl of digested gene 11(orf2) (-100 ng/pl). 
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Digested pGS62 vector was ligated with gene 11 or gene 11(orf 2) insert at a 
ratio of 20: 1. The ligated DNA was then electroporated into competent E. coli MCI 061 
cells. Selection was allowed by the presence of the ampicillin gene in pGS62 and some of 
the resulting colonies were picked for screening. 
DNA from mini-plasmid preparations made from colonies were screened for 
positive clones by PCR. PCR not only confirmed ligation of the gene 11 inserts into the 
pGS62 vector but also checked that the insert was in the correct orientation with respect to 
the vaccinia P7.5 promoter within pGS62 (see Figure 13). PCR amplification using the 3' 
TK and 5' gene 11 or gene 11(orf2) primers (see Table 5) lead to positive PCR products of 
760 bp for gene 11 and 351 bp for genel l(orf2). However, due to 5' primer being situated 
within the insert and the 3' primer being situated within the vector, PCR amplification 
would only proceed if the insert was in the correct orientation. The PCR products were 
analysed using agarose gel electrophoresis (see Figure 14) and positive clones (in the 
correct orientation) were obtained for both gene 11 and gene 11(orf2). 
Purified plasmid DNA was prepared from one positive pGS62 clone for either 
insert using the maxi-plasmid preparation method. 
Both gene 11 pGS62 clones were sequenced in duplicate by L. Ward, University of 
Warwick, using an automated sequencer. The 5' and 3' gene 11 and gene Il (orf2) primers 
were used to sequence the gene 11 inserts within the pGS62 vector. Sequencing was 
performed to check that the PCR amplification or cloning steps had not introduced any 
serious errors, such as stop codons, into the genes. 
A single nucleotide change from the published gene 11 sequence was obtained at 
position 91 (A: T to C: G). This results in an amino acid change at position 30 in gene 11 
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FIGURE 13. CONFIRMATION OF pGS62 CLONED GENE 11 INSERT 
DIRECTION BY PCR AMPLIFICATION 
PCR was used to confirm that the inserted rotavirus gene 11/gene II(orf2) fragment (shown 
in red) had been cloned into the vaccinia pGS62 shuttle vector and that the orientation of 
insertion was correct with respect to the P7.5 vaccinia promoter. This was achieved by using 
the 5' gene 11 or 5' gene 11(orf2) primer with the 3' TK primer (in blue). Gene 11 insertion 
in the correct orientation would allow the PCR amplification to proceed giving a product of 
760 bp for gene 11 and 351 bp for gene 11(orf2). This includes an additional 50 bp added to 
the insert size because the 3' TK primer is 50 bp in distance from the insertion position. If 
there was no insertion, or the inserts were in the wrong orientation, no PCR products would 
be obtained. 
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FIGURE 14. PCR AMPLIFIED PRODUCTS OF POTENTIAL pGS62 CLONES 
CONTAINING ROTAVIRUS UKTC GENE 11 AND GENE 11(ORF2) 
Digested and prepared gene 11 and gene 1l (orf2) DNA from the pCRTM II vector were 
cloned into pGS62 shuttle plasmid at the Smal site as described in Materials and Methods. 
Following mini-plasmid preparations, potential clones were screened using PCR 
amplification as described in section 4.3.15 of Materials and Methods. The 5' gene l1 and 
3' TK primers and the 5' gene 11(orf2) and 3' TK primers (Table 5) resulted in products of 
760 bp and 351 bp, respectively. The amplified products were analysed using a 1% agarose 
gel. In both panels lane M shows the DNA size markers and lane A shows the PCR positive 
control consisting of Adenovirus DNA and a primer pair that gave a product of 
approximately 500 bp from the left hand end of the Adenovirus genome. 
Panel A: Lanes 1 to 8 show screening of potential pGS62 clones containing gene 11 (lanes 
1,3,4,6 and 7 were deemed positive). 
Panel B: Lanes I to 10 show screening of potential pGS62 clones containing gene 11(orf2) 
(lanes 3,4,5,7 and 8 were deemed positive). 
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FIGURE 14 
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(ser-a pro) (data not shown). No changes were observed in gene 11(orf2) (data not 
shown). 
5.6 CONCLUSIONS 
The complete rotavirus UKtc gene 11 and the second open reading frame within gene 11, 
termed gene 11(orf2), have been successfully cloned into the vaccinia shuttle plasmid 
pGS62. Sequencing revealed one amino acid change within the gene 11 insert of pGS62 
from the published sequence, which may have been introduced during the cloning 
procedure (aa 30 of gene 11, ser-* pro). 
This completed the cloning of the full complement of rotavirus UKtc genes into 
the pGS62 shuttle vector. This vector, in turn, allowed the construction of recombinant 
vaccinia viruses. 
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CHAPTER 6 
CONSTRUCTION OF RECOMBINANT VACCINIA VIRUSES 
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6.1. AIMS 
The aim of the work described in this chapter was to use vaccinia shuttle plasmids 
containing various rotavirus genes (see Table 6) to construct recombinant vaccinia virus 
containing those genes. The vaccinia virus expression system was used because these 
viruses have a wide host range. In addition, vaccinia virus DNA replication begins within 
a few hours post-infection and, thus, foreign proteins are expressed in the infected cell 
prior to cpe. The infected cells may, therefore, present foreign protein epitopes in 
association with MHC class I molecules and act as targets during the 51Cr-release assay to 
measure CTL activity. 
Table 6. Constructed vaccinia shuttle plasmids provided 
Rotavirus strain Gene (protein) Fragment Plasmid Constructed by 
UKtc Gene 2 (VP2) pGS62 Prof. McCrae 
UKtc Gene 3 (VP3) pGS62 Prof. McCrae 
RRV 
Hochi Gene 5 (NS53) pGS62 Prof. McCrae 
P9DA5 
RRV 
A64 
Hochi Gene 7,8 or 9 (VP7) pGS62 Prof. McCrae 
69M 
Wa 
WI-61 
UKtc Gene 8 (VP7) ClaI-HhaI pSCI i-30R. 2 F. Xu 
Hinft-EcoRV 
UKtc Gene I1 (NS26) pGS62 R. Heath 
UKtc Gene 11(orf2) (NS12) pGS62 R. Heath 
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6.2 PRODUCTION OF RECOMBINANT VACCINIA VIRUSES CONTAINING 
ROTAVIRUS GENES (USING THE pGS62 VECTOR) 
CV-1 cells were infected with wild-type vaccinia virus (WR+) and transfected with the 
pGS62 shuttle vector containing an individual rotavirus gene using lipofectinTM (see Table 
6). This allowed for homologous recombination to occur between the vaccinia TK gene 
sequences in the plasmid and virus DNA TK gene sequences (see Figure 15). Following 
each rotavirus gene transfection, the cells and medium were harvested, freeze-thawed 
three times and diluted 10- and 100-fold. 
The diluted virus samples were plaqued on HuTK' 143B cells in the presence of 
5-bromodeoxyuridine (BrdU). This allowed vaccinia viruses with a TK- phenotype (and 
potentially containing the rotavirus gene of interest) to be distinguished from those with a 
TK+ phenotype because BrdU is phosphorylated by TK activity and incorporated into the 
virus genome where it causes lethal mutations. Viruses from up to twenty plaques for each 
transfected rotavirus gene, deemed TK- following selection with BrdU, were recovered 
and resuspended in medium. A fifth of each sample was propagated on CV-1 cells and the 
DNA extracted when complete cpe was evident. 
The extracted DNA was subjected to PCR amplification using the 5' and 3' TK 
primers (see Table 5). In the case of WT vaccinia virus DNA (which presumably escaped 
BrdU selection due to mutation in their TK gene), these primers amplified a product 
including part of the TK gene sequence (300 bp). However, with DNA from positive 
recombinant vaccinia viruses, these primers amplified a product which included the 
flanking TK gene sequences (300 bp), the P7.5 promoter (322 bp) and the rotavirus gene 
insert (See Figure 16A and Table 7). 
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FIGURE 15. GENERATION OF RECOMBINANT VACCINIA VIRUS 
Following infection of TK_ cells with WT vaccinia virus, shuttle vector (pGS62 or pSCII- 
30.82) containing a foreign gene was transfected into the cell. A double cross-over event 
occurs between the homologous TK sequences of the vaccinia virus genome and the shuttle 
plasmid. This homologous recombination results in the insertion of the foreign gene and its 
control elements into the vaccinia virus genome rendering it TK-. Recombinant vaccinia 
viruses with a TK_ phenotype are then distinguished from WT vaccinia viruses with a TK+ 
phenotype using the BrdU screening procedure. A TK' cell line is infected with potential 
recombinant vaccinia virus diluted 10 and 100-fold and overlaid with agar containing BrdU. 
The WT vaccinia virus active TK gene phosphorylates BrdU which is then incorporated into 
the WT vaccinia virus genome where it causes lethal mutations. Thus, following incubation, 
the visible virus plaques have a TK- phenotype and probably contain the foreign gene of 
interest. 
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FIGURE 16. ANALYSIS OF RECOMBINANT VACCINIA VIRUS BY PCR 
Potential recombinant vaccinia virus were screened by PCR. Two sets of primers were 
employed depending on the vaccinia shuttle plasmid used in the construction of the 
recombinants. 
(A) When screening for recombinants generated using the pGS62 shuttle plasmid, 5' and 3' 
TK primers (Table 5) were used. In WT vaccinia virus, these primers amplify a product of 
300 bp in size (TK gene sequence). Recombinant vaccinia viruses are easily identified 
because these primers amplify a product of 300 bp (TK gene sequence) plus 322 bp (P7.5 
promoter sequence) plus the foreign gene insert size (see Table 7). 
(b) When screening for recombinants generated using the pSCI1-30R. 2 shuttle plasmid, 5' 
P7 5 and 3' TK primers (Table 5) were used. In WT vaccinia virus, the P7,5 promoter is 
located well away from the TK gene and, consequently, no visible PCR product is 
generated. Recombinant vaccinia viruses are easily identified because these primers amplify 
a product of 230 bp (P7.5 promoter/ TK gene sequence) plus the foreign gene insert size (see 
Table 8). 
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Table 7. The rotavirus gene insert size (in pGS62 shuttle vector) and the predicted 
amplified PCR product size following successful construction of recombinant 
vaccinia viruses 
Gene (protein) pGS62 insert size (bp) PCR product size (bp) 
Gene 2 (VP2) 2691 3313 
Gene 3 (VP3) 2591 3213 
Gene 5 (NS53) 
mutant gene 5 (P9D05) (NS53) 
1581 
1273 
2203 
1895 
Gene 7,8 or 9 (VP7) 1062 1681 
Gene 11 (NS26) 703 1325 
Genei l(orf2) (NS 12) 394 1016 
The PCR products were analysed using agarose gel electrophoresis and positive 
recombinant vaccinia viruses, vaccUKtc. VP2, VP3, NS26 and NS12, were obtained (see 
Figure 17). These recombinants completed the full complement of vaccinia viruses 
carrying rotavirus genes from the UKtc rotavirus strain. The recombinant vaccinia viruses 
were to be used to define all the rotavirus UKtc proteins which elicited a CTL response in 
three different mouse haplotypes. 
A specific CTL response to the rotavirus UKtc NS53 protein was found in the H- 
2b mouse haplotype during the course of this study (S. Stagg, personal communication) 
and, for this reason, the analysis of the CTL response to the NS53 protein was extended to 
cover two more rotavirus strains. Positive recombinant vaccinia viruses, vaccRRV. NS53 
and Hochi. NS53, were obtained (see Figure 18). Also, to locate the position of epitopes 
recognised by CTLs in the UKtc NS53 protein, the rotavirus strain P9DA5 was used. This 
strain was isolated in Scotland and sequence data revealed close sequence homology to the 
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FIGURE 17. SCREENING BY PCR OF POTENTIAL RECOMBINANT VACCINIA 
VIRUSES CONTAINING VARIOUS ROTAVIRUS UKTC GENES 
Following transfection, potential recombinant vaccinia virus was recovered from plaques 
after selection in the presence of BrdU. The virus was used to infect cells and DNA samples 
were extracted from these as described in Materials and Methods. The vaccinia virus DNA 
samples were screened using PCR amplification as described in section 4.3.15 of Materials 
and Methods. 5' and 3' TK primers (Table 5) were used and the amplified products analysed 
using a 1% agarose gel. In all panels, lane M shows the DNA size markers and lane A is the 
Adenovirus PCR control (see Figure 14). 
Panel A: Lanes I to 5 show screening of potential recombinant vaccinia virus containing 
rotavirus UKtc gene 2 (vaccUKtc. VP2). The PCR amplification gave a product of 3313 bp 
for positive recombinant vaccinia virus (all lanes were deemed positive). 
Panel B: Lanes I to 13 show screening of potential recombinant vaccinia virus containing 
rotavirus UKtc gene 3 (vaccUKtc. VP3). The PCR amplification gave a product of 3213 bp 
for positive recombinant vaccinia virus (lanes 1 to 3 and 5 to 13 were deemed positive). 
Panel C: Lanes 1 to 13 show screening of potential recombinant vaccinia virus containing 
rotavirus UKtc gene 11 (vaccUKtc. NS26). The PCR amplification gave a product of 1325 
bp for positive recombinant vaccinia virus (lanes 4,5,8 and 11 were deemed positive) and 
300 bp for WT vaccinia virus. 
Panel D: Lanes I to 10 show screening of potential recombinant vaccinia virus containing 
rotavirus UKtc gene I l(orf2) (vaccUKtc. NS12). The PCR amplification gave a product of 
1016 bp for positive recombinant vaccinia virus (lanes 4 and 7 were deemed positive) and 
300 bp for WT vaccinia virus. 
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FIGURE 17 
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515/506 bp 
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1635 bp 
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FIGURE 18. SCREENING BY PCR OF POTENTIAL RECOMBINANT VACCINIA 
VIRUSES CONTAINING GENE 5 FROM VARIOUS ROTAVIRUS STRAINS 
The PCR amplification and subsequent analysis of the products was carried out as detailed 
in Figure 17 again using the 5' and 3' TK primers. In both panels, lane M shows the DNA 
size markers. 
Panel A: Lanes I to 8 show screening of potential recombinant vaccinia virus containing 
rotavirus RRV gene 5 (vaccRRV. NS53). The PCR amplification gave a product of 2203 bp 
for positive recombinant vaccinia virus (all lanes were deemed positive) and 300 bp for WT 
vaccinia virus (lane 7 appears to be mixed plaque containing both recombinant vaccinia 
virus and WT vaccinia virus). 
Panel B: Lanes 1 to 3 show screening of potential recombinant vaccinia virus containing 
rotavirus Hochi gene 5 (vacdHochi. NS53) and lanes 4 to 6 show potential recombinant 
vaccinia virus containing rotavirus P9D05 gene 5 (vaccP9D05. NS53). The PCR 
amplification gave a product of 2203 bp for Hochi gene 5 recombinant vaccinia virus (all 
lanes were deemed positive) and 1895 bp for P9DA5 gene 5 recombinant vaccinia virus (all 
lanes were deemed positive). 
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FIRURE 18 
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M12345678M 
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2036 bp 
1635 bp 
516/506 bp 
UKtc strain gene 5 (Tian et al., 1993). However, the P9Dz5 gene 5 has a 300 bp deletion 
starting at nucleotide 450. The deletion is followed by an `out of frame' translation stop 
codon which becomes `in frame' due to the deletion and this leads to the expression of 
only the first 150 amino acids of the NS53 protein (Tian et al., 1993). A positive NS53 
recombinant vaccinia virus with a 300 bp shorter PCR product, vaccP9DA5. NS53, was 
obtained (see Figure 18). 
Previous work, involving the rotavirus group at the University of Warwick, 
showed that the outer shell glycoprotein VP7 is a major target antigen for a CTL response 
that is serotype-independent between two of the fourteen VP7 serotypes (Offit et al., 
1994). Therefore, to extend and confirm the serotype independence of the VP7-specific 
CTL response, recombinant vaccinia viruses containing VP7 from seven of the fourteen 
serotypes were constructed. Positive recombinant vaccinia viruses, vaccRRV. VP7, 
A64. VP7, Hochi. VP7,69M. VP7, Wa. VP7 and WI-61. VP7, were obtained (see Figure 19). 
6 .3 PRODUCTION 
OF RECOMBINANT VACCINIA VIRUSES CONTAINING 
FRAG NTs a FR S GENES (USING THEVSC11-30R 2 VECTOR 
As mentioned in the above section, previous work found that the rotavirus VP7 protein is a 
major target antigen for a CTL response that is serotype-independent between two of the 
fourteen VP7 serotypes (Offit et al., 1994). To locate the position of epitopes in the UKtc 
VP7 protein recognised by CTLs, F. Xu began the construction of a panel of recombinant 
vaccinia viruses containing restriction enzyme digested 
fragments of UKtc gene 8 (VP7) 
(see Figure 20). 
Previous work at Warwick had shown that a rotavirus UKtc VP7 recombinant 
vaccinia virus which did not containing the 5' end of the gene to the Clal site at nucleotide 
90 gave the same CTL response as a recombinant containing a cDNA of the entire gene. 
The UKtc gene 8 also contains two in-frame ATG's used for translation initiation at 
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FIGURE 19. SCREENING BY PCR OF POTENTIAL RECOMBINANT VACCINIA 
VIRUSES CONTAINING THE GENE (7,8 OR 9) ENCODING THE VP7 PROTEIN 
OF VARIOUS ROTAVIRUS STRAINS 
The PCR amplification and subsequent analysis of the products was carried out as detailed 
in Figure 17 using the 5' and 3' TK primers. In all panels, lane M shows the DNA size 
markers and lane A shows the Adenovirus PCR control (see Figure 14). The PCR 
amplification gave a product of 1681 bp for gene 9 recombinant vaccinia virus and 300 bp 
for WT vaccinia virus. 
Panel A: Lanes 1 to 11 show screening of potential recombinant vaccinia virus containing 
rotavirus RRV gene 9 (vaccRRV. VP7). Lanes 1,2,7,8,10 and II were deemed positive. 
Panel B: Lanes I to II show screening of potential recombinant vaccinia virus containing 
rotavirus A64 gene 9 (vaccA64. VP7). Lanes I and 7 were deemed positive. 
Panel C: Lanes I to 9 show screening of potential recombinant vaccinia virus containing 
rotavirus Hochi gene 9 (vaccHochi. VP7). Lane 3 was deemed positive. 
Panel D: Lanes 1 to II show screening of potential recombinant vaccinia virus containing 
rotavirus 69M gene 9 (vacc69M. VP7). Lanes 1,3,4,5 and 9 were deemed positive. 
Panel E: Lanes I to 1I show screening of potential recombinant vaccinia virus containing 
rotavirus Wa gene 9 (vaccWa. VP7). Lanes 3,5 and 9 were deemed positive. 
Panel F: Lanes 1 to 11 show screening of potential recombinant vaccinia virus containing 
rotavirus WI-61 gene 9 (vaccWl-61. VP7). Lanes 1,2,3,8,9 and 10 were deemed positive. 
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FIGURE 20. UKTC GENE 8 (VP7 PROTEIN) FRAGMENTS CLONED INTO pSC1I- 
30R. 2 
The fragments of rotavirus UKtc gene 8 were derived from a full-length cDNA inserted into 
the Bluescribe cloning vector. F. Xu digested UKtc gene 8 with a number of restriction 
enzymes to produce four fragments. After purification using the Gene Clean® II kit, the 
fragments were rendered `blunt-ended' before insertion into the pSC11-30R. 2 vaccinia 
shuttle vector (see Figure 21). The vector was digested with the appropriate enzyme to 
allow `in-frame' insertion. The fragments Clal-IIhaI and Iiinfl-EcoRV were received cloned 
into pSCI 1-308.2 whereas, Dral-EcoRV and EcoRV-Ilincll were received as recombinant 
vaccinia viruses. 
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nucleotides 49 and 139 respectively, the second having a stronger consensus sequence for 
initiation. For these reasons, F. Xu concentrated on cloning fragments of UKtc gene 8 
spanning from the Clal site to the 3' end of this gene. During the period of her study, she 
had cloned the ClaI-HhaI, Dral-EcoRV, Hinfl-EcoRV and EcoRV-HinclI UKtc gene 8 
fragments into the pSC11-30R. 2 vaccinia shuttle vector and, in addition, constructed 
recombinant vaccinia viruses, vaccUKtc. VP7(Dral-EcoRV) and (EcoRV-Hincll), from 
their corresponding shuttle vectors. 
The pSCI1-30R. 2 vector (see Figure 21) is similar to the pGS62 vaccinia shuttle 
vector in that the cloned genes are linked to the vaccinia virus compound early/late P7.5 
promoter and both are flanked by components of the non-essential vaccinia virus TK gene. 
The pSC11-30R. 2 vector was used, rather than the pGS62, because the fragments of UKtc 
VP7 do not contain their own ATG translation initiation codons. The pSC11-30R. 2 vector 
contains an inserted oligonucleotide downstream of the P7.5 promoter which has an 
initiator ATG followed by three restriction enzyme sites (Ncol, Smal and Stul) to allow 
translation of the inserted DNA in each of the three potential reading frames. Three stop 
codons are also included in the inserted oligonucleotide, 
downstream of the insert site, to 
terminate translation in each of the three reading frames. 
The transfection method used to construct recombinant vaccinia viruses from the 
pSCll-30R. 2 vaccinia shuttle vector was identical to that employed for pGS62 (see 
section 6.2). Viruses from up to twenty plaques 
for each transfected UKtc gene 8 
fragment, deemed TK- following selection with BrdU, were again recovered and 
resuspended in medium. A fifth of each sample was propagated on CV-1 cells and the 
DNA extracted following complete cpe. 
The extracted DNA was subjected to PCR amplification using the 5' P7.5 and 3' 
TK primers (see Table 5). In WT vaccinia virus , the P7.5 promoter is located well away 
from the TK gene and, as a consequence, no visible PCR products were generated. From 
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FIGURE 21. MAP OF THE SHUTTLE PLASMIID VECTOR pSC11-308.2 
pSC II is a well-known vaccinia shuttle vector (Chakrabarti et al. 1985). Shown in blue is 
the bacterial component of this plasmid containing an origin of replication for propagation 
in E. coli and an ampicillin resistance gene (Amp`) to allow selection of bacteria carrying 
this plasmid. The lacZ gene of E. coli is shown in yellow and can be used to screen potential 
recombinant vaccinia virus. The vaccinia virus components (in black) consist of two 
promoters, P, 1 and P7 5 which drive expression of the lacZ gene and the foreign gene 
respectively. These elements had been placed within the vaccinia virus thymidine kinase 
(TK) gene which allows recombination, within infected cells, between the shuttle plasmid 
and the wild-type vaccinia virus genome. This generates a recombinant vaccinia virus (with 
a TK- phenotype) which contains the gene of interest and control elements for its expression 
during virus replication. 
The pSCI I vector was modified by insertion of an oligonucleotide (sequence 
shown) at the Smal site to generate pSC11-30R. 2. The oligonucleotide contains an initiator 
ATG downstream of which are three unique restriction enzymes sites (Ncol, Smal and Stul) 
providing for insertion of foreign gene fragments in each reading frame and, finally, stop 
codons in each of the three frames. 
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FIGURE 21 
Ncol Smal Stul 
CCATGGCCCGGGAAGGCCTAGCTGACTAGATCT 
positive recombinant vaccinia viruses, these primers amplified a product including the 
flanking P7.5/TK gene sequences (230 bp) plus the foreign gene insert (See Figure 16B and 
Table 8). 
Table S. The rotavirus UKtc gene 8 restriction enzyme fragment insert. size (in 
pSC11-30R. 2 shuttle vector) and the predicted amplified PCR product size following 
successful construction of recombinant vaccinia viruses 
Restriction enzyme fragment pSCI 1-30R. 2 insert size (bp) PCR product size (bp) 
CIaI-HhaI 106 336 
Hinfl-EcoRV 119 349 
Positive recombinant vaccinia viruses, vaccUKtc. VP7(ClaI-Hhal) and (Hinfl- 
EcoRV), were obtained (see Figure 22) and this completed the construction of a panel of 
recombinant vaccinia viruses containing restriction enzyme digested fragments of UKtc 
gene 8 (VP7). These were used in the localisation of the rotavirus UKtc VP7-specific CTL 
epitope(s). 
4 CONCLUSIONS 
Firstly, the construction of recombinant vaccinia viruses containing rotavirus genes 2,3, 
11 and 11(orf2) completed the full complement of recombinant vaccinia viruses carrying 
rotavirus genes from the UKtc strain. Recombinant vaccinia viruses containing the gene 
5 
from rotavirus strains RRV, Hochi and P9D05, and the gene (7,8 or 9) encoding the VP7 
protein from rotavirus strains RRV, A64, 
Hochi, 69M, Wa and WI-61 were also 
constructed. In addition, recombinant vaccinia viruses containing restriction enzyme 
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FIGURE 22. SCREENING BY PCR OF POTENTIAL RECOMBINANT VACCINIA 
VIRUSES CONTAINING VARIOUS FRAGMENTS OF UKTC GENE 8 (VP7 
PROTEIN) 
The PCR amplification and subsequent analysis of the products was carried out as detailed 
in Figure 17 using the 5' P7 s and 3' TK primers (see Table 5). In both panels, lane M shows 
the DNA size markers and lane A is the Adenovirus PCR control (see Figure 14). 
Panel A: Lane B is a WT vaccinia virus DNA control which, due to the large distance 
between the P7 5 promoter and the TK gene in the WT vaccinia virus genome, did not give a 
product using these PCR primers. Lane C is a PCR primer positive control for the primer 
pair used for the experimental samples. The primer pair was used on pSCI l-30R. 2 shuttle 
plasmid containing the Clal-IIhaI insert and the PCR amplification gave a product of 336 
bp. Lanes I to 10 show screening of potential recombinant vaccinia virus containing the 
Clat-Hhal fragment of rotavirus UKtc gene 8 [vaccUKte. VP7(Clal-IIhaI)]. The PCR 
amplification gave a product of 336 bp for the positive recombinants (lanes 3,8 and 10 were 
deemed positive). 
Panel B: Lanes Ito 3 show screening of potential recombinant vaccinia virus containing the 
Ilinfl-EcoRV fragment of rotavirus UKtc gene 8 [vaccUKtc. VP7(Ilinfl-EcoRV)]. The PCR 
amplification gave a product of 349 bp for positive recombinants (lane 3 was deemed 
positive). 
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Table 9. Recombinant vaccinia viruses constructed to-date 
Strain Protein fragment vaccinia name produced by 
UKtc VP1 vaccUKtc. VP1 S. Stagg 
UKtc VP2 vaccUKtc. VP2 R. Heath 
UKtc VP3 vaccUKtc. VP3 R. Heath 
UKtc VP4 vaccUKtc. VP4 R. Jenkins 
Uktc vaccUKtc. NS53 S. Stagg 
RRV NS53 vaccRRV. NS53 R. Heath 
Hochi vaccHochi. NS53 R. Heath 
P9DA5 vaccP9DA5. NS53 R. Heath 
UKtc VP6 vaccUKtc. VP6 R. Jenkins 
UKtc NS35 vaccUKtc. NS35 S. Stagg 
Uktc vaccUKtc. VP7 R. Jenkins 
RRV vaccRRV. VP7 R. Heath 
A64 VP7 vaccA64. VP7 R. Heath 
Hochi vaccHochi. VP7 R. Heath 
69M vacc69M. VP7 R. Heath 
Wa vaccWa. VP7 R. Heath 
WI-61 vaccWl-61 . VP7 R. Heath 
CIaI-Hhal vaccUKtc. VP7(C1aI-Hhal) R. Heath 
UKtc VP7 Dral-EcoRV vaccUKtc. VP7(DraI-EcoRV) F. Xu 
Hinfl-EcoRV vaccUKtc. VP7(Hinfl-EcoRV) R. Heath 
EcoRV-HincIl vaccUKtc. VP7(EcoRV-HincIl) F. Xu 
UKtc NS34 vaccUktc. NS34 S. Stagg 
UKtc NS28 vaccUKtc. NS28 S. Stagg 
UKtc NS26 vaccUKtc. NS26 R. Heath 
UKtc NS12 vaccUKtc. NS12 R. Heath 
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fragments of rotavirus UKtc gene 8 (VP7 protein), ClaI-HhaI and Hinfl-EcoRV were 
constructed. 
Table 9 shows all the recombinant vaccinia viruses which were used in this 
project and the name of the constructor. All the recombinants were plaque purified before 
growing to high titre stock and were used to infect target cells in 51Cr-release assays to 
measure CTL activity. 
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CHAPTER 7 
ANALYSIS AND EXPRESSION OF RECOMBINANT 
VACCINIA VIRUSES 
124 
7.1 AIMS 
The aim of the work described in this chapter was first to confirm the nucleotide sequence 
of the fragments of rotavirus UKtc gene 8 (VP7) within the recombinant vaccinia virus 
genome. Of particular importance was the sequence at the vector-insert 5' junction within 
the recombinant vaccinia virus which allows in-frame translation of the insert using the 
vector ATG. The second aim was to confirm the expression of the rotavirus protein in cells 
infected with recombinant vaccinia virus. Immunofluorescence was used to detect the 
expression of vaccUKtc. VP2, VP3, NS26 and NS 12. 
7 .2 SEQUENCE ANALYSIS OF RECOMBINANT VACCINIA VIRUSES 
CONTAINING FRAGMENTS OF UKTC GENE 8 (yam) 
VaccUKtc. VP7(ClaI-Hhal), (Dral-EcoRV), (Hinfl-EcoRV) and (EcoRV-HincII) were 
used to infect separate wells of a 6-well tissue culture dish of confluent CV-1 cells at an 
moi of < 0.1. After two days of incubation, viral DNA was extracted and PCR 
amplification performed using the 5' P7.5 and 3' TK primers (see Table 5). The amplified 
PCR products were excised from the agarose gel and purified using the Gene Cleari II 
purification kit. The DNA products were sequenced by L. Ward, University of Warwick, 
using an automated DNA sequencer. Two separate sequencing reactions were performed 
on the DNA, using either the 5' P7.5 or 3' TK primer, to span the fragment. 
Figure 23 shows the predicted vector-insert (5' end) sequence within the vaccinia 
virus genome and the corresponding data from the automated sequencer. The results 
indicate that the 5' end of all four gene 8 fragments contained the predicted junction 
required for in-frame translation from the initiating ATG (provided by the vector). The 
sequence data spanning the fragments from both ends also confirmed that, although base 
changes were observed (due to bona-fide gene mutations or sequencing errors), no stop 
codons had been introduced into the gene 8 fragments (data not shown). 
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FIGURE 23. SEQUENCE ANALYSIS OF VECTOR-INSERT 5' JUNCTION 
WITHIN RECOMBINANT VACCINIA VIRUS TK- GENE 
Recombinant vaccinia viruses containing fragments of rotavirus UKtc gene 8, 
vaccUKtc. VP7(Clal-Hhal), (Dral-EcoRV), (Ilinfl-EcoRV) and (EcoRV-IiincII) were used 
to inoculate cells at an moi of < 0.1. After two days of incubation the DNA samples were 
extracted as described in Materials and Methods. 5' P7 5 and 3' TK primers (see Table 5) 
were used to PCR amplify the gene 8 fragment from each DNA sample. Following agarose 
gel electrophoresis, the PCR product was excised from the gel and purified as described in 
Materials and Methods. The PCR product was sequenced using the 5' P7.5 primer and the 3' 
TK primer in separate reactions. Automated sequencing was carried out as described in 
section 4.3.12 of materials and methods by L. Ward, University of Warwick. 
The first column shows the names of the recombinant vaccinia viruses with their 
predicted vector-insert junction for in-frame translation from the vector ATG. The second 
column shows the results obtained from the automated sequencer. 
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FIGURE 23 
RECOMBINANT NAME WITH 
PREDICTED SEQUENCE 
VaccUKtc. VP7(CIaI-Hhal) 
ATG GCC C CG ATT ACA 
VaccUKtc. VP7(Dral-EcoRV) 
CC ATG AAA GAA 
VaccUKtc. VP7(Hinfl-EcoRV) 
AUTOMATED SEQUENCER DATA 
ATGGCCCCGATTACA 
CCATGAAAGAA 
ANGGCCCATCCTA 
i- 
ký&i 
A 
ATG GCC C: AT TCT A 
VaccU Ktc. VP7( EcoRV-H incl 1) 
ATG GCC CGG GAA GG: A TCA ATG 
ATGGC C CGGGAAGGATCAATG 
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7.3 ROTAVIR PRa D IXL DN FOLLOWING RE OM BINA2 
VACCINIA VIRUS INFECTION OF CELLS 
The expression of the complete set of rotavirus UKtc proteins was checked using 
immunofluorescence by Prof. M. McCrae and N. Broughton, University of Warwick. 
Expression of the VP2, VP3, NS26 and NS12 proteins was of particular importance 
because the corresponding recombinant vaccinia viruses were constructed in the current 
project (see Table 9). 
Confluent BS-C-1 cells were grown on glass coverslips in a 12-well tissue 
culture dish. Individual wells were infected with either (i) WT vaccinia virus at an moi of 
0.002 (negative control), (ii) UKtc rotavirus at an moi of 0.1 (positive control), (iii) 
vaccUKtc. VP7 at an moi of 0.002 (positive control) or (iv) vaccUKtc. VP2, VP3, VP6, 
NS26 and NS12 (one recombinant per well) at an moi of 0.002. Cells were fixed after 7 
hours incubation and rabbit anti-rotavirus primary antibody was then added. After 
washing, biotinylated anti-rabbit secondary antibody was added to the cells, followed by 
streptavidin fluorescein. The cells were washed again and viewed under a UV microscope. 
Figure 24 shows photographs taken of the virus controls and the recombinant 
vaccinia viruses under examination. The results show no fluorescence when cells were 
infected with the WT vaccinia virus (negative control) and bright fluorescence with the 
UKtc rotavirus (positive control) (Figure 24A and B). The vaccUKtc. VP7 was also used as 
a positive control since there was a VP7-specific CTL response against target cells 
infected with this recombinant (see Chapter 8) and, indeed, fluorescence was seen in the 
vaccUKtc. VP7 infected cells (Figure 24C). 
VaccUKtc. VP2, VP3, NS26 and NS12 infected cells, although exhibiting a 
relatively weak fluorescence signal, were deemed positive for rotavirus protein expression 
(Figure 24D, E, G and H) and, indeed, expression was confirmed by a VP3-specific CTL 
EIN EXP 
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FIGURE 24. IMMUNOFLUORESCENCE OF ROTAVIRUS PROTEINS (VI'2, VP3, 
VI16, NS26 AND NS12) EXPRESSED IN RECOMBINANT VACCINIA VIRUS 
INFECTED CELLS 
Confluent BS-C-I cells were grown on glass coverslips in a 12-well tissue culture dish. 
Individual wells were infected with either (i) WT vaccinia virus at an moi of 0.002 (positive 
control). (ii) UKtc rotavirus at an moi of 0.1 (positive control), (iii) vaccUKtc. VP7 at an moi 
of 0.002 (positive control) or (iv) vaccUKtc. VP2, VP3, V1'6, NS26 and NS12 (one 
recombinant per well) at an moi of 0.002. Immunofluorescence was performed as described 
in section 4.4.4 of Materials and Methods by Prof. M. McCrae and N. Broughton, 
University of Warwick. All cells were photographed using a UV microscope at X20 
objective magnification. 
Panel A: Wild-type vaccinia virus (WR') (negative control) 
Panel B: UKtc rotavirus (positive control) 
Panel C: vaccUKtc. VP7 (positive recombinant control) 
Panel A: vaccUKte. VP2 
Panel E: vaccUKte. VP3 
Panel F: vaccUKtc. VP6 
Panel G: vaccUKtc. NS26 
Panel It: vaccUKte. NS)2 
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response against target cells infected with vaccUKtc. VP3 (see Chapter 8). This mirrors the 
experiments by Townsend et al. (1984) in which immunoprecipitation of influenza A virus 
nucleoprotein was only achieved with two out of three transfected L-cell clones despite the 
nucleoprotein-specific CTL lysis of all three clones. Both these results suggest that the 
amount of expressed protein required for recognition by CTLs is less than that required for 
detection by immunofluorescence (or immunoprecipitation). It should be noted that 
vaccUKtc. VP6 infected cells show very bright fluorescence and were deemed positive for 
VP6 expression (Figure 24F). In this case, however, there does not appear to be a VP6- 
specific CTL response against target cells infected with vaccUKtc. VP6 (see Chapter 8). 
Immunofluorescence was also used to detect the expression of rotavirus proteins 
by cells infected with vaccUKtc. VPI, VP4, NS53, NS35, NS34 and NS28. In those 
experiments NS53 and NS28 fluorescence was strongly positive, whereas, VPI, VP4, 
NS35 and NS34 gave much weaker fluorescence (data not shown). 
7 .4 CONCLUSIONS 
Sequence analysis has revealed that the recombinant vaccinia viruses containing fragments 
of UKtc gene 8 have been successfully constructed without the addition/deletion of 
nucleotides at the vector-insert (5' end) junction within the vaccinia virus genome. The 
sequence analysis of the gene 8 fragments also showed that no stop codons had been 
introduced. The sequence data therefore predicts expression of the four rotavirus UKtc 
VP7 protein fragments in target cells infected with the corresponding recombinant 
vaccinia viruses. 
Immunofluorescence of rotavirus proteins in cells infected with vaccUKtc. VP2, 
VP3, NS26 and NS12 was weakly positive. These recombinant vaccinia viruses can, 
therefore, be used in the 
51Cr-release assay to measure specific CTL activity to individual 
rotavirus proteins. 
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CHAPTER 8 
THE CTL RESPONSE TO INDIVIDUAL ROTAVIRUS UKtc 
PROTEINS IN THREE MHC CLASS I HAPLOTYPES 
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8.1 AIMS 
The initial task of this project was aimed at extending work carried out in the group on the 
CTL response to rotavirus (S. Stagg, personal communication) and to complete the 
coverage of the rotavirus UKtc proteins not dealt with in that work, i. e., VP2, VP3, NS26 
and NS12. In addition, previous studies on the CTL response to rotavirus have been 
confined to single class I mouse haplotypes (Franco et al., 1994; Offit et al., 1994) and, 
therefore, a primary objective of this project was to gauge the likely applicability of those 
observations for an outbred population in which any CTL-based vaccine would be used. 
8 .2 RATIONALE TO 
THE 51CR-RELEASE ASSAY 
The CTL response is routinely measured in viral systems using the 
51Cr-release assay. 
This assay utilises the fact that the 
51Cr-isotope (sodium chromate, Na251Cr04) is taken up 
by cells in the hexavalent form and released from lysed cells in the trivalent form, which is 
not reutilised. 
The 51Cr-release assay utilises two cell populations, effectors and targets (see 
Figure 25). The effectors are generated from splenocytes taken from in vivo inoculated 
animals (responder cells) which are in vitro stimulated with naive splenocytes presenting 
the inoculating virus (stimulator cells). The targets (which, in principle, may be any MHC 
class I matched cell) are loaded with 
51Cr and normally infected with the inoculating virus. 
The effector cells recognise processed antigen presented on the surface of the target cells 
in association with MHC class I and this leads to cell binding and subsequent target cell 
lysis. The released 5 1Cr is measured and expressed as the percentage specific lysis. 
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FIGURE 25. TIIE 51CR-RELEASE ASSAY FOR CTL ACTIVITY 
Two 6 to 10 week old female mice were orally inoculated with 107 pfu of rotavirus and 
sacrificed 7 days later. The spleens were removed and splenocytes prepared at 6X 106 
cells/ml (responders). 2X 107 splenocytes from two naive 6 to 10 week old female mice 
were infected with the inoculating rotavirus strain at an moi of I for 1 hr (stimulators). 6X 
I06 responder cells were cultured in vitro with stimulator cells at a ratio of 2: 1 for 6 or 7 
days (effectors) as described in sections 4.6.1 to 4.6.3 of Materials and Methods. 
IX 106 MFIC class I matched cells were loaded with 50 µCi 
51Cr and infected 
with either wild-type (WT) vaccinia virus strain WR+ or recombinant vaccinia virus at an 
moi of 10 for 5 hr (targets), as described in section 4.6.4 of Materials and Methods. 
IX l04 target cells were mixed with (i) effector cells at ratios of 1: 1,3: 1,10: 1 and 
30: 1 (effector: target) (test 51Cr-release), (ii) medium (spontaneous 51 Cr-release) or (iii) 
detergent (total 51Cr-release), in 200 µl volume for 5 hr. 100 . tl of supernatant was removed 
and the 51Cr-release measured on a y-radiation counter as described in section 4.6.5 of 
Materials and Methods. 
The % specific lysis was calculated for each effector: target ratio, as described in 
section 4.6.6 of Materials and Methods, and the results displayed on a bar graph. Positive 
CTL killing of target cells (infected with recombinant vaccinia virus) was defined by (i) a 
minimum 10% specific lysis, and (ii) a minimum threefold greater % specific lysis than the 
negative control (target cells infected with WT vaccinia virus). To confirm any positive 
results, all assays were repeated at least twice. 
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8 .3 
CTL RECOGNITION OF TARGET CELLS EXPRESSING VARIOUS 
ROTAVIRUS UKTC PROTEINS IN THREE DIFFERENT MOUSE MHC CLASS I 
HAPLOTYPES 
The homotypic CTL response was first examined to the VP2, VP3, NS26 and NS 12 
rotavirus UKtc proteins. The CTL response to these proteins completed the full analysis of 
the twelve rotavirus UKtc proteins. No specific CTL response was directed to these 
proteins in the H-2b mouse haplotype (see Figure 26). The specific CTL response to 
rotavirus UKtc NS53 and VP7 proteins in the H-2b mouse haplotype (S. Stagg, personal 
communication) was confirmed by the use of these recombinant vaccinia viruses as 
positive controls. 
The homotypic CTL response to the four rotavirus UKtc proteins under 
examination was also studied in the H-2d and H-2k mouse haplotypes. In both these 
haplotypes there was a specific CTL response directed against the rotavirus UKtc VP3 
protein (see Figures 27 and 28). There was no CTL response against rotavirus UKtc NS53 
or VP7 proteins in these haplotypes (S. Stagg, personal communication). 
Since the CTL response against rotavirus UKtc VP3 in Balb/c (H-2d) was 
positive by the narrowest margin (exactly three times the WT vaccinia virus response at 
the 30: 1 effector to target ratio) it was decided to boost the in vivo immune response. Mice 
inoculated with 107 pfu rotavirus were normally sacrificed one week later, however, 
following three weeks the mice were further inoculated with 107 pfu of a second rotavirus 
strain (UKtc). A week later the mice were sacrificed and the splenocytes removed and 
stimulated in vitro as normal. It was found that this inoculation schedule gave an enhanced 
indication of the CTL response to rotavirus UKtc VP3 in Balb/c mice (twelve times the 
WT vaccinia virus response at the 30: 1 effector to target ratio) (see Figure 29). Because of 
the `quantal' nature of the CTL response (CTLs being either lytic or not) it is believed that 
repeated immunisation increases the 
lytic and recycling rates of CTLs. For example, 
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FIGURE 26. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS UKTC 
PROTEINS BY UKTC PRIMED C57BL/6 (II-2b) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (11-2b) were loaded with 5'Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. VP2, VP3, NS53 (positive control), VP7 (positive 
control), NS26 orNS12] and the 51Cr-release assays set up as described in Figure 25. 
FIGURE 27. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS UKTC 
PROTEINS BY UKTC PRIMED BALB/C (II-2d) EFFECTORS 
Two 6 to 10 week old female Balb/c mice (H-2d) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
P815 target cells (}1-2d) were loaded with StCr, infected with WT vaccinia virus or 
recombinant vaccinia viruses (vaccUKtc. VP2, VP3, NS26 or NS12) and the 51Cr-release 
assays set up as described in Figure 25. 
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FIGURE 28. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS UKTC 
PROTEINS BY UKTC PRIMED C31I/IIE, MG (II-2k) EFFECTORS 
Two 6 to 10 week old female C311/Ile, mg mice (1-1-2k) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Ltk- target cells (II-2k) were loaded with 
51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses (vaccUKtc. VP2, VP3, NS26 or NS12) and the 
51Cr-release 
assays set up as described in Figure 25. 
FIGURE 29. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS UKTC 
PROTEINS BY RRV (3 WEEKS) FOLLOWED BY UKTC (1 WEEK) PRIMED 
BALB/C (I1-2d) EFFECTORS 
Two 6 to 10 week old female Balb/c mice (11-2d) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and after 3 weeks orally inoculated with 107 pfu rotavirus UKtc 
(serotype 6). 7 days later the mice were sacrificed and the spleens removed. The spenocytes 
were in vitro stimulated using UKtc to produce the effector cells as described in Figure 25. 
P815 cells (11-2d) were loaded with S1Cr and infected with either WT vaccinia or 
recombinant vaccinia viruses (vaccUKte. VP1, VP2, VP3, VP4, NS53, VP6, NS35, VP7, 
NS34, NS28, NS26 or NS12) and the 51Cr-release assays were set up as described in Figure 
25. 
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hyper-activation of CTL surface molecules may lead to increased target cell binding rates 
(Berke, 1994). 
The CTL response to the other eleven rotavirus UKtc proteins in Balb/c (H-2d) 
mice was also examined using the enhanced inoculation regime and again it was found 
that there was only a specific CTL response mounted against rotavirus UKtc VP3 protein 
(see Figure 29). It should be noted, however, that the specific CTL response to 
homotypic/heterotypic proteins could only be studied in mice inoculated twice with the 
same strain of rotavirus and that boosting with the same virus has not yet been examined. 
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Purified rotavirus RRV was available in a greater quantity than purified UKtc and, for this 
reason, it was decided to use RRV for the inoculation of mice in these experiments. 
However, similarly to CTL response to UKtc VP7, it had been established during this 
study that the RRV primed VP7-specific CTL response was restricted to the H-2b mouse 
haplotype (data not shown) and was serotype-independent (see Chapter 11). 
C57BL/10 (H-2b) mice (which are closely related to C57BL/6 mice) were used 
with the congenic mouse strains B10. D2/n (H-2d) and B10. BR (H-2k) to examine the 
homotypic CTL response against the rotavirus RRV VP7 protein. These mice only differ 
in regards to their MHC class I antigens and rotavirus RRV VP7-specific CTLs were 
generated in the C57BL/10 (H-2) mice as expected (see Figure 30A). However, no 
rotavirus RRV VP7-specific CTLs were generated in the H-2d or H-2k haplotypes of 
congenic mouse (see Figure 30B and C) as found previously in the Balb/c (H-2d) and 
C3H/He, mg (H-2k) mouse strains (data not shown). By contrast, rotavirus RRV VP7- 
specific CTLs were generated in the Balb/c mouse strain congenic for the H-2b haplotype, 
Balb, B (see Figure 30D). These results suggest that the mouse MHC class I haplotype is 
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FIGURE 30. % SPECIFIC LYSIS OF TARGETS EXPRESSING RRV VP7 PROTEIN 
BY RRV PRIMED C57BL/10 (11-2b), B10. D2/N (II-2d), B10. BR (1I-2k) AND BALB, B 
(II-2b) EFFECTORS 
Two 6 to 10 week old female mice (A) C57BL/10 (11-2b), (B) B10. D2/n (H-2d) (C) B10. BR 
(Fl-2k) or (D) Balb, B (11-2b) were orally inoculated with 107 pfu rotavirus RRV (serotype 3) 
and 7 days later were sacrificed and the spleens removed. The splenocytes were in vitro 
stimulated to produce the effector cells as described in Figure 25. 
The appropriate MHC class I matched target cells [EL4 (H-2 
b), P815 (H-2d) and 
Ltk- (Il-2k)] were loaded with 51 Cr, infected with WT vaccinia virus or recombinant 
vaccinia virus (vaccRRV. VP7) and the 51Cr-release assays set up as described in Figure 25. 
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the fundamental factor for the generation of rotavirus RRV VP7-specific CTLs and the 
response is in no way connected to the minor histocompatibility antigens or any other 
differences between the various mouse strains used in this experimental work. 
8.5 CONCLUSIONS 
(i) The major rotavirus UKtc-specific CTL response was generated against the NS53 and 
VP7 proteins in the mouse H-2b MHC class I haplotype. 
(ii) In the mouse H-2d and H-2k MHC class I haplotypes the major rotavirus UKtc-specific 
CTL response was generated against the VP3 protein. 
(iii) A rotavirus RRV VP7-specific CTL response was generated in the mouse H-2b, but 
not H-2d or H-2k, MHC class I haplotype. 
(iv) The mouse strain restriction of the rotavirus RRV VP7-specific CTL response was 
dependent only on the MHC class I haplotype of the mouse. 
(v) A second oral inoculation three weeks after the first, using a different strain of 
rotavirus at an equal dose (107 pfu), was an improved strategy for producing rotavirus- 
specific CTLs. 
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CHAPTER 9 
THE CTL RESPONSE AGAINST ROTAVIRUS VP3 PROTEIN 
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9.1 AIMS 
Following establishment that the major rotavirus-specific CTL response generated in the 
mouse H-2d and H-2k MHC class I haplotypes was VP3-specific, the next step was to 
gauge the strain-independence of this response. This is of particular importance because a 
rotavirus vaccine would need to protect against many of the different rotavirus strains. 
XPE ýG-M EROTYF RC CCVP 
It has been established that the UKtc NS53 protein did not elicit a specific CTL response 
in the H-2d haplotype (S. Stagg, personal communication). Conversely, there is a RRV 
NS53-specific CTL response in the H-2d mouse haplotype (as detailed in the Chapter 10) 
and, therefore, vaccRRV. NS53 infected targets were used as positive controls in the 51Cr- 
release assays using RRV inoculated H-2d mice (Figure 31). 
No specific CTL response was directed against rotavirus UKtc VP3 protein from 
rotavirus RRV infected mice of either H-2d or H-2k haplotype (see Figures 31 and 32). 
9.3 CONCLUSION 
A UKtc VP3-specific CTL response was not generated in mice of the H-2d or H-2k MHC 
class I haplotype primed with the RRV strain of rotavirus. 
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FIGURE 31. % SPECIFIC LYSIS OF TARGETS EXPRESSING UKTC VP3 
PROTEIN BY RRV PRIMED BALB/C (1I-2d) EFFECTORS 
Two 6 to 10 week old female Balb/c mice (H-2d) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
P815 target cells (H-2d) were loaded with 
51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccRRV. NS53 (positive control) or vaccUKtc. VP3 
(serotype 6)] and the S1Cr-release assays set up as described in Figure 25. 
FIGURE 32. % SPECIFIC LYSIS OF TARGETS EXPRESSING UKTC VP3 
PROTEIN BY RRV PRIMED C3IUIIE, MG (II-2k) EFFECTORS 
Two 6 to 10 week old female C3H/He, mg mice (11-2k) were orally inoculated with W pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Ltk' target cells (H-2k) were loaded with 5'Cr, infected with WT vaccinia virus or 
recombinant vaccinia virus [vaccUKtc. VP3 (serotype 6)] and the 5'Cr-release assays set up 
as described in Figure 25. 
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CHAPTER 10 
THE CTL RESPONSE AGAINST ROTAVIRUS NS53 PROTEIN 
142 
10.1 AIMS 
The confirmation of a CTL response against the rotavirus UKtc NS53 protein in the H-2b 
mouse haplotype (see Chapter 8) prompted work to gauge the strain-independence of this 
response. This is of particular importance because a rotavirus vaccine would need to 
protect against many of the different rotavirus strains. Subsidiary objectives were to begin 
the localisation of the major CTL epitope(s) in this protein and to identify the H-2b locus 
of restriction of these epitope(s). The realisation of these secondary aims may be essential 
in the design of a successful CTL-based rotavirus vaccine. 
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The major CTL response generated against the rotavirus NS53 protein in the H-2b mouse 
haplotype was further examined for a strain-independent CTL response. It was found that 
the CTL response to rotavirus NS53 was strain-dependent in the H-2b mouse haplotype, 
regardless of the inoculating rotavirus strain (UKtc or RRV) (see figures 33 and 34). 
These experiments did, however, reveal a homotypic RRV NS53-specific CTL 
response in the 11-2b mouse haplotype (see Figure 34). The analysis of the RRV NS53- 
specific CTL response was extended to cover, (i) mouse haplotypes other than H-2b, and 
(ii) the strain-independence of this response. 
Only a strain-dependent RRV NS53-specific CTL response was generated in the 
11-2° mouse haplotype (see Figure 35) and no NS53-specific CTL response was observed 
in the RRV primed II-2k mouse haplotype (see Figure 36). 
143 
FIGURE 33. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS NS53 
PROTEINS BY UKTC PRIMED C57BL/6 (11-2) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. NS53 (positive control), vaccRRV. NS53 (serotype 
3) or vaccHochi. NS53 (serotype 4)] and the 
51Cr-release assays set up as described in Figure 
25. 
FIGURE 34. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS NS53 
PROTEINS BY RRV PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 
W pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. NS53 (serotype 6), vaccRRV. NS53 (positive 
control) or vaccHochi. NS53 (serotype 4)] and the 51Cr-release assays set up as described in 
Figure 25. 
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FIGURE 35. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS NS53 
PROTEINS BY RRV PRIMED BALB/C (H-2d) EFFECTORS 
Two 6 to 10 week old female Balb/c mice (H-2d) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
P815 target cells (H-2d) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. NS53 (serotype 6), vaccRRV. NS53 or 
vaccHochi. NS53 (serotype 4)] and the 51Cr-release assays set up as described in Figure 25. 
FIGURE 36. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS NS53 
PROTEINS BY RRV PRIMED C3H/HE, MG (H-2k) EFFECTORS 
Two 6 to 10 week old female C3H/He, mg mice (H-2k) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Ltk- target cells (H-2k) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. NS53 (serotype 6), vaccRRV. NS53 or 
vaccHochi. NS53 (serotype 4)] and the 51Cr-release assays set up as described in Figure 25. 
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10 .3 CTL RECOGNITION 
OF H-2¢ TARGET CELLS EXPRESSING THE 
DELETANT MUTANT ROTAVIRUS P9DA5 NS53 PROTEIN 
Following identification of a UKtc NS53-specific CTL response in the H-2b mouse 
haplotype, the process of localisation of the major CTL epitope(s) was begun using a 
vaccinia virus expressing NS53 of the homotypic deletant mutant rotavirus strain P9D05. 
As detailed in Chapter 6, the P9D05 gene 5 sequence shows close sequence homology 
with the UKtc gene 5 sequence (Tian et al., 1993), however, only the first 150 amino acids 
of the P9D05 NS53 are expressed. The results showed a P9D05 NS53-specific CTL 
response generated in UKtc inoculated H-2b mice (see Figure 37). This revealed that major 
CTL epitope(s) are present in the first 150 amino acids of the rotavirus UKtc NS53 
protein. However, there was no CTL response generated to the P9DA5 NS53 protein in H- 
2b mice inoculated with RRV (see Figure 38). In other words, the CTL epitope(s) in the 
first 150 amino acids of rotavirus UKtc NS53 are strain-dependent and this confirms the 
homotypic nature of the NS53-specific CTL response. 
10.4 CTL RECOGNITION OF MOUSE Db AND Kb RESTRICTED TARGET 
QE IS EXPRESSING HOMOTYPIC ROTAVIRUS NS53 PROTEIN 
The establishment of a UKtc NS53-specific CTL response generated in the H-2b mouse 
haplotype and the location of at least one CTL epitope in the first 150 amino acids of this 
protein lead to analysis being extended to identify the CTL epitope(s) H-2b locus of 
restriction. Using transformed Ltk- cell lines presenting either Db or Kb it was found that 
the CTL response to UKtc NS53 was restricted at H-2D 
b (see Figure 39). 
To confirm the H-2Db restriction of the NS53-specific CTL response found to 
rotavirus UKtc strain, the NS53 homotypic response from a second rotavirus strain, 
namely RRV, was examined. In this case, however, 
it was not possible to clearly define 
the Db or Kb locus of restriction of this response (see Figure 40). There was normal CTL 
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FIGURE 37. % SPECIFIC LYSIS OF TARGETS EXPRESSING P9DA5 NS53 
PROTEIN BY UKTC PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia virus [vaccP9DA5. NS53 (serotype 6)] and the 
51Cr-release assays set 
up as described in Figure 25. 
FIGURE 38. % SPECIFIC LYSIS OF TARGETS EXPRESSING P9DA5 NS53 
PROTEIN BY RRV PRIMED C57BL/6 (H-2b EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with l07 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccRRV. NS53 (positive control) or vaccP9DA5. NS53 
(serotype 6)] and the 51Cr-release assays set up as described in Figure 25. 
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FIGURE 39. % SPECIFIC LYSIS OF TARGETS EXPRESSING UKTC NS53 
PROTEIN BY UKTC PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female mice C57BL/6 (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Target cells (A) Ltk" (H-2k), (B) L-Db (L-2Db) or (C) L-Kb (H-2Kb) were loaded 
with 51 Cr, infected with WT vaccinia virus or recombinant vaccinia virus (vaccUKtc. NS53) 
and the 51 Cr-release assays set up as described in Figure 25. 
FIGURE 40. % SPECIFIC LYSIS OF TARGETS EXPRESSING RRV NS53 
PROTEIN BY RRV PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female mice C57BL/6 (H-2b) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Target cells (A) EL4 (H-2b), (B) L-Db (L-213b) or (C) L-Kb (H-2K) were loaded 
with 51Cr, infected with WT vaccinia virus or recombinant vaccinia virus (vaccRRV. NS53) 
and the 51Cr-release assays set up as described in Figure 25. 
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lysis of the positive target cell line (H-2b) infected with vaccRRV. NS53 and, therefore, the 
poor CTL lysis of the restricted cell lines could not be easily explained by either clonal 
CTL expansion against an unexpected antigen or MHC non-restricted cytolytic activity of 
NK cells. It is more likely that RRV NS53 contains at least two CTL epitopes, one 
bb 
restricted at H-2D and the second at H-2K. 
10.5 CONCLUSION'S 
(i) A rotavirus RRV NS53-specific CTL response was generated in the mouse H-2d and H- 
2 '', but not in H-2k MEIC class I haplotypes. 
(ii) A rotavirus strain-dependent NS53-specific CTL response was generated in mice, 
regardless of the inoculating rotavirus serotype or mouse haplotype. 
(iii) Rotavirus strain-dependent CTL epitope(s) were present in the first 150 amino acids 
of the UKtc NS53 protein. 
(iv) The UKtc NS53-specific CTL response was restricted at N-2D b, whereas, the RRV 
NS53-specific CTL response probably involved at least two CTL epitopes, one restricted 
at 11-21) and a second at 11-2K . 
bb 
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CHAPTER 11 
THE CTL RESPONSE AGAINST ROTAVIRUS VP7 PROTEIN 
150 
11.1 AIMS 
Following confirmation of the rotavirus UKtc VP7-specific CTL response in the H-2b 
mouse haplotype (see Chapter 8), the next step was to gauge the serotype-independence of 
this response. This is of particular importance because a rotavirus vaccine would need to 
protect against many of the different rotavirus serotypes. A second objective was to begin 
the localisation of the major CTL epitope(s) in this protein and to identify the H-2b locus 
of restriction of these epitope(s). This localisation and classification of epitopes may be 
essential in the design of a successful CTL-based rotavirus vaccine. 
11 .2 CTL RECOGNITION 
OF TARGET CELLS EXPRESSING VARIOUS 
HETEROTYPIC ROTAVIRUS VP7 PROTEINS 
The major CTL response generated against the rotavirus VP7 protein in the H-2b mouse 
haplotype was further examined for a serotype-independent CTL response. It was found 
that the CTL response was serotype-independent across seven different rotavirus VP7 
serotypes, regardless of the inoculating serotype (3 or 6) (see Figures 41 and 42). 
11.3 CTL RECOGNITION OF---H-2b ARG T CELLS EXPRESSING 
FRAGMENTS OF ROTAVIRUS UKTC VP7 PROTEIN 
After establishment of a UKtc VP7-specific CTL response in the H-2b mouse haplotype, 
the localisation of the CTL epitope(s) was performed using target cells expressing 
restriction enzyme fragments of UKtc VP7 protein (see Figure 20). There was only a 
VP7(CIaI-Hhal)-specific CTL response generated in UKtc inoculated H-2b mice (see 
Figure 43). This reveals that CTL epitope(s) are present between amino acids 13 and 48 of 
the rotavirus UKtc VP7 protein. However, there was no CTL response generated to the 
VP7(Clal-IIhaI) fragment in II-2b mice inoculated with RRV virus (see Figure 44), in 
other words, the CTL epitope(s) between amino acids 13 and 48 of the UKtc VP7 protein 
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FIGURE 41. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS VP7 
PROTEINS BY UKTC PRIMED C57BL/6 (H-2) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccWa. VP7 (serotype 1), vaccRRV. VP7 (serotype 3), 
vaccHochi. VP7 (serotype 4), vaccUKtc. VP7 (serotype 6), vacc69M. VP7 (serotype 8), 
vaccWl-61. VP7 (serotype 9) or vaccA64. VP7 (serotype 10)] and the 51Cr-release assays set 
up as described in Figure 25. 
FIGURE 42. % SPECIFIC LYSIS OF TARGETS EXPRESSING VARIOUS VP7 
PROTEINS BY RRV PRIMED C57BL/6 (H-26) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccWa. VP7 (serotype 1), vaccRRV. VP7 (serotype 3), 
vaccHochi. VP7 (serotype 4), vaccUKtc. VP7 (serotype 6), vacc69M. VP7 (serotype 8), 
vaccWl-61. VP7 (serotype 9) or vaccA64. VP7 (serotype 10)] and the 5'Cr-release assays set 
up as described in Figure 25. 
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FIGURE 43. % SPECIFIC LYSIS OF TARGETS EXPRESSING FRAGMENTS OF 
UKTC VP7 PROTEIN BY UKTC PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccUKtc. VP7(ClaI-HhaI), (Dral-EcoRV), (Hinfl-EcoRV) or 
(EcoRV-HinclI)] and the 51Cr-release assays set up as described in Figure 25. 
FIGURE 44. % SPECIFIC LYSIS OF TARGETS EXPRESSING FRAGMENTS OF 
UKTC VP7 PROTEIN BY RRV PRIMED C57BL/6 (H-2) EFFECTORS 
Two 6 to 10 week old female C57BL/6 mice (H-2b) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
EL4 target cells (H-2b) were loaded with 51Cr, infected with WT vaccinia virus or 
recombinant vaccinia viruses [vaccRRV. VP7 (positive control), vaccUKtc. VP7(ClaI-Hhal), 
(Dral-EcoRV), (Hinfl-EcoRV) or (EcoRV-Hincll)] and the 51Cr-release assays set up as 
described in Figure 25. 
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are not the serotype-independent epitope(s) of this protein. In addition, there was no 
measurable specific lysis of target cells expressing the rotavirus UKtc VP7(Dral-EcoRV), 
(Hinfl-EcoRV) or (EcoRV-Hincll) fragments. This suggests that no major CTL epitopes 
are located between amino acids 117 and 232 of the UKtc VP7 protein (except, possibly, 
in the vicinity of amino acid position 184 which, due to the use of EcoRV in the 
construction of the gene 8 fragments, was not covered in these experiments). 
114 CTL RECOGNITION OF MOUSE Db AND Kb RESTRICTED TARGET 
CELLS EXPRESSING IIOMMOTYPIC ROTAVIRUS VP7 PROTEIN 
A UKtc VP7-specific CTL response generated in the H-2b mouse haplotype and at least 
one CTL epitope situated between amino acids 13 and 48 of this protein had been 
detected. Analysis was then extended to find the CTL epitope(s) H-2b locus of restriction 
and using transformed Ltk- cell lines presenting either Db or Kb it was found that the CTL 
response to UKtc VP7 was restricted at H-2Kb (see Figure 45). 
To confirm the H-2Kb restriction of the VP7-specific CTL response found to 
rotavirus UKtc strain, the VP7 homotypic response from a second rotavirus strain, namely 
RRV, was examined. The RRV-specific CTL response was also restricted at H-2Kb (see 
Figure 46). 
11.5 CONCLUSIONS 
(i) A rotavirus serotype-independent VP7-specific CTL response was generated across 
seven of the fourteen VP7 serotypes in the mouse H-2b MHC class I haplotype, regardless 
of the inoculating rotavirus serotype. 
(ii) Rotavirus serotype-dependent CTL epitope(s) were present between amino acids 13 
and 48 of the UKtc VP7 protein. 
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FIGURE 45. % SPECIFIC LYSIS OF TARGETS EXPRESSING UKTC VP7 
PROTEIN BY UKTC PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female mice C57BL/6 (H-2b) were orally inoculated with 107 pfu 
rotavirus UKtc (serotype 6) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Target cells (A) EL4 (H-2b), (B) L-Db (L-2Db) or (C) L-Kb (H-2K) were loaded 
with 51Cr, infected with WT vaccinia virus or recombinant vaccinia virus (vaccUKtc. VP7) 
and the 51Cr-release assays set up as described in Figure 25. 
FIGURE 46. % SPECIFIC LYSIS OF TARGETS EXPRESSING RRV VP7 PROTEIN 
BY RRV PRIMED C57BL/6 (H-2b) EFFECTORS 
Two 6 to 10 week old female mice C57BL/6 (H-2b) were orally inoculated with 107 pfu 
rotavirus RRV (serotype 3) and 7 days later were sacrificed and the spleens removed. The 
splenocytes were in vitro stimulated to produce the effector cells as described in Figure 25. 
Target cells (A) EL4 (H-2b), (B) Ltk' (H-2 k), (C) L-Db (L-213b) or (D) L-Kb (H- 
2Kb) were loaded with 
51Cr, infected with WT vaccinia virus or recombinant vaccinia virus 
(vaccRRV. VP7) and the 51Cr-release assays set up as described in Figure 25. 
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(iii) No major CTL epitopes were located between amino acids 117 and 232 of the UKtc 
VP7 protein (except, possibly, in the vicinity of amino acid position 184 which was not 
covered). 
(iv) The UKtc and RRV rotavirus VP7-specific CTL responses were both restricted at H- 
b 2K. 
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CHAPTER 12 
GENERAL DISCUSSION AND FUTURE EXPERIMENTS 
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Rotaviruses are the major etiological agents of severe infantile gastroenteritis, causing 
millions of cases of diarrhoea in children under five years of age and resulting in 850,000 
deaths annually (WHO, 1989). Although rotavirus is rarely fatal in the developed world, 
nearly all children are infected by 3 years of age and rotaviral diarrhoea is believed to 
account for 209,000 hospitalisations annually in the United States (Ho et al., 1988; 
Blacklow and Greenberg, 1991). A clean and plentiful water supply in developing 
countries would obviously help to prevent fatality by allowing for the replacement of the 
fluids and electrolytes lost during infection. However, even if this was provided, the scale 
of hospitalisations in developed countries, and the resulting economic burden (estimated to 
be 500 million to 1 billion dollars annually in the United States), make the development of 
a rotavirus vaccine a priority (Off it et al., 1991a). 
Initial studies focused on the rotavirus VP4 and VP7 proteins and established 
that both proteins could independently evoke a protective antibody response (Offit et al., 
1986b; Matsui et al., 1989). Consequently, several vaccine trials using traditional types of 
vaccine (live, oral, attenuated viruses), or modified traditional vaccines (genetic 
reassortant viruses containing genes encoding VP7 and/or VP4 of selected human 
rotavirus strains in an animal rotavirus background), have been undertaken. As mentioned 
in chapter 3, the large field trials with these vaccines have revealed mixed efficacy, 
regardless of the development of neutralising antibodies (reviewed in Conner et al., 1994). 
Nine VP7 (G) serotypes have been found to-date in humans, G1 to G4 being the most 
common (Beards et al., 1992; Gerna et al., 1992; Woods et al., 1992), and several G 
serotypes can co-circulate within a population (Gomez et al., 1990; Padilla-Noreiga et al., 
1990). Also, eleven VP4 (P) serotypes have been identified in group A viruses (Gorziglia 
et al., 1990a) but, because P serotypes are difficult to differentiate serologically, VP4 is 
classified into nineteen genotypes using VP4 amino acid homology sequence analysis 
(Estes and Cohen, 1989). Nine VP4 genotypes have been identified in humans to-date and 
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genotypes 4,8 to 10 and 14 are frequently associated with symptomatic infections (Qian 
and Green, 1991; Das et al., 1993). Initial studies suggest that, like G serotypes, several 
VP4 genotypes can co-circulate within a population (Das et al., 1994; Timenetsky et al., 
1994). From the total of VP7 serotypes and VP4 genotypes, and the capability of gene 
segment reassortment during mixed infection (VP4 and VP7 can independently segregate) 
(Offit et a!., 1986a), it is perhaps not surprising that the traditional vaccine strategies have 
provided mixed results. 
CTLs appear to recognise serotype-independent epitopes in rotavirus proteins 
(Off it and Dudzik, 1988; Offit et al., 1991a) which could be harnessed in vaccine design. 
However, although the antibody response to rotavirus has been studied extensively, little is 
known about the specificity and protection offered by the rotavirus-specific CTL response. 
The identification of antigenic epitopes capable of eliciting specific CTLs that can lyse 
infected cells is a fundamental step in the successful development of a CTL-promoting 
rotavirus vaccine, especially if those epitopes elicit a serotype/strain-independent CTL 
response. 
Investigating the immune response to rotavirus in humans presents particular difficulties: 
(i) the prior rotavirus exposure history is unknown, (ii) the inoculation "take" rates depend 
on the maternal antibody status, (iii) the timing between inoculation and natural rotavirus 
exposure is variable, and (iv) variation occurs in the virulence of the natural rotavirus 
strains. Thus, initial studies are best performed in animals rather than humans and can, at 
the very least, provide insight for future studies in humans. In the present study, the mouse 
was used to examine the CTL response to rotavirus infection. 
An animal model is required which mirrors the human immune response to 
rotavirus. Large animals, such as piglets and calves, accurately reflect human rotavirus 
illness (Bridger and Brown, 1981; Davidson et al., 1983; Saif et al., 1983), but are 
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expensive and difficult to maintain; caesarean delivery and gnotobiotic conditions often 
being required. Consequently, experiments requiring multiple animals are virtually 
impossible. Also, well-characterised immunological reagents for large animals may be 
expensive and difficult to obtain. Rabbits, although easier to handle than the large animals, 
are relatively expensive and also lack well-characterised immunological reagents (Conner 
et al., 1991). The most important problem with all these animals is, however, the absence 
of inbred lines that are vital for the initial characterisation of the MHC class I restricted 
CTL response. 
The mouse has many benefits over other animal models, the principal advantages 
being the availability of a number of inbred lines and a well-characterised immune system. 
Also, several commercial sources provide many high-quality reagents for detailed 
immunological studies. In addition, the mouse is priced modestly, requires less space and 
is easy to handle. The use of mice therefore allows a greater number of animals to be 
analysed per experiment leading to more meaningful data. 
Although rotaviruses and influenza viruses have different structures and replication cycles, 
similarities do exist between the two viruses. Firstly, both rotavirus and influenza virus 
have segmented genomes which contain genes encoding two independently segregating 
surface proteins [in the case of influenza, hemagglutinin (HA) (neutralising) and 
neuraminidase (NA)] which are the basis for the classification into subtypes/serotypes (in 
the case of influenza, III to H14 and NI to N9 subtypes with H1 to H3, and Ni and N2, 
identified in humans) (Murphy and Webster, 1990). Furthermore, the antibody response to 
both influenza virus and, probably, rotavirus generates a selection pressure directed to the 
surface proteins, which results in antigenic drift; the antibody response becoming 
progressively less effective as the virus changes antigenically (Kilbourne, 1973; Palombo 
et al., 1993). Lastly, completely new subtypes/serotypes of both influenza and, probably, 
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rotavirus appear following interspecies transmission (Nakagomi and Nakagomi, 1989; 
Murphy and Webster, 1990; Das et al., 1993). 
Comparable to the recent rotavirus vaccine trials, the early influenza virus 
vaccines did not provide protection equal to natural influenza virus infection, even though 
virus-specific antibody levels were presumably boosted (Hoskins et al., 1979). Focus then 
turned to the cell-mediated immunity and it was discovered that transferred CTLs could 
reduce influenza virus infection in the lungs of mice (Yap et al., 1978). It was also found 
that the influenza virus-specific CTL response was subtype-independent (McMichael et 
al., 1983b). The initial findings lead to a more detailed analysis of the CTL response to 
this virus with the aim of developing a CTL promoting vaccine. In humans, however, 
memory CTLs to influenza A virus decline within two to three years in the absence of 
further challenge (McMichael et al., 1983a). The short lived nature of influenza virus- 
specific memory CTLs suggested that regular immunisations (perhaps annually) would be 
required to ensure a sufficiently high level of CTL protection against the challenge virus. 
Although the lack of feasibility of a CTL-promoting vaccine to influenza virus 
has become apparent, the CTL response to this virus had been well defined and, with the 
above similarities to rotavirus, provided a relevant and well defined virus-specific CTL 
response to compare with rotavirus. 
By contrast to influenza virus, the short lived nature of the CTL response to 
rotavirus should not be a problem as disease is restricted, in the main, to the first two years 
of life (Kapikian et al., 1976). This apparent age restriction may be due to (i) the 
development of the gastric acid and pepsin secretions seen with increased age (Bass et al., 
1992), (ii) an age related change in the quantity of rotavirus binding receptors 
(Rienpenhoff-Tatty et al., 1982), or (iii) acquired immunity following asymptomatic 
infections of neonates with nursery rotavirus strains (Albert et al., 1987). Therefore, in 
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principle, a CTL promoting vaccine could provide the host with protection during the two 
years of high disease susceptibility. 
The lysis of target cells expressing individual rotavirus proteins by splenocytes from mice 
immunised with rotavirus has been described in this study. It might be argued that the 
cytolytic activity was due to other immune mechanisms since the splenocyte populations 
used in the 51Cr-release assays contained many different cell types. However, previous 
studies using the same technique have showed that rotavirus-specific CTLs were indeed 
responsible for this activity because cytotoxic activity was (i) detected seven days after 
primary oral inoculation, (ii) not detected in uninoculated animals, (iii) specific for 
rotavirus infected target cells, (iv) eliminated by treatment with Thy 1.2-specific IgM and 
complement and (v) restricted by MHC class I antigens (Offit and Dudzik, 1988). 
Recently, magnetic beads were used to separate the splenocyte population from rotavirus 
UKtc inoculated C57BL/6 (H-2b) mice, providing a positive population containing 78% 
CD8+ cells and a negative population containing 0% CD8+ cells. In 
51Cr-release 
assays, 
only the positive population lysed target cells expressing the UKtc NS53 or VP7 proteins, 
which directly showed that the cytolytic activity was mediated by CD8+ CTLs (S. Stagg, 
personal communication). 
In the present study, congenic mouse strains were used to detect if the CTL 
unresponsiveness to RRV VP7 in the Balb/c (H-2d) and C3H/He, mg (H-2k), but not 
C57BL/6 (H-2 b), mice strains was related to background differences other than the MHC 
class I haplotype, for example, the minor histocompatibility antigens. Studies in congenic 
C57BL/I0 and Balb/c mice showed that the mouse strain restriction of the rotavirus- 
specific CTL response was dependent solely on the MHC class I haplotype of the mouse. 
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This study has shown that the virus strain origin of a particular protein affects whether it 
will be recognised by CTLs in a particular haplotype. For example, the UKtc NS53 was 
recognised in the H-2b, but not in the H-2d or H-2k haplotype, whereas, RRV NS53 was 
recognised in both the H-2b and H-2 d' but not the H-2k haplotype. Indeed, Dharakul et al. 
(1991) did not detect a CTL response to RF NS53 using recombinant baculovirus 
expressed protein to inoculate H-2d haplotype mice. This raises two points; firstly, to 
obtain a comprehensive picture, many different rotavirus strains would have to be 
examined in many different haplotypes to pin point the majority of CTL epitopes and, 
secondly, the proteins of different rotavirus strains that are specific for a CTL response can 
only be compared with caution and certainly not combined together. 
It should be noted that previous studies on the CTL response to individual 
rotavirus proteins used different strains of rotavirus to inoculate mice than the present 
study [bovine RF (G6, VP4 genotype 1), Franco et al. (1994); simian SAIL (G3, VP4 
genotype 1), Off it et al. (1994)], and so direct comparisons with these studies have to be 
viewed with caution. 
For the above reason, the validity of the experiment which adoptively transfers 
into chronically infected SCID mice, CTLs generated from mice inoculated with 
baculovirus expressed individual rotavirus proteins, is doubted. In this experiment, VP1, 
VP2 and NS53 were from the RF strain, VP6 and NS28 were from the SA11 strain, VP4, 
VP7 and NS35 were from the simian RRV strain (G3, VP4 genotype 3) and the SCID mice 
were chronically infected with the murine EDIM strain (probably G3; VP4 genotype 16 or 
17). The study found that protective CTLs were generated by baculovirus expressing VP I, 
VP4, VP6 and VP7 (Dharakul et al., 1991). However, with so many different strains of 
rotavirus involved, the authors should have interpreted their results with more caution. 
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The present study was the first in which the CTL response to a full complement of 
rotavirus proteins from a single virus strain was examined. It has been known for some 
time that the virus protein recognised by CTLs depends on the MHC class I haplotype of 
the mouse (Bennink et al., 1987; Whitton et al., 1988b). For this reason, the immune 
response to the full complement of rotavirus proteins was examined in three different 
mouse MHC class I haplotypes: C57BL/6 (H-2b), Balb/c (H-2d) and C3H/He, mg (H-2 k). 
In the H-2b haplotype, the present study found a CTL response directed to the 
rotavirus UKtc VP7 and NS53 proteins. Most of the previous studies on CTL response to 
rotavirus have been performed in H-2b haplotype mice and a VP7-specific CTL response 
has been detected often (Dharakul et al., 1991; Offit et al., 1991a; Franco et al., 1994; 
Offit et al., 1994). However, this was the first study (in collaboration with S. Stagg, 
personal communication) to detect a NS53-specific CTL response. Because of the 
qualitative nature of the 51Cr-release assay, the relative levels to which rotavirus-specific 
CTLs recognise UKtc VP7 compared to UKtc NS53 in the H-2b haplotype remains to be 
determined. 
The CTL response previously detected to UKtc VP4 in the H-2b haplotype (Offit 
et al., 1991a) was not detected in later studies (Offit et al., 1994) or indeed in recent 
experiments (S. Stagg, personal communication). Also, the CTL response previously 
found to the VP6 protein, of both the SAI I and RF strains (Offit et al., 1991a; Franco et 
al., 1994), was not detected using UKtc virus. Furthermore, the CTL responses to RF VP2 
and VP3, using baculovirus expressed proteins to inoculate mice, were not detected using 
corresponding UKtc proteins. 
In the case of the inoculation of mice with recombinant baculovirus expressed 
individual rotavirus proteins, it appears that the available CTL repertoire is greater than 
that induced by infectious rotavirus itself. This may arise from the difference in the 
presentation to the immune system of endogenously synthesised proteins compared to 
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exogenous proteins. However, unlike these previous studies, this study has detected the 
rotavirus proteins that elicit a CTL response following whole active rotavirus inoculation 
of mice and is, therefore, more indicative of the actual CTL response that follows a natural 
rotavirus infection. Therefore, in the design of a CTL-promoting rotavirus vaccine, the 
results of this study are probably of more value than the results gained using recombinant 
baculovirus expressed proteins or recombinant vaccinia virus to inoculate mice. 
In the H-2d mouse haplotype, the current study detected only a UKtc VP3- 
specific CTL response. Interestingly, Franco et al. (1994) were unable to detect a CTL 
response using the baculovirus expressed VP3 (or VPI, VP2 or VP6) to inoculate H-2d 
mice, perhaps, because the RF strain was examined in this case. In variance to Franco et 
al. (1994), but using the same methods, Dharakul et al., (1991) did find a RF VP1-specific 
CTL response in this haplotype. Dharakul et al. (1991) also found a CTL response to VP6, 
but of the SA 11 strain in this case. 
In addition, Dharakul et al. (1991) found RRV VP4 and VP7-specific CTL 
responses in the H-2d mouse haplotype. Of note, the present study failed to detect a RRV 
VP7-specific CTL response in this haplotype and, as described above, this may be due to 
the greater CTL repertoire induced by recombinant baculovirus protein inoculation. 
In the H-2k mouse haplotype, the current study also detected only a UKtc VP3- 
specific CTL response. This agrees with preliminary results cited by Franco et al. (1994) 
in which a rotavirus-specific CTL response was generated using the baculovirus expressed 
RF VP3 (but not VP1, VP2 or VP6) to inoculate H-2k mice. 
To summarise, examination of the full complement of rotavirus UKtc proteins 
revealed a NS53 and VP7-specific CTL response 
in the H-2b mouse haplotype and a VP3- 
specific CTL response in the H-2d and H-2k mouse 
haplotypes. Unlike the present work, 
studies concerning the CTL response to influenza virus have not covered the full 
complement of proteins from one subtype. Using various methods to express individual 
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influenza virus proteins (of many different subtypes) in different mouse haplotypes, virus- 
specific CTLs have been generated against: - the surface glycoproteins, HA (Bennink et al., 
1984) and NA (Wysocka and Hackett, 1990), the internal proteins, matrix protein (Reay et 
al., 1989), nucleoprotein (NP) (Townsend et al., 1984; Yewdell et al., 1985), and the three 
viral polymerases (PA, PBI and PB2) and the non-structural protein (NS1) (Bennink et al., 
1987). In common with rotavirus, the CTL recognition of individual influenza viral 
epitopes depended on the mouse haplotype (Bennink et al., 1987; Reay et al., 1989), a 
situation also found with lymphocytic choriomeningitis virus (LCMV) (Whitton et al., 
1988b). 
Resulting from detection of a rotavirus UKtc VP3-specific CTL response in the H-2d and 
H-2k (but not H-2b) haplotypes, the CTL response to VP3 was examined in more detail. 
Since peptides which bind to MHC class I molecules have a unique motif, it appears that 
UKtc VP3 contains at least two CTL epitopes (presented by H-2d and H-2k). Franco et al. 
(1994) also found a VP3-specific CTL response in two haplotypes when using 
recombinant baculovirus expressed protein to inoculate mice and this suggested that RF 
VP3 also contained at least two epitopes (presented by H-2b and H-2k in their case). 
The location of both the RF VP3 and UKtc VP3 epitopes expressed by the H-2k 
haplotype is not known and further studies may find that the CTL response to these two 
proteins is strain-independent. However, having established a CTL response to UKtc VP3 
in both H-2d and H-2k mouse haplotypes, this study suggested that the VP3 response was 
strain-dependent, at least between RRV and UKtc, regardless of the haplotype (H-2d or H- 
2k). Although it is not known if a CTL response is directed to RRV VP3, this result 
suggests that the epitope(s) in VP3 are not conserved between rotavirus strains (i. e., in 
variable region(s) of the protein). Of note, Franco et al. (1994) used allele-specific motifs 
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to predict the H-2b epitope(s) of the RF VP3 and found a response to a peptide mapping to 
amino acids 585 to 593 which was restricted at 
kb. 
In common with the responses to VP3 of rotavirus, CTLs are induced to the 
internal, conserved non-glycosylated proteins of many viruses including; influenza 
(Townsend et al., 1984; Yewdell et al., 1985), respiratory syncitial virus (RSV) (Bangham 
et al., 1986) and vesicular stomatitis virus (VSV) (Puddington et al., 1986; Yewdell et al., 
1986). Indeed, the responses to the conserved internal proteins often predominate during 
the polyclonal CTL response and are frequently strain-independent. It is unusual that, at 
least between the RRV and UKtc rotavirus strains, the VP3-specific CTL response does 
not appear to be cross-reactive. 
Following the detection of a rotavirus UKtc NS53-specific CTL response in the H-2b 
haplotype and a RRV NS53-specific CTL response in the H-2b and H-2d haplotypes, the 
CTL response to NS53 was examined in more detail. Because the peptides which bind to 
MHC class I molecules have a unique motif, it appears UKtc NS53 contains at least one 
CTL epitope (presented by H-2b), whereas, RRV NS53 contains at least two CTL epitopes 
(presented by H-2b and H-2d). 
This study found that the NS53-specific CTL response was strain-dependent 
(between UKtc, RRV and Hochi), regardless of the inoculating strain (UKtc or RRV) and 
irrespective of the haplotype (H-2b or H-2d). Although it is unknown if a CTL response is 
directed to Hochi NS53 in either haplotype, this result suggests that the epitope(s) on 
NS53 are not conserved between rotavirus strains 
(i. e., in variable regions of the protein). 
The study also showed that the UKtc NS53-specific CTL response was restricted 
at H-213b. The RRV NS53-specific 
CTL response in the H-2b haplotype could not be 
clearly defined as Db or Kb restricted and this suggests that at 
least two CTL epitopes are 
presented, at least one H-2Db and H-2Kb, respectively. 
This hypothesis is supported by the 
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earlier suggestion that RRV NS53 contains at least two CTL epitopes due to the CTL 
response in two different haplotypes. In comparison, the simian virus 40 large tumour (T) 
antigen contains three H-2Db and one H-2K b restricted CTL epitopes (Mylin et al., 1995). 
Not only was the current study the first to show a H-2Db restricted, strain- 
dependent CTL response directed at the UKtc NS53 protein, but, at least one CTL epitope 
has been located to the first 150 amino acids of this protein. 
The strain-dependent CTL response to rotavirus NS53 is in contrast to the strain- 
independent CTL response of the non-structural proteins of both influenza virus NS1 
(Kuwano et al., 1990) and hepatitis C virus (HCV) NS5 (Shirai et al., 1992). However, it 
should be noted that the influenza virus NSI and HCV NS5 proteins are both relatively 
conserved between isolate groups, whereas rotavirus NS53 protein has great genetic 
diversity between strains (for example, UKtc and RRV NS53 have only 37.8% amino acid 
conservation) (Xu et al., 1994) and, thus, the absence of strain-independent CTL epitopes 
is not surprising. It is possible that the genetic diversity of NS53 is a result of selection 
pressure bestowed by the cell-mediated immune response, as has been shown to be the 
case in Epstein Barr virus (EBV), LCMV and HIV-1 (Pircher et al., 1990; Campos-Lima 
et al., 1993; Couillin et al., 1994). It is believed that induced mutational changes either 
prevent the binding of the viral CTL epitopes to the MHC molecules, or prevent the T-cell 
receptor (TCR) from binding to the MHC-peptide complex. In either event, a sub- 
population of CTLs no longer recognise the virally infected cells and, depending on the 
hierachal control of other CTL epitopes, the virus replication may continue undetected 
(Lewicki et al., 1995; Moskophidis and Zinkernagel, 1995). 
The present study found that the UKtc and RRV VP7-specific CTL response was restricted 
to the H-2b mouse haplotype. The VP7-specific CTL response in this haplotype has been 
well documented using the UKtc, RRV, SA11 and RF rotavirus strains (Offit et al., 1991a; 
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Franco et al., 1993; Offit et al., 1994). An RRV VP7-specific CTL response was also 
found in the H-2d haplotype when baculovirus expressed protein was used to inoculate 
mice (Dharakul et al., 1991). 
A previous study had shown that the VP7-specific CTL response was serotype- 
independent between serotypes 3 (SA11 and RRV) and 6 (UKtc) (Offit et al., 1994). 
However, because fourteen different VP7 serotypes have been classified to-date, it was 
decided to extend the previous findings to cover a large number (7) of the serotypes. This 
study found that the VP7-specific CTL response was serotype-independent between all the 
rotavirus serotypes tested, regardless of the immunising serotype (3 or 6) in the 11-2b 
haplotype. Since the VP7-specific CTL response is serotype-independent between seven of 
the fourteen serotypes, it would appear reasonable to hypothesise that the CTL response 
probably cross-reacts between all fourteen VP7 serotypes, regardless of the inoculating 
rotavirus serotype. These results suggest that the CTL epitope(s) on the VP7 protein are 
conserved between rotavirus strains. 
The study also showed that the serotype-independent UKtc and RRV VP7- 
specific CTL epitopes were both restricted at H-2Kb. This disagrees with Offit et al. 
(1994) who found that either the UKtc or SA11 (they do not specify) VP7-specific CTL 
response was restricted at H-2Db and, interestingly, that RRV-specific CTL recognition of 
RRV infected target cells was restricted at H-2Db (Offit and Dudzik, 1988). By contrast, 
and in agreement with the results reported here, the immunodominant epitope on RF VP7 
(as well as VP3 and VP6) was found to be restricted at H-2Kb (Franco et al., 1993/1994). 
Therefore, the conclusions reached by Offit and colleagues have to be questioned. 
Using allele-specific motifs to predict MHC class I H-2b epitopes, a synthesised 
peptide covering amino acids 33 to 40 of the rotavirus RF VP7 protein (which overlaps the 
H2 signal peptide located between amino acid positions 33 to 48) was recognised by 
rotavirus-specific CTLs (Franco et al., 1993). 
This epitope was found to be restricted at H- 
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2Kb and, in addition, the region of the VP7 protein containing this epitope is conserved, 
although not completely conserved, between different rotavirus strains (see Table 10). In 
the light of this, the view emerged that this region defined the VP7 serotype-independent 
CTL epitope, however, no experimental evidence for this had been reported. The present 
study showed that UKtc VP7 contains a serotype-dependent CTL epitope between amino 
acids 13 and 48; this region containing the immunodominant epitope detected previously 
which is fully conserved between the UKtc and RF rotavirus strains (see Table 10). This 
suggests that the immunodominant CTL epitope found by Franco et al. (1993) was not the 
serotype-independent epitope. 
Table 10. Comparison of the VP7 amino acid sequence (between amino acid positions 
33 and 40) corresponding to the H-2Kb restricted CTL epitope detected by Franco et 
a!. (1993). Amino acid residues which differ from the rotavirus RF strain sequence are 
shown in bold (Estes and Cohen, 1989). 
Rotavirus strain VP7 serotype VP7 sequence between amino 
acid positions 33 to 40 
RF 6 IIYRFLLI 
Wa I IIYRFLLI 
RRV 3 IIYRFLFI 
ST3 4 IIYRIAFV 
OSU 5 IIYRFLLV 
UKtc 6 IIYRFLLI 
69M 8 ILYHFLLF 
WI-61 9 IIYRFLLL 
A64 10 IIYKFLLI 
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These results have shown that, although CTL epitopes can be predicted from the 
amino acid sequence of a protein (Franco et al., 1993), a better method is to examine 
progressively smaller protein fragments (as utilised in this study). The problem of 
predicting CTL epitopes is highlighted by the fact that HCV epitopes exist in which no 
binding motif has yet been proposed (Koziel et al., 1995). In addition, apart from the three 
immunodominant LCMV H-2b restricted CTL epitopes, only three out of a further thirty- 
four predicted CTL epitopes were functional and even those were not recognised in vivo 
following the mutation of the immunodominant CTL epitopes (Oldstone et al., 1995). 
In summary, VP7 contains at least one serotype-dependent and one serotype- 
independent epitope recognised by CTLs and all the epitopes are restricted at H-2Kb. The 
rotavirus VP7-specific CTL response is in contrast to viruses such as influenza (Townsend 
et al., 1984), RSV (Bangham et al., 1986) and VSV (Puddington et al., 1986; Yewdell et 
al., 1986) where the surface glycoprotein-specific CTL response is either a minor 
component of the polyclonal CTL response or undetectable. It should be noted that 
although the majority of the CTL response to the influenza virus HA is subtype specific 
(Townsend et al., 1984), minor subtype-independent CTL epitopes have also been detected 
in this protein (Saikh et al., 1995). Conversely, the serotype-independent LCMV envelope 
glycoprotein-specific CTL response mirrors the rotavirus VP7-specific CTL response 
(Whitton et al., 1988a/b). 
The identification of those rotavirus protein(s) involved in stimulating a CTL response 
may be important in the development of vaccines based on vectors expressing individual 
rotavirus genes, particularly if the proteins concerned evoke serotype-independent CTLs. 
Mice inoculated with an infectious virus or with recombinant vaccinia virus expressing 
VP7 induce VP7-specific serotype-independent CTLs (Offit et al., 1994) and, with the 
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development of naturally attenuated poxvirus vectors for use in humans, these types of 
expression systems may be utilised in future vaccine design (Taylor et al., 1992). With 
regards to the influenza virus nucleoprotein (NP) (which contains the immunodominant 
subtype-independent CTL epitope), there is still debate as to the level of protection offered 
by immunisation with vaccinia virus recombinants containing this protein. Immunisation 
with recombinant vaccinia virus expressing NP offered protection to mice from 
heterotypic virus challenge (Endo et al., 1991), however, this protection has not been 
found by other investigators (Lawson et al., 1994). Immunisations with recombinant 
vaccinia viruses containing proteins which elicit virus-specific CTLs have also been found 
to elicit protection against subsequent virus infections of both LCMV and RSV (Hany et 
al., 1989; Kulkarni et al., 1993). 
In contrast to antibody producing B-lymphocytes, CTLs do not require 
con formational ly correct protein presentation for their stimulation and, indeed, a subunit 
vaccine could potentially contain individual CTL epitopes rather than complete proteins. 
Thus, utilising CTL epitopes might bypass the difficulty of achieving correct protein 
conformation found in heterologous expression systems. Since the rotavirus protein used 
as a source of CTL determinants is dependent on the haplotype of the mouse, an effective 
subunit vaccine for use in an outbred population would probably have to contain a variety 
of CTL epitopes. Indeed, coupling of LCMV CTL-specific epitopes within vaccinia virus 
to form a "string-of-beads" vaccine was found to not only confer protective CTL responses 
in several MHC backgrounds but, also, to enhance the CTL response within individual 
MHC backgrounds (Whitton et al., 1993). In addition, the efficient use of individual 
rotavirus-specific CTL epitopes in a subunit vaccine requires coupling to Th-lymphocyte 
epitopes. However, the search for immunodominant rotavirus Th-lymphocyte epitopes is 
not necessary because coupling to defined Th-lymphocyte epitopes of an unrelated virus 
(for example, IIIV) is sufficient to provide the additional help (Shirai et al., 1996). Shirai 
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and colleagues also speculated that the attachment of these epitopes may broaden the 
range of MIUC haplotypes in which the potential vaccine would be effective. 
A recent discovery was that virus-specific CTLs could be generated in animals 
by intravenous, intra-muscular and gene gun immunisation of DNA vectors (Yokoyama et 
al., 1995; Yasutomi et al., 1996). For example, heterotypic protection of mice from 
influenza virus infection was provided by the intra-muscular immunisation of a DNA 
plasmid vector encoding the influenza NP protein (Ulmer et al., 1993). In addition, the 
intra-muscular immunisation of a DNA plasmid containing the HBV small surface antigen 
(HBsAg), into a mouse haplotype (H-2b) previously considered a non-responder to the 
HBsAg, revealed a CTL response to this protein (Schirmbeck et al., 1995). The conclusion 
of this work was that, depending on the method of antigen delivery, CTL subunit vaccines 
have the potential to elicit heterotypic protection and overcome the non-responsiveness of 
particular proteins in certain haplotypes. 
Future experiments leading directly on from this work would include precisely locating the 
serotype-independent epitope(s) on VP7 and the strain-dependent CTL epitope(s) on 
NS53, for each appropriate mouse haplotype. Also the location of the VP3-specific CTL 
epitopes should be determined and the strain-specificity of these epitopes confirmed. 
Furthermore, the M11IC class I locus of restriction with regard to rotavirus proteins in 
mouse haplotypes other than 11-2b have yet to be determined. It would also be interesting 
to see if immunisation with the recombinant vaccinia viruses expressing VP3, NS53 and 
VP7 could protect infant mice from subsequent rotavirus disease. Different vaccination 
strategies could be examined with the recombinant viruses given either singularly (in the 
appropriate mouse haplotype) or in a combination to perhaps elicit a mouse haplotype- 
independent protective CTL response. 
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Despite the above details that remain unresolved, the information to be gained on 
the CTL response to rotavirus using the inbred mouse model has virtually been completed. 
The CTL response appears complicated and varies according to both the mouse haplotype 
and rotavirus strain. The next step is to look at the CTL response to rotavirus in an outbred 
population. This could also be done in mice, however, because a rotavirus vaccine is 
urgently required for humans, it would be more practical to look at the CTL response to all 
the rotavirus proteins using humans as the outbred population. Indeed, the 51Cr-release 
assay for measuring CTL activity to individual virus proteins using targets infected with 
vaccinia virus recombinants, has been performed using human CTLs (Tarnaki et al., 
1995). Autologous EBV-transformed B-lymphoblastoid cell lines from each patient are 
normally established by in vitro transformation of the peripheral blood B-lymphocytes 
with the supernatant from an EBV-producing marmoset cell line. The autologous B- 
lymphocyte blasts are used as both the antigen presenting cell during the in vitro 
stimulation of CTLs and as the target cells in the 
51Cr-release assays. 
The rotavirus-specific CTL response in humans has not been examined to-date 
and this probably stems from the fact that adult volunteers have an unknown 
immunological history to rotavirus. Since memory CTLs are believed to decline within 
three or four years, a CTL response may not be detected in adult volunteers. One may 
argue that the probable asymptomatic rotavirus re-infections throughout the life of an 
individual may help to preserve rotavirus-specific memory CTLs, however, the 
development of an antibody response may prevent sufficient infection for stimulation of 
memory CTLs. Consequently, immunisation of adult volunteers with rotavirus prior to the 
examination of their CTLs may not be sufficient in generating a rotavirus-specific 
response. It would therefore seem more prudent to perform the initial experiments on the 
rotavirus-specific CTL response in humans, although technically more difficult, using 
infants following their primary rotavirus infection. 
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